WO2017074914A1 - Novel tricyclic compounds as inhibitors of mutant idh enzymes - Google Patents
Novel tricyclic compounds as inhibitors of mutant idh enzymes Download PDFInfo
- Publication number
- WO2017074914A1 WO2017074914A1 PCT/US2016/058614 US2016058614W WO2017074914A1 WO 2017074914 A1 WO2017074914 A1 WO 2017074914A1 US 2016058614 W US2016058614 W US 2016058614W WO 2017074914 A1 WO2017074914 A1 WO 2017074914A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrido
- dihydro
- methanone
- azabicyclo
- benzo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 174
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 13
- 239000003112 inhibitor Substances 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 151
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 8
- -1 2-azabicyclo[2.2.2]octanyl Chemical group 0.000 claims description 181
- 229910052739 hydrogen Inorganic materials 0.000 claims description 89
- 239000001257 hydrogen Substances 0.000 claims description 89
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 41
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 16
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 15
- 206010018338 Glioma Diseases 0.000 claims description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 208000032612 Glial tumor Diseases 0.000 claims description 12
- 208000005017 glioblastoma Diseases 0.000 claims description 12
- 229910052703 rhodium Inorganic materials 0.000 claims description 12
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 12
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- DHYFKMCPXOXGHI-UHFFFAOYSA-N (8-chloro-3,9-difluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl)-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound ClC=1C(=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F DHYFKMCPXOXGHI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 6
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 6
- JAYSMAUSONUIDZ-UHFFFAOYSA-N [3,9-difluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound C12OCC(N(C1)C=1C(=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)C3CCN(CC3)CC(F)(F)F)C=1)F)CC2 JAYSMAUSONUIDZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000007312 paraganglioma Diseases 0.000 claims description 6
- SJUWIUDEKKLYRD-UHFFFAOYSA-N (8-chloro-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl)-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound ClC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1 SJUWIUDEKKLYRD-UHFFFAOYSA-N 0.000 claims description 5
- ARZREWANQFTWTJ-UHFFFAOYSA-N (9-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl)-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1 ARZREWANQFTWTJ-UHFFFAOYSA-N 0.000 claims description 5
- OPLUIOYZCKWUHG-CPONINCNSA-N ClC=1C=CC2=C(N(C(C3=C(N2)N=CC=C3)C)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 Chemical compound ClC=1C=CC2=C(N(C(C3=C(N2)N=CC=C3)C)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 OPLUIOYZCKWUHG-CPONINCNSA-N 0.000 claims description 5
- JKFNMSRFGJBVPX-UHFFFAOYSA-N [9-fluoro-8-(1-methylpyrazol-4-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1C=1C=NN(C=1)C JKFNMSRFGJBVPX-UHFFFAOYSA-N 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- VCDHIULWIHQKRC-UHFFFAOYSA-N (3,9-difluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl)-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)C2CCN(CC2)CC(F)(F)F)C=CC(=C3)F)N=C1 VCDHIULWIHQKRC-UHFFFAOYSA-N 0.000 claims description 4
- IAMWUSJCSWQJTC-UHFFFAOYSA-N (8-methoxy-5-methyl-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl)-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound COC=1C=CC2=C(N(C(C3=C(N2)N=CC=C3)C)C(=O)C2CCN(CC2)CC(F)(F)F)C=1 IAMWUSJCSWQJTC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- KWNFTQOYGSMHQG-PPUGGXLSSA-N BrC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 Chemical compound BrC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 KWNFTQOYGSMHQG-PPUGGXLSSA-N 0.000 claims description 4
- SCXFGKLXTUHSMT-RVZUZXSLSA-N C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1C2=C(NC3=C(C1C)C=CC=N3)C=CC(=C2)N1CCOCC1 Chemical compound C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1C2=C(NC3=C(C1C)C=CC=N3)C=CC(=C2)N1CCOCC1 SCXFGKLXTUHSMT-RVZUZXSLSA-N 0.000 claims description 4
- DFJLVRJALPMFFI-ZNUUHSPMSA-N C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1C2=C(NC3=C(C1C)C=CC=N3)C=CC(=C2)OC Chemical compound C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1C2=C(NC3=C(C1C)C=CC=N3)C=CC(=C2)OC DFJLVRJALPMFFI-ZNUUHSPMSA-N 0.000 claims description 4
- HDMHVZJYESAQHW-BIHRQFPBSA-N C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C(=C3)C)N1[C@@H]3CO[C@H](C1)CC3)N=CC=C2 Chemical compound C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C(=C3)C)N1[C@@H]3CO[C@H](C1)CC3)N=CC=C2 HDMHVZJYESAQHW-BIHRQFPBSA-N 0.000 claims description 4
- IMTQUGOIFSTEJD-VDVKDMFPSA-N C1=C(C)C=NC2=C1CN(C1=CC(=CC=C1N2)N1C[C@H]2OC[C@@H]1CC2)C(=O)[C@H]1CC[C@@H](CC1)OC(C)C Chemical compound C1=C(C)C=NC2=C1CN(C1=CC(=CC=C1N2)N1C[C@H]2OC[C@@H]1CC2)C(=O)[C@H]1CC[C@@H](CC1)OC(C)C IMTQUGOIFSTEJD-VDVKDMFPSA-N 0.000 claims description 4
- MWCWTOAPMNWRBE-IMNFJDCFSA-N C1=C(C=C2C(=N1)NC1=C(N(C2)C(=O)[C@H]2CC[C@@H](CC2)OC(C)C)C=C(C=C1)N1C[C@H]2OC[C@@H]1CC2)Cl Chemical compound C1=C(C=C2C(=N1)NC1=C(N(C2)C(=O)[C@H]2CC[C@@H](CC2)OC(C)C)C=C(C=C1)N1C[C@H]2OC[C@@H]1CC2)Cl MWCWTOAPMNWRBE-IMNFJDCFSA-N 0.000 claims description 4
- CPEFPFONOADIDM-SAZUREKKSA-N ClC=1C(=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1)F Chemical compound ClC=1C(=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1)F CPEFPFONOADIDM-SAZUREKKSA-N 0.000 claims description 4
- XTIKJNIXATZALT-PPUGGXLSSA-N ClC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 Chemical compound ClC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 XTIKJNIXATZALT-PPUGGXLSSA-N 0.000 claims description 4
- SXAQTJPWGFWVIQ-HCUBDLJJSA-N N1=CC(=CC2=C1NC1=C(N(C2)C(=O)[C@H]2CC[C@@H](CC2)OC(C)C)C=C(N2C[C@H]3OC[C@@H]2CC3)C=C1)S(=O)(=O)C Chemical compound N1=CC(=CC2=C1NC1=C(N(C2)C(=O)[C@H]2CC[C@@H](CC2)OC(C)C)C=C(N2C[C@H]3OC[C@@H]2CC3)C=C1)S(=O)(=O)C SXAQTJPWGFWVIQ-HCUBDLJJSA-N 0.000 claims description 4
- MRXLOZJBGMMECX-NBGIEHNGSA-N [3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=C(C(=C3)F)N2CC3(C2)COCCC3)N=C1 MRXLOZJBGMMECX-NBGIEHNGSA-N 0.000 claims description 4
- CNUHIEXZNDMQEL-UHFFFAOYSA-N [3-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1CC2CCC1CO2 CNUHIEXZNDMQEL-UHFFFAOYSA-N 0.000 claims description 4
- BSRVLEPUWIFNMY-UHFFFAOYSA-N [3-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound C12OCC(N(C1)C=1C=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)C3CCN(CC3)CC(F)(F)F)C=1)CC2 BSRVLEPUWIFNMY-UHFFFAOYSA-N 0.000 claims description 4
- WEALFDMDNWSPJG-PLISQRNSSA-N [3-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1C[C@@H]2C[C@H]1CO2 WEALFDMDNWSPJG-PLISQRNSSA-N 0.000 claims description 4
- COJUCQAWOGIMSE-PMACEKPBSA-N [3-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound Fc1cnc2Nc3ccc(cc3N(Cc2c1)C(=O)C1CCN(CC(F)(F)F)CC1)N1C[C@@H]2C[C@H]1CO2 COJUCQAWOGIMSE-PMACEKPBSA-N 0.000 claims description 4
- XYFUJTRBVLTSQZ-UHFFFAOYSA-N [7-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cccnc2Nc2ccc(N3CC4CCC3CO4)c(F)c12 XYFUJTRBVLTSQZ-UHFFFAOYSA-N 0.000 claims description 4
- AXBZIQVMJPDJIP-QFUKKKHRSA-N [7-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cccnc2Nc2ccc(N3C[C@@H]4CC[C@H]3CO4)c(C)c12 AXBZIQVMJPDJIP-QFUKKKHRSA-N 0.000 claims description 4
- CKQLKKZABDREKX-IRXMKASPSA-N [8-(1,4-dioxan-2-yl)-3,9-difluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound O1C(COCC1)C=1C(=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=1)F CKQLKKZABDREKX-IRXMKASPSA-N 0.000 claims description 4
- QKCDIIOEHZUWLP-IRXMKASPSA-N [8-(1,4-dioxan-2-yl)-9-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound O1C(COCC1)C=1C(=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=1)F QKCDIIOEHZUWLP-IRXMKASPSA-N 0.000 claims description 4
- NTBPQMAKDYFKOK-PMOQBDJRSA-N [8-[(2R)-1,4-dioxan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound O1[C@@H](COCC1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=1 NTBPQMAKDYFKOK-PMOQBDJRSA-N 0.000 claims description 4
- QHFULQDWQFARPU-NRFANRHFSA-N [8-[(2R)-1,4-dioxan-2-yl]-9-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound O1[C@@H](COCC1)C=1C(=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F QHFULQDWQFARPU-NRFANRHFSA-N 0.000 claims description 4
- NTBPQMAKDYFKOK-WWPVKYPJSA-N [8-[(2S)-1,4-dioxan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound O1[C@H](COCC1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=1 NTBPQMAKDYFKOK-WWPVKYPJSA-N 0.000 claims description 4
- QHFULQDWQFARPU-OAQYLSRUSA-N [8-[(2S)-1,4-dioxan-2-yl]-9-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound O1[C@H](COCC1)C=1C(=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F QHFULQDWQFARPU-OAQYLSRUSA-N 0.000 claims description 4
- FBQPUXUYYHTETQ-UHFFFAOYSA-N [9-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cccnc2Nc2cc(F)c(cc12)N1CC2CCC1CO2 FBQPUXUYYHTETQ-UHFFFAOYSA-N 0.000 claims description 4
- FRPMZDSJYBTKFE-GSRZOBFVSA-N [9-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound CC(C)O[C@H]1CC[C@@H](OC1)C(=O)N1Cc2cccnc2Nc2cc(F)c(cc12)N1C[C@@H]2C[C@H]1CO2 FRPMZDSJYBTKFE-GSRZOBFVSA-N 0.000 claims description 4
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 3
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 3
- MPFLAFDPSRRPLY-OAQYLSRUSA-N [8-[(2S)-1,4-dioxan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound O1[C@H](COCC1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1 MPFLAFDPSRRPLY-OAQYLSRUSA-N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- LMPPQDRVKKRGBU-UHFFFAOYSA-N (1-ethylsulfonylpiperidin-4-yl)-[3-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]methanone Chemical compound C12OCC(N(C1)C=1C=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)C3CCN(CC3)S(=O)(=O)CC)C=1)CC2 LMPPQDRVKKRGBU-UHFFFAOYSA-N 0.000 claims description 2
- PWCAISHEJFRNRJ-UHFFFAOYSA-N C1CNNC1C2=CC3=C(C=C2F)NC4=C(CN3C(=O)C5CCN(CC5)CC(F)(F)F)C=C(C=N4)F Chemical compound C1CNNC1C2=CC3=C(C=C2F)NC4=C(CN3C(=O)C5CCN(CC5)CC(F)(F)F)C=C(C=N4)F PWCAISHEJFRNRJ-UHFFFAOYSA-N 0.000 claims description 2
- QCXBHAVBCWSYDI-YEWNNSEMSA-N [3,9-difluoro-8-(2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound C12OCC(N(C1)C=1C(=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)[C@@H]3OC[C@H](CC3)OC(C)C)C=1)F)CC2 QCXBHAVBCWSYDI-YEWNNSEMSA-N 0.000 claims description 2
- VTSVVHIHYFKVQE-UHFFFAOYSA-N [3,9-difluoro-8-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2cc(F)c(cc12)N1C2CCC1COC2 VTSVVHIHYFKVQE-UHFFFAOYSA-N 0.000 claims description 2
- LHVSTRBGIKJSNB-UHFFFAOYSA-N [3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2cc(F)c(cc12)N1CC2(C1)CCCOC2 LHVSTRBGIKJSNB-UHFFFAOYSA-N 0.000 claims description 2
- SPYRIRSSUCUKAW-UHFFFAOYSA-N [3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)C2CCN(CC2)CC(F)(F)F)C=C(C(=C3)F)N2CC3(C2)COCCC3)N=C1 SPYRIRSSUCUKAW-UHFFFAOYSA-N 0.000 claims description 2
- JAYSMAUSONUIDZ-RTBURBONSA-N [3,9-difluoro-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound [C@H]12OC[C@H](N(C1)C=1C(=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)C3CCN(CC3)CC(F)(F)F)C=1)F)CC2 JAYSMAUSONUIDZ-RTBURBONSA-N 0.000 claims description 2
- CHNWNUVCJSDKKR-IOXCNKERSA-N [3,9-difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2cc(F)c(cc12)N1C[C@@H]2C[C@H]1CO2 CHNWNUVCJSDKKR-IOXCNKERSA-N 0.000 claims description 2
- MZDFRCYXOCIWJF-GSRZOBFVSA-N [3,9-difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound CC(C)O[C@H]1CC[C@@H](OC1)C(=O)N1Cc2cc(F)cnc2Nc2cc(F)c(cc12)N1C[C@@H]2C[C@H]1CO2 MZDFRCYXOCIWJF-GSRZOBFVSA-N 0.000 claims description 2
- CGIFUTNZXMUQOR-ROUUACIJSA-N [3,9-difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound Fc1cnc2Nc3cc(F)c(cc3N(Cc2c1)C(=O)C1CCN(CC(F)(F)F)CC1)N1C[C@@H]2C[C@H]1CO2 CGIFUTNZXMUQOR-ROUUACIJSA-N 0.000 claims description 2
- JAYSMAUSONUIDZ-OALUTQOASA-N [3,9-difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound Fc1cnc2Nc3cc(F)c(cc3N(Cc2c1)C(=O)C1CCN(CC(F)(F)F)CC1)N1C[C@@H]2CC[C@H]1CO2 JAYSMAUSONUIDZ-OALUTQOASA-N 0.000 claims description 2
- YWPFWXZFCBIAJY-VAZDYEOFSA-N [3,9-difluoro-8-[(1S,5R)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound COC1C[C@@H]2CC[C@H](C1)N2c1cc2N(Cc3cc(F)cnc3Nc2cc1F)C(=O)[C@H]1CC[C@@H](CO1)OC(C)C YWPFWXZFCBIAJY-VAZDYEOFSA-N 0.000 claims description 2
- TXFGSJIPKBNCJB-WCRBZPEASA-N [3,9-difluoro-8-[(1S,5R)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound COC1C[C@@H]2CC[C@H](C1)N2c1cc2N(Cc3cc(F)cnc3Nc2cc1F)C(=O)C1CCN(CC(F)(F)F)CC1 TXFGSJIPKBNCJB-WCRBZPEASA-N 0.000 claims description 2
- KLLFVCBDILTEHS-UHFFFAOYSA-N [3-fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1CC2(C1)CCCOC2 KLLFVCBDILTEHS-UHFFFAOYSA-N 0.000 claims description 2
- RZHDHBCNBOFMJI-WIOPSUGQSA-N [3-fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=C(C=C3)N2CC3(C2)COCCC3)N=C1 RZHDHBCNBOFMJI-WIOPSUGQSA-N 0.000 claims description 2
- GUWDBVNKVRFNQB-UHFFFAOYSA-N [3-fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)C2CCN(CC2)CC(F)(F)F)C=C(C=C3)N2CC3(C2)COCCC3)N=C1 GUWDBVNKVRFNQB-UHFFFAOYSA-N 0.000 claims description 2
- CHPQQBZYSJKTOZ-ILSIFQBBSA-N [3-fluoro-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound [C@H]12OC[C@H](N(C1)C=1C=CC3=C(N(CC4=C(N3)N=CC(=C4)F)C(=O)[C@@H]3OC[C@H](CC3)OC(C)C)C=1)CC2 CHPQQBZYSJKTOZ-ILSIFQBBSA-N 0.000 claims description 2
- CHPQQBZYSJKTOZ-DEJKCJRPSA-N [3-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound CC(C)O[C@H]1CC[C@@H](OC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1C[C@@H]2CC[C@H]1CO2 CHPQQBZYSJKTOZ-DEJKCJRPSA-N 0.000 claims description 2
- JCLZYYACFLEPNI-TYABSZSSSA-N [3-fluoro-8-[(1S,5R)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound COC1C[C@@H]2CC[C@H](C1)N2c1ccc2Nc3ncc(F)cc3CN(C(=O)C3CCN(CC(F)(F)F)CC3)c2c1 JCLZYYACFLEPNI-TYABSZSSSA-N 0.000 claims description 2
- AXBZIQVMJPDJIP-RSHDMXJRSA-N [7-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cccnc2Nc2ccc(N3C[C@H]4CC[C@@H]3CO4)c(C)c12 AXBZIQVMJPDJIP-RSHDMXJRSA-N 0.000 claims description 2
- WWEWVBNBHUZXEY-AENCRQEPSA-N [8-(3,9-dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound CC(C)O[C@H]1CC[C@@H](OC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1CC2COCC(C1)O2 WWEWVBNBHUZXEY-AENCRQEPSA-N 0.000 claims description 2
- CMVGYUNHCNMBRL-UHFFFAOYSA-N [8-(3,9-dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound Fc1cnc2Nc3ccc(cc3N(Cc2c1)C(=O)C1CCN(CC(F)(F)F)CC1)N1CC2COCC(C1)O2 CMVGYUNHCNMBRL-UHFFFAOYSA-N 0.000 claims description 2
- QFUVNTNAZDSGRC-SSGKUCQKSA-N [8-[(1R,3R,6R,7R)-5,8-dioxa-2-azatricyclo[4.3.0.03,7]nonan-2-yl]-3,9-difluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)C2CCN(CC2)CC(F)(F)F)C=C(C(=C3)F)N2[C@H]3[C@@H]4[C@H](OC3)[C@H]2CO4)N=C1 QFUVNTNAZDSGRC-SSGKUCQKSA-N 0.000 claims description 2
- ARSFZXFVYYJXSA-XKHWTCNHSA-N [8-[(1R,3R,6R,7R)-5,8-dioxa-2-azatricyclo[4.3.0.03,7]nonan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cc(F)cnc2Nc2ccc(cc12)N1[C@@H]2CO[C@@H]3[C@H]1CO[C@H]23 ARSFZXFVYYJXSA-XKHWTCNHSA-N 0.000 claims description 2
- WZPDVHYPXLQPQZ-SSGKUCQKSA-N [8-[(1R,3R,6R,7R)-5,8-dioxa-2-azatricyclo[4.3.0.03,7]nonan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(NC3=C(N(C2)C(=O)C2CCN(CC2)CC(F)(F)F)C=C(C=C3)N2[C@H]3[C@@H]4[C@H](OC3)[C@H]2CO4)N=C1 WZPDVHYPXLQPQZ-SSGKUCQKSA-N 0.000 claims description 2
- WQNCIVIJMJWPQD-SSGKUCQKSA-N [8-[(1R,3R,6R,7R)-5,8-dioxa-2-azatricyclo[4.3.0.03,7]nonan-2-yl]-9-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1N1[C@H]2[C@@H]3[C@H](OC2)[C@H]1CO3 WQNCIVIJMJWPQD-SSGKUCQKSA-N 0.000 claims description 2
- MPFLAFDPSRRPLY-NRFANRHFSA-N [8-[(2R)-1,4-dioxan-2-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound O1[C@@H](COCC1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1 MPFLAFDPSRRPLY-NRFANRHFSA-N 0.000 claims description 2
- JINPDYPCNIXNAH-HOTGVXAUSA-N [8-[(2S,5S)-2,5-dimethylmorpholin-4-yl]-3,9-difluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound C[C@@H]1OC[C@@H](N(C1)C=1C(=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F)C JINPDYPCNIXNAH-HOTGVXAUSA-N 0.000 claims description 2
- YOJXGHRDNATOHP-IRXDYDNUSA-N [8-[(2S,5S)-2,5-dimethylmorpholin-4-yl]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound C[C@@H]1OC[C@@H](N(C1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)C YOJXGHRDNATOHP-IRXDYDNUSA-N 0.000 claims description 2
- IAFTVSMJEFWHIF-LZOBGLDGSA-N [8-[[3-(chloromethyl)oxan-3-yl]methylamino]-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[(2R,5S)-5-propan-2-yloxyoxan-2-yl]methanone Chemical compound ClCC1(COCCC1)CNC=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)[C@@H]2OC[C@H](CC2)OC(C)C)C=1 IAFTVSMJEFWHIF-LZOBGLDGSA-N 0.000 claims description 2
- GYKFJQLJBWXMQR-UHFFFAOYSA-N [9-fluoro-8-(2-methylpyrazol-3-yl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound FC1=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1C1=CC=NN1C GYKFJQLJBWXMQR-UHFFFAOYSA-N 0.000 claims description 2
- IDBXIGIZPJAPHV-ROUUACIJSA-N [9-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound Fc1cc2Nc3ncccc3CN(C(=O)C3CCN(CC(F)(F)F)CC3)c2cc1N1C[C@@H]2C[C@H]1CO2 IDBXIGIZPJAPHV-ROUUACIJSA-N 0.000 claims description 2
- HDMHVZJYESAQHW-RSHDMXJRSA-N [9-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl]-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-(4-propan-2-yloxycyclohexyl)methanone Chemical compound CC(C)OC1CCC(CC1)C(=O)N1Cc2cccnc2Nc2cc(C)c(cc12)N1C[C@H]2CC[C@@H]1CO2 HDMHVZJYESAQHW-RSHDMXJRSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 189
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 133
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 99
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 61
- 239000011541 reaction mixture Substances 0.000 description 54
- 239000000243 solution Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 50
- 239000007787 solid Substances 0.000 description 49
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 45
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 44
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 239000002904 solvent Substances 0.000 description 35
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 34
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 34
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 32
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 31
- 239000012267 brine Substances 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 30
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 28
- 229940093499 ethyl acetate Drugs 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 23
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000005859 coupling reaction Methods 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000007792 addition Methods 0.000 description 18
- 230000008878 coupling Effects 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- 238000004808 supercritical fluid chromatography Methods 0.000 description 16
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 16
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 239000003937 drug carrier Substances 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 238000004007 reversed phase HPLC Methods 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 13
- PUYRGPLZHGXIMC-JGVFFNPUSA-N (2R,5S)-5-propan-2-yloxyoxane-2-carboxylic acid Chemical compound C(C)(C)O[C@H]1CC[C@@H](OC1)C(=O)O PUYRGPLZHGXIMC-JGVFFNPUSA-N 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 11
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 208000003174 Brain Neoplasms Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 150000001263 acyl chlorides Chemical class 0.000 description 10
- 238000010511 deprotection reaction Methods 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 8
- 206010003571 Astrocytoma Diseases 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 208000035269 cancer or benign tumor Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical group CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 7
- 102000048362 human PDCD1 Human genes 0.000 description 7
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 6
- QNCAUDDXPCGFLZ-UHFFFAOYSA-N 4-propan-2-yloxycyclohexane-1-carboxylic acid Chemical compound CC(C)OC1CCC(C(O)=O)CC1 QNCAUDDXPCGFLZ-UHFFFAOYSA-N 0.000 description 6
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 229960000473 altretamine Drugs 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 229910001873 dinitrogen Inorganic materials 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 102000048776 human CD274 Human genes 0.000 description 6
- 201000000849 skin cancer Diseases 0.000 description 6
- 239000012258 stirred mixture Substances 0.000 description 6
- DMQWBFBJIVODHX-UHFFFAOYSA-N tert-butyl 8-chloro-3,9-difluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound ClC=1C(=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1)F DMQWBFBJIVODHX-UHFFFAOYSA-N 0.000 description 6
- YLOSBJDLCXOSCC-UHFFFAOYSA-N tert-butyl 8-chloro-3-fluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound ClC=1C=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1 YLOSBJDLCXOSCC-UHFFFAOYSA-N 0.000 description 6
- PQUXXLGCBJLNMN-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-dioxin-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=COCCO1 PQUXXLGCBJLNMN-UHFFFAOYSA-N 0.000 description 5
- WAPFBFSGMCGIAL-UHFFFAOYSA-N 2-amino-5-fluoropyridine-3-carbaldehyde Chemical compound NC1=NC=C(F)C=C1C=O WAPFBFSGMCGIAL-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 108010024976 Asparaginase Proteins 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 5
- BRYGXQGKKVAJGB-ACNFANBVSA-N CC(C)O[C@H](CC1)CC[C@@H]1C(N(C1)C(C=C(C=C2)N3[C@@H](CC4)CO[C@@H]4C3)=C2NC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=N2)=O Chemical compound CC(C)O[C@H](CC1)CC[C@@H]1C(N(C1)C(C=C(C=C2)N3[C@@H](CC4)CO[C@@H]4C3)=C2NC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=N2)=O BRYGXQGKKVAJGB-ACNFANBVSA-N 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 206010014967 Ependymoma Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 5
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 5
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000012041 precatalyst Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- 229910052720 vanadium Inorganic materials 0.000 description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 4
- HIZVCIIORGCREW-UHFFFAOYSA-N 1,4-dioxene Chemical compound C1COC=CO1 HIZVCIIORGCREW-UHFFFAOYSA-N 0.000 description 4
- XIUOKZDKFRRRSA-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)piperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1CCN(CC(F)(F)F)CC1 XIUOKZDKFRRRSA-UHFFFAOYSA-N 0.000 description 4
- ORPVVAKYSXQCJI-UHFFFAOYSA-N 1-bromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1Br ORPVVAKYSXQCJI-UHFFFAOYSA-N 0.000 description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- AJAVGHSGEDSWLB-HCUBDLJJSA-N C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1[C@@H]3CO[C@H](C1)CC3)N=CC=C2 Chemical compound C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1[C@@H]3CO[C@H](C1)CC3)N=CC=C2 AJAVGHSGEDSWLB-HCUBDLJJSA-N 0.000 description 4
- 208000021309 Germ cell tumor Diseases 0.000 description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 4
- 229940124060 PD-1 antagonist Drugs 0.000 description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 4
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000003927 aminopyridines Chemical class 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YMICYRYUGTYYHS-UHFFFAOYSA-N tert-butyl 8-(1,4-dioxan-2-yl)-3,9-difluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(COCC1)C=1C(=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1)F YMICYRYUGTYYHS-UHFFFAOYSA-N 0.000 description 4
- NMZQETKSJVVTPC-UHFFFAOYSA-N tert-butyl 8-bromo-3-fluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C2=C(NCC3=C1N=CC(=C3)F)C=C(C=C2)Br NMZQETKSJVVTPC-UHFFFAOYSA-N 0.000 description 4
- AKNJFLTVVZCMCQ-UHFFFAOYSA-N tert-butyl 8-chloro-9-fluoro-6-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-5H-pyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound ClC=1C(=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F AKNJFLTVVZCMCQ-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- NHWSSAZMUGNDIO-UHFFFAOYSA-N 8-(1,4-dioxan-2-yl)-3-fluoro-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine Chemical compound O1C(COCC1)C=1C=CC2=C(NCC3=C(N2)N=CC(=C3)F)C=1 NHWSSAZMUGNDIO-UHFFFAOYSA-N 0.000 description 3
- PGDJXBUXUJIOBQ-UHFFFAOYSA-N 8-bromo-3-fluoro-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine Chemical compound BrC=1C=CC2=C(NCC3=C(N2)N=CC(=C3)F)C=1 PGDJXBUXUJIOBQ-UHFFFAOYSA-N 0.000 description 3
- MJYWSOMIJOJMKR-UHFFFAOYSA-N 8-methoxy-5-methyl-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine Chemical compound COC=1C=CC2=C(NC(C3=C(N2)N=CC=C3)C)C=1 MJYWSOMIJOJMKR-UHFFFAOYSA-N 0.000 description 3
- 102000015790 Asparaginase Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 201000005262 Chondroma Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- VXTQFXVJCJODHA-LSDHHAIUSA-N benzyl (2R,5S)-5-propan-2-yloxyoxane-2-carboxylate Chemical compound C(C)(C)O[C@H]1CC[C@@H](OC1)C(=O)OCC1=CC=CC=C1 VXTQFXVJCJODHA-LSDHHAIUSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000005263 juxtacortical chondroma Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 208000030883 malignant astrocytoma Diseases 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008184 oral solid dosage form Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 208000024975 periosteal chondroma Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 102200093149 rs77938727 Human genes 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 210000000239 visual pathway Anatomy 0.000 description 3
- 230000004400 visual pathway Effects 0.000 description 3
- LMELBOBWJBPENR-RYUDHWBXSA-N (1S,4S)-5-(9-fluoro-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepin-8-yl)-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound FC1=CC2=C(NCC3=C(N2)N=CC=C3)C=C1N1[C@@H]2CO[C@H](C1)C2 LMELBOBWJBPENR-RYUDHWBXSA-N 0.000 description 2
- DIQOUXNTSMWQSA-WHFBIAKZSA-N (1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1O[C@]2([H])CN[C@@]1([H])C2 DIQOUXNTSMWQSA-WHFBIAKZSA-N 0.000 description 2
- MNKCGUKVRJZKEQ-MIXQCLKLSA-N (1z,5z)-cycloocta-1,5-diene;iridium;methanol Chemical compound [Ir].[Ir].OC.OC.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 MNKCGUKVRJZKEQ-MIXQCLKLSA-N 0.000 description 2
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 2
- 0 *C(c1c(Nc2c(c(*)c3*)[Rn])nc(*)c([Rh])c1*)N(C(C1CC*CC1)=O)c2c3[Re] Chemical compound *C(c1c(Nc2c(c(*)c3*)[Rn])nc(*)c([Rh])c1*)N(C(C1CC*CC1)=O)c2c3[Re] 0.000 description 2
- WRGKKASJBOREMB-UHFFFAOYSA-N 1,4-dibromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1Br WRGKKASJBOREMB-UHFFFAOYSA-N 0.000 description 2
- QDVUOFGZUNMBBJ-UHFFFAOYSA-N 1-[2-(2-amino-4-methoxyanilino)pyridin-3-yl]ethanone Chemical compound NC1=C(C=CC(=C1)OC)NC1=NC=CC=C1C(C)=O QDVUOFGZUNMBBJ-UHFFFAOYSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- IBPDXAYILRNZRH-UHFFFAOYSA-N 1-bromo-4-chloro-5-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(F)C=C1Br IBPDXAYILRNZRH-UHFFFAOYSA-N 0.000 description 2
- OWIZXKLQAANVLT-UHFFFAOYSA-N 2-(2-amino-4-bromoanilino)-5-fluoropyridine-3-carbaldehyde Chemical compound NC1=C(C=CC(=C1)Br)NC1=NC=C(C=C1C=O)F OWIZXKLQAANVLT-UHFFFAOYSA-N 0.000 description 2
- IKULFYBCDGGVHE-UHFFFAOYSA-N 2-(4-bromo-2-nitroanilino)-5-fluoropyridine-3-carbaldehyde Chemical compound BrC1=CC(=C(C=C1)NC1=NC=C(C=C1C=O)F)[N+](=O)[O-] IKULFYBCDGGVHE-UHFFFAOYSA-N 0.000 description 2
- VVWKTXMXOHHKKV-UHFFFAOYSA-N 2-(4-chloro-5-fluoro-2-nitroanilino)-5-fluoropyridine-3-carbaldehyde Chemical compound ClC1=CC(=C(C=C1F)NC1=C(C=O)C=C(C=N1)F)[N+](=O)[O-] VVWKTXMXOHHKKV-UHFFFAOYSA-N 0.000 description 2
- KDTYKGBZNSYSAK-UHFFFAOYSA-N 2-(4-chloro-5-fluoro-2-nitroanilino)pyridine-3-carbaldehyde Chemical compound ClC1=CC(=C(C=C1F)NC1=C(C=O)C=CC=N1)[N+](=O)[O-] KDTYKGBZNSYSAK-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GNFWMEFWZWXLIN-UHFFFAOYSA-N 2-bromopyridine-3-carbaldehyde Chemical compound BrC1=NC=CC=C1C=O GNFWMEFWZWXLIN-UHFFFAOYSA-N 0.000 description 2
- OFBVGDCXXGXDKU-UHFFFAOYSA-N 2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=CC=C1C=O OFBVGDCXXGXDKU-UHFFFAOYSA-N 0.000 description 2
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 2
- JNYWVERKQKRXSL-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.2]octane Chemical compound C1NC2CCC1OC2 JNYWVERKQKRXSL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- QGMGHALXLXKCBD-UHFFFAOYSA-N 4-amino-n-(2-aminophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=CC=C1N QGMGHALXLXKCBD-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 2
- SAHBJONPSGLOED-UHFFFAOYSA-N 8-(2,3-dihydro-1,4-dioxin-5-yl)-3-fluoro-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine Chemical compound O1C(=COCC1)C=1C=CC2=C(NCC3=C(N2)N=CC(=C3)F)C=1 SAHBJONPSGLOED-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CQVVRGYSZMINDX-RZDIXWSQSA-N BrC=1C=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 Chemical compound BrC=1C=CC2=C(N(CC3=C(N2)N=CC=C3)C(=O)[C@@H]2CC[C@H](CC2)OC(C)C)C=1 CQVVRGYSZMINDX-RZDIXWSQSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VDZSEZWXVBCLAD-UHFFFAOYSA-N C(C)(=O)C=1C(=NC=CC=1)N(C(OC(C)(C)C)=O)C1=C(C=C(C=C1)Cl)[N+](=O)[O-] Chemical compound C(C)(=O)C=1C(=NC=CC=1)N(C(OC(C)(C)C)=O)C1=C(C=C(C=C1)Cl)[N+](=O)[O-] VDZSEZWXVBCLAD-UHFFFAOYSA-N 0.000 description 2
- IWUMAIYKKFOTRV-VHSXEESVSA-N C(C)(C)O[C@H]1CC[C@@H](OC1)C(=O)OCC Chemical compound C(C)(C)O[C@H]1CC[C@@H](OC1)C(=O)OCC IWUMAIYKKFOTRV-VHSXEESVSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- USJMNNRMXHKQAM-UHFFFAOYSA-N ClC1=CC(=C(C=C1)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F)[N+](=O)[O-] Chemical compound ClC1=CC(=C(C=C1)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F)[N+](=O)[O-] USJMNNRMXHKQAM-UHFFFAOYSA-N 0.000 description 2
- HFXZETFUVKERFN-UHFFFAOYSA-N ClC1=CC(=C(C=C1F)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F)[N+](=O)[O-] Chemical compound ClC1=CC(=C(C=C1F)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F)[N+](=O)[O-] HFXZETFUVKERFN-UHFFFAOYSA-N 0.000 description 2
- UXYHBAIXJSOEBI-UHFFFAOYSA-N ClC1=CC(=C(C=C1F)N(C(OC(C)(C)C)=O)C1=NC=CC=C1C=O)[N+](=O)[O-] Chemical compound ClC1=CC(=C(C=C1F)N(C(OC(C)(C)C)=O)C1=NC=CC=C1C=O)[N+](=O)[O-] UXYHBAIXJSOEBI-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- GNSVWCLGEHDKOX-UHFFFAOYSA-N N-(5-fluoropyridin-2-yl)-1,1-diphenylmethanimine Chemical compound C1(=CC=CC=C1)C(=NC1=NC=C(C=C1)F)C1=CC=CC=C1 GNSVWCLGEHDKOX-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MKAVMSBDEVPQLR-UHFFFAOYSA-N NC1=C(C=CC(=C1)Br)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F Chemical compound NC1=C(C=CC(=C1)Br)N(C(OC(C)(C)C)=O)C1=NC=C(C=C1C=O)F MKAVMSBDEVPQLR-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- 201000009365 Thymic carcinoma Diseases 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- MPFLAFDPSRRPLY-UHFFFAOYSA-N [8-(1,4-dioxan-2-yl)-3-fluoro-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-6-yl]-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methanone Chemical compound O1C(COCC1)C=1C=CC2=C(N(CC3=C(N2)N=CC(=C3)F)C(=O)C2CCN(CC2)CC(F)(F)F)C=1 MPFLAFDPSRRPLY-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229950005993 brivanib alaninate Drugs 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000012972 dimethylethanolamine Substances 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- VQRWRQYGTACTSK-UHFFFAOYSA-N ditert-butyl 8-chloro-3-fluoro-5H-pyrido[3,2-c][1,5]benzodiazepine-6,11-dicarboxylate Chemical compound ClC=1C=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C(=O)OC(C)(C)C)C=1 VQRWRQYGTACTSK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940003183 hexalen Drugs 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229940099279 idamycin Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000003866 lung sarcoma Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 2
- 229960003058 methotrexate sodium Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- DCHHGGYJXRRFGW-UHFFFAOYSA-N n-(5-fluoro-3-formylpyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=NC=C(F)C=C1C=O DCHHGGYJXRRFGW-UHFFFAOYSA-N 0.000 description 2
- WIAYCNUDQFSZFQ-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(F)C=N1 WIAYCNUDQFSZFQ-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical class [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229940063179 platinol Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012363 selectfluor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- AIJWTMUAMWOTAX-UHFFFAOYSA-N tert-butyl 3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound FC1=CC2=C(N(C3=C(NC2)C=C(C(=C3)F)N2CC3(C2)COCCC3)C(=O)OC(C)(C)C)N=C1 AIJWTMUAMWOTAX-UHFFFAOYSA-N 0.000 description 2
- YTOFDXKBAIWLER-UHFFFAOYSA-N tert-butyl 8-(1,4-dioxan-2-yl)-3-fluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(COCC1)C=1C=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1 YTOFDXKBAIWLER-UHFFFAOYSA-N 0.000 description 2
- WMHKZFZQMYYPJA-UHFFFAOYSA-N tert-butyl 8-(2,3-dihydro-1,4-dioxin-5-yl)-3,9-difluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(=COCC1)C=1C(=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1)F WMHKZFZQMYYPJA-UHFFFAOYSA-N 0.000 description 2
- BQATYRCXAZQBMN-UHFFFAOYSA-N tert-butyl 8-(2,3-dihydro-1,4-dioxin-5-yl)-3-fluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(=COCC1)C=1C=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC(=C3)F)C=1 BQATYRCXAZQBMN-UHFFFAOYSA-N 0.000 description 2
- BOPISRKBEAWTMU-UHFFFAOYSA-N tert-butyl 8-(2,3-dihydro-1,4-dioxin-5-yl)-9-fluoro-6-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-5H-pyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(=COCC1)C=1C(=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F BOPISRKBEAWTMU-UHFFFAOYSA-N 0.000 description 2
- MTECEWFDFDQDTI-UHFFFAOYSA-N tert-butyl 8-chloro-5-methyl-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound ClC=1C=CC2=C(NC(C3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C)C=1 MTECEWFDFDQDTI-UHFFFAOYSA-N 0.000 description 2
- OULXKMIDERCMSU-UHFFFAOYSA-N tert-butyl 8-chloro-9-fluoro-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound ClC=1C(=CC2=C(NCC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C=1)F OULXKMIDERCMSU-UHFFFAOYSA-N 0.000 description 2
- UYOLJLDNRCEVED-UHFFFAOYSA-N tert-butyl 9-fluoro-8-(1-methylpyrazol-4-yl)-6-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-5H-pyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound FC1=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1C=1C=NN(C=1)C UYOLJLDNRCEVED-UHFFFAOYSA-N 0.000 description 2
- DVPUELRTTLHFMU-GJZGRUSLSA-N tert-butyl 9-fluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-5,6-dihydropyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound CC(C)(C)OC(=O)N1c2cc(F)c(cc2NCc2cccnc12)N1C[C@@H]2C[C@H]1CO2 DVPUELRTTLHFMU-GJZGRUSLSA-N 0.000 description 2
- UGZPFICGUFJHID-UHFFFAOYSA-N tert-butyl N-(3-acetylpyridin-2-yl)-N-(2-amino-4-chlorophenyl)carbamate Chemical compound C(C)(=O)C=1C(=NC=CC=1)N(C(OC(C)(C)C)=O)C1=C(C=C(C=C1)Cl)N UGZPFICGUFJHID-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KFUSEUYYWQURPO-UHFFFAOYSA-N 1,2-dichloroethene Chemical compound ClC=CCl KFUSEUYYWQURPO-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- UQPXYEYBUROSJF-UHFFFAOYSA-N 1,6-diazaspiro[3.3]heptane Chemical compound N1CCC11CNC1 UQPXYEYBUROSJF-UHFFFAOYSA-N 0.000 description 1
- VYJZSPNXTDPUJW-UHFFFAOYSA-N 1-(2-bromopyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=CN=C1Br VYJZSPNXTDPUJW-UHFFFAOYSA-N 0.000 description 1
- KEEHTCBOJCVCNO-UHFFFAOYSA-N 1-(2-fluoropyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=CN=C1F KEEHTCBOJCVCNO-UHFFFAOYSA-N 0.000 description 1
- UKTIMFAJRPSNGR-UHFFFAOYSA-N 1-bromo-4-chloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1Br UKTIMFAJRPSNGR-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 1
- KVYOWXUQJLOCIA-UHFFFAOYSA-N 1-oxa-8-azaspiro[4.5]decane Chemical compound C1CCOC21CCNCC2 KVYOWXUQJLOCIA-UHFFFAOYSA-N 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- DJWDAKFSDBOQJK-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.2]octane Chemical compound C1NC2CCC1NC2 DJWDAKFSDBOQJK-UHFFFAOYSA-N 0.000 description 1
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- QOGXQLSFJCIDNY-UHFFFAOYSA-N 2-chloro-5-fluoropyridine Chemical compound FC1=CC=C(Cl)N=C1 QOGXQLSFJCIDNY-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- PWHSLHBTQUHNGP-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.2]octane;oxalic acid Chemical compound OC(=O)C(O)=O.C1NC2CCC1OC2.C1NC2CCC1OC2 PWHSLHBTQUHNGP-UHFFFAOYSA-N 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- XYFRHHAYSXIKGH-UHFFFAOYSA-N 3-(5-methoxy-2-methoxycarbonyl-1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=C(OC)C=C2C(C=CC(O)=O)=C(C(=O)OC)NC2=C1 XYFRHHAYSXIKGH-UHFFFAOYSA-N 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N 3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1OCC2CCC1N2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- PBGKNXWGYQPUJK-UHFFFAOYSA-N 4-chloro-2-nitroaniline Chemical compound NC1=CC=C(Cl)C=C1[N+]([O-])=O PBGKNXWGYQPUJK-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NEDNLJNECQUGFI-UHFFFAOYSA-N 5-oxa-6-azabicyclo[2.1.1]hexane Chemical compound C1CC2OC1N2 NEDNLJNECQUGFI-UHFFFAOYSA-N 0.000 description 1
- BDHMQGDCUCSDHX-UHFFFAOYSA-N 6-oxa-2-azaspiro[3.4]octane Chemical compound C1NCC11COCC1 BDHMQGDCUCSDHX-UHFFFAOYSA-N 0.000 description 1
- LKXLRIJAPMIXGR-UHFFFAOYSA-N 6-oxa-2-azaspiro[3.5]nonane Chemical compound C1NCC11COCCC1 LKXLRIJAPMIXGR-UHFFFAOYSA-N 0.000 description 1
- WDJAQSJMDRFZIX-UHFFFAOYSA-N 6-oxa-3-azabicyclo[3.1.1]heptane Chemical compound C1NCC2CC1O2 WDJAQSJMDRFZIX-UHFFFAOYSA-N 0.000 description 1
- SFMSJIJLKWISQE-UHFFFAOYSA-N 7-oxa-2,5-diazaspiro[3.4]octane Chemical compound C1NCC11NCOC1 SFMSJIJLKWISQE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
- PWMXAJGXKNTFMF-UHFFFAOYSA-N 8-bromo-6,11-dihydro-5H-pyrido[3,2-c][1,5]benzodiazepine Chemical compound BrC=1C=CC2=C(NCC3=C(N2)N=CC=C3)C=1 PWMXAJGXKNTFMF-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N 8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1O2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010073127 Anaplastic meningioma Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- AJAVGHSGEDSWLB-OTUUDDROSA-N C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1[C@H]3CO[C@@H](C1)CC3)N=CC=C2 Chemical compound C(C)(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1[C@H]3CO[C@@H](C1)CC3)N=CC=C2 AJAVGHSGEDSWLB-OTUUDDROSA-N 0.000 description 1
- YVYSFZYPEXFPDS-UHFFFAOYSA-N C(CNC1)C11NCOC1 Chemical compound C(CNC1)C11NCOC1 YVYSFZYPEXFPDS-UHFFFAOYSA-N 0.000 description 1
- RTTGLASBVVBBNJ-UHFFFAOYSA-N C1NC1N(CC1)CCC11OCCC1 Chemical compound C1NC1N(CC1)CCC11OCCC1 RTTGLASBVVBBNJ-UHFFFAOYSA-N 0.000 description 1
- GOECQBIGQRLRMR-KYZUINATSA-N CC(C)O[C@@H]1CC[C@H](CC1)C(=O)Cl Chemical compound CC(C)O[C@@H]1CC[C@H](CC1)C(=O)Cl GOECQBIGQRLRMR-KYZUINATSA-N 0.000 description 1
- AJAVGHSGEDSWLB-SRVRYNIDSA-N CC(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1C3COC(C1)CC3)N=CC=C2 Chemical compound CC(C)O[C@@H]1CC[C@H](CC1)C(=O)N1CC2=C(NC3=C1C=C(C=C3)N1C3COC(C1)CC3)N=CC=C2 AJAVGHSGEDSWLB-SRVRYNIDSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000202285 Claravis Species 0.000 description 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 101100224482 Drosophila melanogaster PolE1 gene Proteins 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000012247 Oligodendroglial tumor Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 201000007288 Pleomorphic xanthoastrocytoma Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NPIHYFCXNIDUJZ-UHFFFAOYSA-N [2-chloro-6-[2,6-di(propan-2-yloxy)phenyl]phenyl]-dicyclohexylphosphane Chemical group ClC=1C(=C(C=CC=1)C1=C(C=CC=C1OC(C)C)OC(C)C)P(C1CCCCC1)C1CCCCC1 NPIHYFCXNIDUJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940022824 amnesteem Drugs 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 208000014534 anaplastic ependymoma Diseases 0.000 description 1
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- QJKJIULTPCUPFN-UHFFFAOYSA-M bis(1-adamantyl)-butylphosphane chloropalladium(1+) 2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 QJKJIULTPCUPFN-UHFFFAOYSA-M 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FINPLSBBDVRBPA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-methoxy-2-methylpropane;2-phenylethanamine Chemical compound [Pd+]Cl.COC(C)(C)C.NCCC1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FINPLSBBDVRBPA-UHFFFAOYSA-M 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940031301 claravis Drugs 0.000 description 1
- 229940060799 clarus Drugs 0.000 description 1
- 201000000292 clear cell sarcoma Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229940059359 dacogen Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229940052372 daunorubicin citrate liposome Drugs 0.000 description 1
- 229940041983 daunorubicin liposomal Drugs 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- FAZJABPYGSTHCD-UHFFFAOYSA-N dicyclohexyl-[2-(2,6-dipropoxyphenyl)phenyl]phosphane Chemical group CCCOC1=CC=CC(OCCC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FAZJABPYGSTHCD-UHFFFAOYSA-N 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- FAFFTXUYPBPPKZ-UHFFFAOYSA-N ditert-butyl 8-chloro-9-fluoro-5H-pyrido[3,2-c][1,5]benzodiazepine-6,11-dicarboxylate Chemical compound ClC=1C(=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)OC(C)(C)C)C=1)F FAFFTXUYPBPPKZ-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- LUBZMSYQUPSNNY-UHFFFAOYSA-N ethyl 5-oxooxane-2-carboxylate Chemical compound CCOC(=O)C1CCC(=O)CO1 LUBZMSYQUPSNNY-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 201000011610 giant cell glioblastoma Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 102000055869 human IDH1 Human genes 0.000 description 1
- 102000012084 human isocitrate dehydrogenase 2 Human genes 0.000 description 1
- 108010036396 human isocitrate dehydrogenase 2 Proteins 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 201000004057 myxopapillary ependymoma Diseases 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000003538 neomorphic effect Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 208000013937 oligoastrocytic tumor Diseases 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- UFSCUAXLTRFIDC-UHFFFAOYSA-N oxalosuccinic acid Chemical compound OC(=O)CC(C(O)=O)C(=O)C(O)=O UFSCUAXLTRFIDC-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 1
- 229960005415 pasireotide Drugs 0.000 description 1
- 108700017947 pasireotide Proteins 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229940034345 sotret Drugs 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940099419 targretin Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NIFYXJIUWRFPMN-UHFFFAOYSA-N tert-butyl 8-(1,4-dioxan-2-yl)-9-fluoro-6-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-5H-pyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound O1C(COCC1)C=1C(=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=1)F NIFYXJIUWRFPMN-UHFFFAOYSA-N 0.000 description 1
- WPBHVPWGKKROPZ-UHFFFAOYSA-N tert-butyl 9-fluoro-6-[1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-5H-pyrido[3,2-c][1,5]benzodiazepine-11-carboxylate Chemical compound FC1=CC2=C(N(CC3=C(N2C(=O)OC(C)(C)C)N=CC=C3)C(=O)C2CCN(CC2)CC(F)(F)F)C=C1 WPBHVPWGKKROPZ-UHFFFAOYSA-N 0.000 description 1
- SWAXTRYEYUTSAP-UHFFFAOYSA-N tert-butyl ethaneperoxoate Chemical compound CC(=O)OOC(C)(C)C SWAXTRYEYUTSAP-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229940035307 toposar Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 229940111528 trexall Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- NNLPAMPVXAPWKG-UHFFFAOYSA-N trimethyl(1-methylethoxy)silane Chemical compound CC(C)O[Si](C)(C)C NNLPAMPVXAPWKG-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053890 zanosar Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- Isocitrate dehydrogenase is a family of enzymes found in cellular metabolism. They are NADP + /NAD + and metal dependent oxidoreductases of the enzyme class EC 1.1.1.42.
- the wild type proteins catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, generating carbon dioxide and NADPH/NADH in the process. They are also known to convert oxalosuccinate into alpha-ketoglutarate.
- IDH1 cytosolic
- IDH2 mitochondrial
- glioma glioblastoma multiforme
- paraganglioma supratentorial primordial neuroectodermal tumors
- AML acute myeloid leukemia
- prostate cancer thyroid cancer
- colon cancer colon cancer
- chondrosarcoma cholangiocarcinoma
- peripheral T-cell lymphoma melanoma.
- novel tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. Also disclosed herein are uses of these novel tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of such cancers. DETAILED DESCRIPTION OF THE INVENTION
- A is–CH(R 1 )- or–N(R 2 )-;
- R 1 is selected from the group consisting of hydrogen,–O-C 1-10 alkyl, and C 1-10 alkyl optionally substituted with one to four halogens;
- R 2 is selected from the group consisting of hygrogen, -S(O) 2 -C 1-4 alkyl, and C 1-10 alkyl optionally substituted with one to four halogens;
- B is–CH 2 - or -O-;
- R is selected from the group consisting of:
- R x and R y are independently selected from the group consisting of (a) hydrogen and (b) C 1-6 alkyl, optionally substituted with one to four substituents independently selected from halogen and heterocyclyl; wherein the heterocyclyl is optionally substituted with one to four substituents independently selected from methyl, ethyl, propyl, butyl, -CH 2 -Cl, -CH 2 -F, - CH 2 CH 2 -Cl, -CH 2 CH 2 -F, and–CH 2 CF 3 ; and
- heterocyclyl optionally substituted with one to four substituents independently selected from halogen, hydroxyl, -C 1-10 alkyl, and–O-C 1-10 alkyl;
- R e is selected from the group consisting of:
- R f , R , R h , R m , R n and R is independently selected from the group consisting of:
- each occurrence of a heterocyclyl is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 2-azaspiro[3.3]heptanyl, azaindolyl, 1,6-diazaspiro[3.3]heptanyl, 2,3-dihydro-1,4-dioxinyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, hexahydro- 1H-furo[3,4-c]pyrrolyl, imidazolyl, isoxazolyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa
- each occurrence of a heterocyclyl is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl, pyrazolyl, and tetrahydropyranyl.
- the compounds of formula (I) :
- A is–CH(R 1 )- or–N(R 2 )-;
- R 1 is selected from the group consisting of hydrogen, -C 1-6 alkyl and– O-C 1-6 alkyl;
- R 2 is selected from the group consisting of hygrogen, methyl, ethyl, propyl, butyl,–CH 2 CF 3 , and -S(O) 2 -C 1-4 alkyl;
- B is–CH 2 - or -O-.
- A is–CH(R 1 )- or–N(R 2 )-;
- R 1 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, -O-methyl,–O-ethyl,–O-propyl and–O-isopropyl;
- R 2 is selected from the group consisting of hygrogen,–CH 2 CF 3 , and -S(O) 2 -ethyl;
- B is–CH 2 - or -O-.
- R is selected from the group consisting of:
- R y is selected from the group consisting of (a) hydrogen and (b) C 1-4 alkyl, optionally substituted with one to four substituents independently selected from halogen and heterocyclyl; wherein the heterocyclyl is optionally substituted with methyl, ethyl, propyl, -CH 2 -Cl, -CH 2 -F, or–CH 2 CF 3 ; and (6) heterocyclyl, optionally substituted with one to four substituents independently selected from halogen, hydroxyl, -C 1-6 alkyl, and–O-C 1-6 alkyl.
- R is selected from the group consisting of:
- heterocyclyl optionally substituted with one to four substituents independently selected from halogen, C 1-4 alkyl, and -O-C 1-4 alkyl; wherein each occurrence of the heterocyclyl of (4) and (5) is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 2- azaspiro[3.3]heptanyl, azaindolyl, 1,6-diazaspiro[3.3]heptanyl, 2,3-dihydro-1,4- dioxinyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, hexahydro-1H- furo[3,4-c]pyrrolyl, imidazolyl, isoxazolyl, morpholinyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 6-
- R is selected from the group consisting of:
- heterocyclyl optionally substituted with one to two substituents independently selected from–F, -Cl, methyl, ethyl, propyl,–O-methyl,–O-ethyl, and–O-propyl; wherein each occurrence of the heterocyclyl of (7) and (8) is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl,
- R is selected from the group consisting of:
- heterocyclyl optionally substituted with one to two substituents independently selected from -Cl, -F, methyl, ethyl, propyl,–O-methyl,–O-ethyl, and–O-propyl; wherein the heterocyclyl is selected from the group consisting of 2- azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro- 3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
- R e is hydrogen, -F, -Cl, methyl or ethyl
- R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
- R e is -F, -Cl, methyl or ethyl
- R f , R g , R h , R m , R n and R p is hydrogen.
- R e is hydrogen
- each of R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
- A is–CH(R 1 )- or–N(R 2 )-;
- R 1 is selected from the group consisting of hydrogen, methyl, -O- methyl, -O-ethyl and–O-propyl and–O-isopropyl;
- R 2 is selected from the group consisting of hygrogen,–CH 2 CF 3 , and-S(O) 2 -ethyl;
- B is–CH 2 - or -O-;
- R is selected from the group consisting of:
- heterocyclyl optionally substituted with one to two substituents independently selected from -Cl, -F, methyl, ethyl, propyl,–O-methyl,–O-ethyl,–O-propyl and –O-isopropyl;
- heterocyclyl is selected from the group consisting of 2- azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro- 3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl;
- R e is hydrogen, -Cl, -F, methyl or ethyl
- R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
- a compound disclosed herein is of formula (Ia), or a pharmaceutically acceptable salt thereof:
- A is–CH(R 1 )- or–N(R 2 )-;
- R 1 is selected from the group consisting of hydrogen, methyl, -O- propyl and–O-isopropryl;
- R 2 is–CH 2 CF 3 or -S(O) 2 -ethyl;
- R e is hydrogen, -Cl, -F, methyl or ethyl
- R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
- R is as defined for formula (I).
- R e is–F or methyl
- R e is hydrogen
- each of R m and R n is hydrogen
- each of R f , R g , R h , and R p is independently selected from the group consisting of:
- a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof:
- A is–CH(R 1 )-; and R 1 is -O-propyl or–O-isopropyl;
- R e is hydrogen
- each of R h and R p is independently selected from the group consisting of:
- R is as defined for formula (I).
- R is a heterocyclyl selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6- oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
- a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof, wherein:
- A is–CH(R 1 )-; and R 1 is -O-propyl or–O-isopropyl;
- R e is hydrogen
- each of R h and R p is independently selected from the group consisting of:
- R is a heterocyclyl selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8- azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
- a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof, wherein:
- A is–CH(R 1 )-; and R 1 is -O-propyl or–O-isopropyl;
- R e is hydrogen
- R h is -F or–Cl
- R is a heterocyclyl selected from the group consisting of 1,4-dioxanyl, morpholinyl, oxazolidinyl and pyrazolyl.
- a compound is selected from the group consisting of:
- a compound disclosed herein or a pharmaceutically acceptable salt thereof is used in medicine.
- composition which comprises an inert carrier or excipient and a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof.
- a method for treating or preventing a disease or disorder associated with mutant IDH enzyme activity in a subject which comprises administering to the subject an effective amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof.
- a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of a disease or disorder associated with mutant IDH enzyme activity.
- a method for treating a disease or disorder associated with mutant IDH enzyme activity in a subject comprises administering to the subject an effective amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, in combination with another anti-cancer agent.
- the disease or disorder associated with mutant IDH enzyme activity is cancer.
- the cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), breast cancer, prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma.
- the cancer is selected from glioma, glioblastoma multiforme, acute myeloid leukemia and breast cancer.
- Alkyl refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups of 1 to 18 carbon atoms, or more specifically, 1 to 12 carbon atoms.
- Examples of such groups include, but are not limited to, methyl (Me), ethyl (Et), n-propyl (Pr), n-butyl (Bu), n-pentyl, n-hexyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), sec-butyl (s-Bu), tert-butyl (t-Bu), isopentyl, and isohexyl.
- Alkyl groups may be optionally substituted with one or more substituents as defined herein.“C 1-66 alkyl” refers to an alkyl group as defined herein having 1 to 6 carbon atoms.
- Halo or“halogen” refers to fluoro, chloro, bromo or iodo, unless otherwise noted.
- Heterocycle refers to a saturated, partially unsaturated or aromatic ring moiety having at least one ring heteroatom and at least one ring carbon atom.
- the heteroatom is oxygen, sulfur, or nitrogen.
- a heterocycle containing more than one heteroatom may contain different heteroatoms.
- Heterocyclyl moieties include both monocyclic and multicyclic (e.g., bicyclic) ring moieties.
- Bicyclic ring moieties include fused, spirocycle and bridged bicyclic rings and may comprise one or more heteroatoms in either of the rings.
- the ring attached to the remainder of the molecule may or may not contain a heteroatom.
- Either ring of a bicyclic heterocycle may be saturated, partially unsaturated or aromatic.
- the heterocycle may be attached to the rest of the molecule via a ring carbon atom, a ring oxygen atom or a ring nitrogen atom. Non-limiting examples of heterocycles are described below.
- partially unsaturated and aromatic 4-7 membered monocyclic heterocyclyl moieties include, but are not limited to, 2,3-dihydro-1,4-dioxinyl, dihydropyranyl, dihydropyrazinyl, dihydropyridazinyl, dihydropyridinyl, dihydropyrimidinyl, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydropyrazinyl, tetrahydropyridazinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrazolyl, thiadiazolyl, thiazolyl, thiazolyl
- saturated 4-7 membered monocyclic heterocyclyl moieties include, but are not limited to, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, morpholinyl, 1,4- oxazepanyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiomorpholinyl, tetrahydrothienyl, and
- a heterocyclyl is a spirocycle (“spiro”) bicyclic moiety wherein two rings are connected through one atom, and either or both of the rings comprise at least one heteroatom.
- a spiro bicyclic heterocycle comprises a 4-7 membered heterocyclic ring comprising 1-4 heteroatoms selected from oxygen, sulfur and nitrogen connected through a single atom to either a 3-6 membered ring comprising 1-2 heteroatoms selected from oxygen, sulfur and nitrogen or a 3-6 membered carbocyclic ring.
- Exemplary spiro heteroc cles of this type include, but are not limited to: (2- azaspiro[3.3]heptane), (2-oxa-6-azaspiro[3.3]heptane), (1,6- diazaspiro[3.3]heptane), (2,6-diazaspiro[3.3]heptane), (6-oxa-2- azaspiro[3.4]octane), (7-oxa-2,5-diazaspiro[3.4]octane), (6-oxa-2- azaspiro[3.5]nonanyl), -oxa-1,7-diazaspiro[4.4]nonane), (4-oxa-7-
- Such spiro bicyclic moieties may be attached to the rest of the molecule via a carbon atom or a nitrogen atom on either ring.
- a heterocycle is a bridged bicyclic moiety selected from the group consisting of: (6-oxa-3-azabicyclo[3.1.1]heptane), (8-oxa-3- azabicyclo[3.2.1]octane), (2-oxa-5-azabicyclo[2.2.2]octane), (3-oxa-8- azabicyclo[3.2.1]octane), (2-oxa-5-azabicyclo[2.2.1]heptane), (3,8- diazabicyclo[3.2.1]octane), (2,5-diazabicyclo[2.2.2]octane), (8- azabicyclo[3.2.1]octane), and (5-oxa-6-azabicyclo[2.1.1]hexane).
- Such bridged bicyclic moieties may be attached to the rest of the molecule via a carbon atom or a nitrogen atom on either ring.
- Heterocyclic groups may be optionally substituted with one or more substituents as defined herein.
- Optionally substituted refers to“unsubstituted or substituted,” and therefore, the generic structural formulas described herein encompass compounds containing the specified optional substituent(s) as well as compounds that do not contain the optional substituent(s). Each substituent is independently defined each time it occurs within the generic structural formula definitions.
- a compound of formula (I), including a salt or solvate thereof may exist in crystalline form, non-crystalline form, or a mixture thereof.
- a compound or a salt or solvate thereof may also exhibit polymorphism, i.e. the capacity of occurring in different crystalline forms. These different crystalline forms are typically known as "polymorphs". Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, all of which may be used for identification.
- isomers refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution
- a compound of formula (I) may have one or more asymmetric carbon atom and may occur as a racemic mixture or as individual enantiomers or diastereomers. All such isomeric forms are included herein, including mixtures thereof. If a compound of formula (I) contains a double bond, the substituent may be in the E or Z configuration. If a compound of formula (I) contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans- configuration. All tautomeric forms are also intended to be included.
- any asymmetric atom (e.g., carbon) of a compound of formula (I) can be present in racemic mixture or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration.
- each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)- configuration.
- Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
- a compound of formula (I) can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
- Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
- any resulting racemates of the final compounds of the examples or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
- a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor- 10-sulfonic acid. Racemic compounds can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
- HPLC high pressure liquid chromatography
- Compounds of formula (I) include unlabeled forms, as well as isotopically labeled forms.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as 2 H (i.e., Deuterium or“D”), 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl.
- the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
- isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- substitution with positron emitting isotopes such as 11 C, 18 F, 15 O and 13 N, may be particularly desirable for PET or SPECT studies.
- Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art. Furthermore, substitution with heavier isotopes, particularly deuterium (i.e., 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
- Pharmaceutically Acceptable Salts particularly deuterium (i.e., 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
- salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particular embodiments include ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N ' -dibenzylethylene-diamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl- morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine,
- basic ion exchange resins such as arginine, betaine, caffeine, choline, N,N ' -dibenzylethylene-diamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethy
- a salt may be prepared from a pharmaceutically acceptable non-toxic acid, including an inorganic and organic acid.
- Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, trifluoroacetic acid (TFA) and the like.
- Particular embodiments include the citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, tartaric and
- the compounds disclosed herein are inhibitors of a mutant IDH enzyme. These compounds are potentially useful in treating diseases or disorders associated with such enzymes including, but not limited to, cell proliferation disorders, such as cancer.
- mutant IDH1 and mutant IDH2 are mutant IDH1 and mutant IDH2.
- a mutation in human IDH1 enzyme includes a mutation at amino acid residue 97, 100, or 132, e.g. G97D, R100Q, R132H, R132C, R132S, R132G, R132L, or R132V.
- a mutation in human IDH2 enzyme includes a mutation at amino acid residue 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, or R172W.
- Cell-proliferation disorders that may be associated with a mutant IDH enzyme activity include, but are not limited to, cancer.
- cancers include, but are not limited to, Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Adrenocortical Carcinoma; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma; Bile Duct Cancer; Bladder Cancer; Bone Cancer, Osteosarcoma/Malignant Fibrous
- Brain Tumor Cerebellar Astrocytoma
- Brain Tumor Cerebral Astrocytoma/Malignant Glioma
- Brain Tumor Ependymoma
- Brain Tumor Ependymoma
- Adenomas/Carcinoids Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Central Nervous System Lymphoma, Primary; Cerebral Astrocytoma/Malignant Glioma; Cervical Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer; Ewing's Family of Tumors; Extracranial Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach)
- Glioma Childhood Brain Stem; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer; Hodgkin's Lymphoma; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Leukemia, Acute Lymphoblastic; Leukemia, Acute Myeloid; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia; Lymphoma, AIDS- Related; Lymphoma, Central Nervous System (Primary);
- Lymphoma Cutaneous T-Cell; Lymphoma, Hodgkin's; Lymphoma, Hodgkin's During
- Lymphoma Non-Hodgkin's
- Lymphoma Primary Central Nervous System
- Macroglobulinemia Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer; Oral Cancer; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; steosar
- Neoplasm/Multiple Myeloma Pleuropulmonary Blastoma; Pregnancy and Breast Cancer;
- Pregnancy and Hodgkin's Lymphoma Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma; Salivary Gland Cancer; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Soft Tissue; Sezary Syndrome; Skin Cancer; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Supratentorial Primitive
- T- Cell Lymphoma Cutaneous; Testicular Cancer; Thymoma, Malignant; Thyroid Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter;
- Trophoblastic Tumor Gestational; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.
- a cancer potentially associated with mutant IDH enzyme activity is brain cancer, such as an astrocytic tumor (e.g., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma); oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma); oligoastrocytic tumor (e.g.,
- oligoastrocytoma oligoastrocytoma, and anaplastic oligoastrocytoma
- ependymoma e.g., myxopapillary ependymoma, and anaplastic ependymoma
- medulloblastoma primitive neuroectodermal tumor, schwannoma, meningioma, meatypical meningioma, anaplastic meningioma
- pituitary adenoma adenoma
- the brain cancer is glioma, glioblastoma multiforme, paraganglioma, or suprantentorial primordial neuroectodermal tumors (sPNET).
- sPNET suprantentorial primordial neuroectodermal tumors
- a cancer potentially associated with mutant IDH enzyme activity is leukemia, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML, post-MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma and acute lymphoblastic leukemia.
- AML acute myeloid leukemia
- MDS myelodysplastic syndrome
- CML chronic myelogenous leukemia
- MPN myeloproliferative neoplasm
- post-MPN AML post-MPN AML
- post-MDS AML post-MDS AML
- del(5q)-associated high risk MDS or AML blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphom
- a cancer potentially associated with mutant IDH enzyme activity is skin cancer, including melanoma.
- a cancer potentially associated with mutant IDH enzyme activity is prostate cancer, breast cancer, thyroid cancer, colon cancer, or lung cancer.
- a cancer potentially associated with mutant IDH enzyme activity is sarcoma, including central chondrosarcoma, central and periosteal chondroma, and fibrosarcoma.
- a cancer potentially associated with mutant IDH enzyme activity is cholangiocarcinoma.
- a subject administered with a compound disclosed herein, or a pharmaceutically acceptable salt thereof is generally a mammal, such as a human being, male or female.
- a subject also refers to cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, and birds. In one embodiment, the subject is a human.
- treatment refers to all processes wherein there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of a disease or disorder described herein that may be associated with mutant IDH enzyme activity.
- the terms do not necessarily indicate a total elimination of all disease or disorder symptoms.
- the terms also include the potential prophylactic therapy of the mentioned conditions, particularly in a subject that is predisposed to such disease or disorder.
- administering should be understood to include providing a compound described herein, or a pharmaceutically acceptable salt thereof, and compositions of the foregoing to a subject.
- the amount of a compound administered to a subject is an amount sufficient to inhibit mutant IDH enzyme activity in the subject.
- the amount of a compound can be an“effective amount”, wherein the subject compound is administered in an amount that will elicit a biological or medical response of a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- An effective amount does not necessarily include considerations of toxicity and safety related to the administration of a compound. It is recognized that one skilled in the art may affect physiological disorders associated with an IDH mutation by treating a subject presently afflicted with the disorders, or by prophylactically treating a subject likely to be afflicted with the disorders, with an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
- An effective amount of a compound will vary with the particular compound chosen (e.g. considering the potency, efficacy, and/or half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the subject being treated; the medical history of the subject being treated; the duration of the treatment; the nature of a concurrent therapy; the desired therapeutic effect; and like factors and can be routinely determined by the skilled artisan.
- the compounds disclosed herein may be administered by any suitable route including oral and parenteral administration.
- Parenteral administration is typically by injection or infusion and includes intravenous, intramuscular, and subcutaneous injection or infusion.
- the compounds disclosed herein may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound disclosed herein depend on the pharmacokinetic properties of that compound, such as absorption, distribution and half-life which can be determined by a skilled artisan.
- suitable dosing regimens including the duration such regimens are administered, for a compound disclosed herein depend on the disease or condition being treated, the severity of the disease or condition, the age and physical condition of the subject being treated, the medical history of the subject being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual subject's response to the dosing regimen or over time as the individual subject needs change. Typical daily dosages may vary depending upon the particular route of administration chosen. Typical daily dosages for oral administration, to a human weighing approximately 70 kg would range from about 0.1 mg to about 2 grams, or more specifically, 0.1 mg to 500 mg, or even more specifically, 0.2 mg to 100 mg, of a compound of formula (I).
- One embodiment of the present invention provides for a method of treating a disease or disorder associated with mutant IDH enzyme activity comprising administration of an effective amount of a compound of formula (I) to a subject in need of treatment thereof.
- the disease or disorder associated with a mutant IDH enzyme is a cell proliferation disorder.
- the cell proliferation disorder is cancer.
- the cancer is a cancer associated with mutant IDH1 enzyme activity.
- the cancer is associated with human mutant IDH1 enzyme activity, having a mutation at amino acid residue 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, or R132V.
- the cancer is associated with human mutant IDH2 enzyme activity having a mutation at amino acid residue 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, or R172W.
- the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma.
- the cancer is glioma, glioblastoma multiforme, paraganglioma, suprantentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, breast, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.
- a compound of formula (I) in a therapy.
- the compound may be useful in a method of inhibiting mutant IDH enzyme activity in a subject, such as a mammal in need of such inhibition, comprising administering an effective amount of the compound to the subject.
- a pharmaceutical composition comprising at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in potential treatment of a disorder or disease related to mutant IDH1 enzyme activity.
- a compound of formula (I) in the manufacture of a medicament for the treatment of a disease or disorder associated with mutant IDH enzyme activity.
- the disease or disorder associated with a mutant IDH is a cell proliferation disorder.
- the cell proliferation disorder is cancer.
- the cancer is brain cancer, leukemia, skin cancer, breast, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma.
- the cancer is glioma, glioblastoma multiforme, paraganglioma, suprantentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, breast, prostate, thyroid, colon, lung, central
- chondrosarcoma central and periosteal chondroma tumors, fibrosarcoma, and/or
- composition as used herein is intended to encompass a dosage form comprising a specified compound in a specified amount, as well as any dosage form which results, directly or indirectly, from combination of a specified compound in a specified amount. Such term is intended to encompass a dosage form comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. Accordingly, the compositions of the present invention encompass any composition made by admixing a compound of the present invention and one or more pharmaceutically acceptable carrier or excipients. By “pharmaceutically acceptable” it is meant the carriers or excipients are compatible with the compound disclosed herein and with other ingredients of the composition.
- compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
- the composition may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to a subject, such as with powders or syrups.
- the composition may be prepared and packaged in unit dosage form wherein each physically discrete unit contains an effective amount of a compound of formula (I).
- the composition of the invention typically contains from about 0.1 mg to 2 grams, or more specifically, 0.1 mg to 500 mg, or even more specifically, 0.2 mg to 100 mg, of a compound of formula (I), or a
- dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution.
- suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen.
- suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition. For example, certain
- pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the carrying or transporting of a compound disclosed herein, once administered to the subject, from one organ or portion of the body to another organ or another portion of the body. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to enhance patient compliance.
- Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, lubricants, binders, disintegrants, fillers, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
- compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
- the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
- Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives, (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
- the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
- the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
- the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
- dosage unit formulations for oral administration can be microencapsulated.
- the composition can also be prepared to prolong or sustain the release as, for example, by coating or embedding particulate material in polymers, wax, or the like.
- the compounds disclosed herein may also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyrancopolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or
- the compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates and cross- linked or amphipathic block copolymers of hydrogels.
- biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates and cross- linked or amphipathic block copolymers of hydrogels.
- the invention is directed to a liquid oral dosage form.
- Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound disclosed herein.
- Syrups can be prepared by dissolving the compound of the invention in a suitably flavored aqueous solution; while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated by dispersing a compound disclosed herein in a non-toxic vehicle.
- Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or other natural sweeteners or saccharin or other artificial sweeteners and the like can also be added.
- compositions for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
- a compound disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents, that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition (e.g., cell proliferation disorders).
- a compound disclosed herein is combined with one or more other anti-cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful.
- Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
- compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound disclosed herein.
- a compound disclosed herein may be administered either simultaneously with, or before or after, one or more other therapeutic agent(s).
- a compound disclosed herein may be administered separately, by the same or different route of
- Products provided as a combined preparation include a composition comprising a compound of formula (I) and one or more other active agent(s) together in the same
- composition or a compound of formula (I) and one or more other therapeutic agent(s) in separate form, e.g. in the form of a kit.
- the weight ratio of a compound disclosed herein to a second active agent may be varied and will depend upon the effective dose of each agent. Generally, an effective dose of each will be used. Thus, for example, when a compound disclosed herein is combined with another agent, the weight ratio of the compound disclosed herein to the other agent will generally range from about 1000:1 to about 1:1000, such as about 200:1 to about 1:200. Combinations of a compound disclosed herein and other active agents will generally also be within the aforementioned range, but in each case, an effective dose of each active agent should be used. In such combinations, the compound disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
- the invention provides a composition comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
- the therapy is the treatment of a disease or disorder associated with mutant IDH enzyme activity.
- the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I).
- the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
- kits of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
- a kit of the invention typically comprises directions for administration.
- Disclosed herein is a use of a compound of formula (I) for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the medicament is prepared for administration with another active agent.
- the invention also provides the use of another active agent for treating a disease or disorder associated with a mutant IDH enzyme, wherein the medicament is administered with a compound of formula (I).
- the invention also provides the use of a compound of formula (I) for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the patient has previously (e.g. within 24 hours) been treated with another active agent.
- the invention also provides the use of another therapeutic agent for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
- the second agent may be applied a week, several weeks, a month, or several months after the administration of a compound disclosed herein.
- the other active agent is selected from the group consisting of vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, immunomodulatory agents including but not limited to anti-cancer vaccines, CTLA-4, LAG-3 and PD-1 antagonists.
- VEGF vascular endothelial growth factor
- vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark AVASTIN by
- topoisomerase II inhibitors include but are not limited to, etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames TOPOSAR, VEPESID and ETOPOPHOS), and teniposide (also known as VM-26, sold under the tradename VUMON).
- etoposide also known as VP-16 and Etoposide phosphate, sold under the tradenames TOPOSAR, VEPESID and ETOPOPHOS
- teniposide also known as VM-26, sold under the tradename VUMON.
- alkylating agents include but are not limited to, 5-azacytidine (sold under the trade name VIDAZA), decitabine (sold under the trade name of DECOGEN), temozolomide (sold under the trade names TEMODAR and TEMODAL by Schering- Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename COSMEGEN), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename ALKERAN), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename HEXALEN), carmustine (sold under the tradename BCNU), bendamustine (sold under the tradename TREANDA), busulfan (sold under the tradenames Busulfex(R) and Myleran(R)), carboplatin (sold under the tradename Paraplatin(R)), lomustine (also known as
- anti-tumor antibiotics examples include, but are not limited to, doxorubicin (sold under the tradenames Adriamycin(R) and Rubex(R)), bleomycin (sold under the tradename lenoxane(R)), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine(R)), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome(R)), mitoxantrone (also known as DHAD, sold under the tradename Novantrone(R)), epirubicin (sold under the tradename Ellence(TM)), idarubicin (sold under the tradenames Idamycin(R), Idamycin
- anti-metabolites include, but are not limited to, claribine (2- chlorodeoxyadenosine, sold under the tradename leustatin(R)), 5-fluorouracil (sold under the tradename Adrucil(R)), 6-thioguanine (sold under the tradename Purinethol(R)), pemetrexed (sold under the tradename Alimta(R)), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U(R)), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt(TM)), decitabine (sold under the tradename Dacogen(R)), hydroxyurea (sold under the tradenames Hydrea(R), Droxia(TM) and Mylocel(TM)), fludarabine (sold under the tradename Fludara(R)), floxuridine (s
- methotrexate also known as amethopterin, methotrexate sodium (MTX), sold under the tradenames Rheumatrex(R) and Trexall(TM)), and pentostatin (sold under the tradename Nipent(R)).
- retinoids examples include, but are not limited to, alitretinoin (sold under the tradename Panretin(R)), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid(R)), Isotretinoin (13-c/s-retinoic acid, sold under the tradenames
- PD-1 antagonist means any chemical compound or biological molecule that blocks binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T cell, B cell or NKT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1.
- Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279 and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274 and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc and CD273 for PD-L2.
- the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1.
- Human PD-1 amino acid sequences can be found in NCBI Locus No.: NP_005009.
- Human PD-L1 and PD-L2 amino acid sequences can be found in NCBI Locus No.: NP_054862 and NP_079515, respectively.
- PD-1 antagonists useful in any of the treatment method, medicaments and uses of the present invention include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1.
- the mAb may be a human antibody, a humanized antibody or a chimeric antibody, and may include a human constant region.
- the human constant region is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region.
- the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab') 2 , scFv and Fv fragments.
- mAbs that bind to human PD-1 are described in US7488802, US7521051, US8008449, US8354509, US8168757, WO2004/004771, WO2004/072286, WO2004/056875, and US2011/0271358.
- mAbs that bind to human PD-L1 are described in WO2013/019906, W02010/077634 A1 and US8383796.
- Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C and an antibody which comprises the heavy chain and light chain variable regions of SEQ ID NO:24 and SEQ ID NO:21, respectively, of WO2013/019906.
- immunoadhesion molecules that specifically bind to PD-1 are described in WO2010/027827 and
- fusion proteins useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include AMP-224 (also known as B7- DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
- AMP-224 also known as B7- DCIg
- examples of other cytotoxic agents include, but are not limited to, arsenic trioxide (sold under the tradename Trisenox(R)), asparaginase (also known as L-asparaginase, and Erwinia L-asparaginase, sold under the tradenames Elspar(R) and Kidrolase(R)).
- the compounds of formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and synthetic procedures and conditions for the illustrative intermediates and examples.
- protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry.
- Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
- the compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
- compounds of formula (8) can be formed in multiple ways.
- Substituted aminopyridine (1) and a nitro bromobenzene (2) can be combined in a palladium- mediated C-N coupling reaction to afford (3).
- Formation of a carbamate followed by reduction of the nitro group with palladium on carbon affords the substituted tricyclic compound (5).
- Deprotection followed by amide coupling affords the desired tricycle (8).
- a direct amide coupling can lead to the bis-Boc-protected tricyclic compound (7).
- Deprotection of the Boc groups affords the tricyclic compound (8).
- compound (9) can be used in a multitude of reactions. TFA deprotection followed by amide coupling affords tricycle (11), which can be further derivatized either through C-N coupling reaction with appropriate amines affording product (12) or via Suzuki reaction affording product (13). Alternatively, compound (9) can be protected to afford the bis-Boc protected tricycle (14). C-N coupling reaction between (14) and appropriate amines affords (15). TFA deprotection of (15) affords de-Boc tricycle (16). Alternatively, (16) can be obtained from (9) via a C-N coupling/TFA reaction sequence. Amide coupling of (16) affords compounds of formula (12). Alternatively, amide coupling of compound (9) affords compound (18).
- compounds of formula (35) can be prepared via a three-step sequence starting with aryl chloride (32). Suzuki coupling between (32) and boronate ester affords (33). Pd-catalyzed hydrogenation of alkene (33) affords (34). Amide coupling between (34) with an appropriate amine affords compounds of formula (35).
- compounds of formula (38) can be prepared in two steps from (36) through an amide coupling and C-N coupling.
- Compound (38) can be used in a multitude of reactions. Radical reaction of (38) with t-butyl peroxyacetate under LED light affords (39) and (40). Electrophilic fluorination of (38) with selectfluor affords (41) and (42). Iridium-catalyzed regioselective C-H borylation of (38) affords boronate ester (43). Pd- catalyzed alkylation of (43) with iodomethane affords the product (44). Copper-mediated sulfonylation of (43) affords compounds of formula (45). Copper(II) chloride reacts with boronate ester (43) affording compounds of formula (46).
- substituted nitroaniline (47) and a formyl bromopyridine (48) can be combined in a palladium-mediated C-N coupling reaction to afford (49). Formation of a carbamate followed by reduction of the nitro group with platinum on carbon affords aniline (50). Reductive amination of (50) affords the substituted tricyclic compound (51). Amide coupling followed by deprotection affords the desired tricycle (52). Further Pd-catalyzed C-N coupling of (52) with morpholine affords compound of formula (53).
- ketone (59) reacts with TMS-protected isopropanol to give (60). Saponification of ester (60) with lithium hydroxide affords compound of formula (61). Protection with benzylbromide followed by chiral separation affords (62). Hydrogenation of (62) affords compound of formula (63).
- Step 1 A flask containing ethyl 5-oxotetrahydro-2H-pyran-2-carboxylate (2.0g, 12mmol) and dichloromethane (100mL) was cooled to -78°C. Isopropoxytrimethylsilane (2.5mL, 14mmol), followed by trimethylsilyl trifluoromethanesulfonate (0.53 mL, 2.9 mmol) were added and the mixture was stirred for 1 h at -78°C. Triethylsilane (2.0mL, 13mmol) was added, the dry ice bath was removed and the reaction was allowed to warm to RT for 18 h.
- Step 2 To a mixture of trans ethyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (8.4g, 39mmol) in THF (100mL), water (32mL) and ethanol (32mL) was added lithium hydroxide (3.5g, 0.15mol) and the mixture was stirred at RT for 18 h. HCl (2.0 M in water, 78mL, 0.16mmol) was added and then the mixture was extracted with ethyl acetate (2X 150mL). The organic extracts were combined, dried over sodium sulfate, filtered and concentrated to afford trans 5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid that was taken on to the next step without further purification.
- Step 3 To a mixture of trans 5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (10.3g, 54.5mmol), potassium carbonate (15.1g, 109mmol) and sodium iodide (1.6g, 11mmol) in DMF (160mL) was added benzyl bromide (7.1mL, 60mmol). The mixture was stirred for 16 h. The reaction mixture was diluted with ethyl acetate (500mL) and washed with water (6 x 100mL) and brine (1 x 50mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product.
- Step 4 To a mixture of trans benzyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (peak 2 from SFC, 3.4g, 12mmol) in ethyl acetate (120 mL) was added palladium on carbon (10% by weight, 2.60g, 2.4mmol) under an atmosphere of argon. The flask was fitted with a hydrogen balloon and the mixture was evacuated and purged 5 times with hydrogen. The mixture was stirred overnight at RT, then filtered through celite and the celite was washed with ethyl acetate.
- Trans benzyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (peak 1 from SFC) can be hydrogenated as described in Step 4 to afford trans 5-isopropoxytetrahydro-2H-pyran-2- carboxylic acid as a single enantiomer.
- Intermediate 2 2-(5,6-Dihydro-1,4-dio -tetramethyl-1,3,2-dioxaborolane
- Step 1 Into a 20-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed 2-chloro-5-fluoro-pyridine (750 g, 5.70 mol), xantphos (165 g, 285.16 mmol), Cs 2 CO 3 (5600 g), Pd(OAc) 2 (120 g) and dioxane (8000 mL). This was followed by the addition of benzophenone imine (1139 g) dropwise with stirring. The resulting solution was stirred overnight at 50 o C. The reaction was then quenched by the addition of water/ice. The resulting solution was extracted with 3x1000 mL of ethyl acetate and the organic layers were combined.
- 2-chloro-5-fluoro-pyridine 750 g, 5.70 mol
- xantphos 165 g, 285.16 mmol
- Cs 2 CO 3 5600 g
- Pd(OAc) 2 120 g
- Step 2 Into a 20-L 4-necked round-bottom flask was placed a solution of N- (diphenylmethylidene)-5-fluoropyridin-2-amine (1100 g, 3.98 mol) in dichloromethane (8000 mL). This was followed by the addition of trifluoroacetic acid (4500 g, 39.81 mol) dropwise with stirring. The resulting solution was stirred overnight at RT. The reaction was then quenched by the addition of water/ice. The resulting solution was extracted with 2x2000 mL of ethyl acetate and the aqueous layers combined and the organic layers combined. The pH value of the solution was adjusted to 9-10 with sodium carbonate.
- Step 3 Into a 5-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 5-fluoropyridin-2-amine (230 g, 2.05 mol), TEA (415 g, 4.10 mol), and dichloromethane (3000 mL). This was followed by the addition of 2,2-dimethylpropanoyl chloride (271 g, 2.25 mol, 1.10 equiv) dropwise with stirring. The resulting solution was stirred for 5 h at RT. The resulting mixture was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford N-(5-fluoropyridin-2-yl)-2,2- dimethylpropanamide as a solid.
- Step 4 Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed N-(5-fluoropyridin-2-yl)-2,2-dimethylpropanamide (332 g, 1.69 mol) and ether (6000 mL). This was followed by the addition of t-BuLi (3257 mL, 2.50 equiv) dropwise with stirring at -78 o C. The mixture was stirred for 1h at -78 o C. To this was added N,N-dimethylformamide (1236 g, 16.91 mol) dropwise with stirring. The resulting solution was stirred for 2 h at -60 o C.
- Step 5 Into a 5-L 4-necked round-bottom flask, was placed N-(5-fluoro-3-formylpyridin-2-yl)- 2,2-dimethylpropanamide (300 g, 1.34 mol) and hydrogen chloride(2N) (3500 mL). The resulting solution was stirred for 2 h at 100 o C and then cooled to RT. The pH value of the solution was adjusted to 8-9 with sodium bicarbonate. The solids were collected by filtration to afford 2-amino-5-fluoropyridine-3-carbaldehyde as a solid.
- Step 6 Into a 3-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-amino-5-fluoropyridine-3-carbaldehyde (130 g, 927.81 mmol), xantphos (53.7 g, 92.81 mmol), Pd 2 (dba) 3 /CHCl 3 (28.8 g) and 1,4-dibromo-2-nitrobenzene (285 g, 1.01 mol). This was followed by the addition of dioxane (1500 mL). The mixture was degassed by N 2 . To this was added Cs 2 CO 3 (455 g). The resulting solution was stirred for 3 h at 100 o C.
- 2-amino-5-fluoropyridine-3-carbaldehyde 130 g, 927.81 mmol
- xantphos 53.7 g, 92.81 mmol
- Step 7 Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-[(4-bromo-2-nitrophenyl)amino]-5-fluoropyridine-3- carbaldehyde (280 g, 823.28 mmol), tetrahydrofuran (3000 mL), water (3000 mL), sodium carbonate (219 g, 2.07 mol) and Na 2 S 2 O 4 (326 g). The resulting solution was stirred for 5 h at RT and the reaction mixture was cooled. The organic was collected and diluted with brine. The solids were collected by filtration to afford 2-[(2-amino-4-bromophenyl)amino]-5- fluoropyridine-3-carbaldehyde as a solid.
- Step 8 Into a 2000-mL 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-[(2-amino-4-bromophenyl)amino]-5- fluoropyridine-3-carbaldehyde (150 g, 483.68 mmol) in tetrahydrofuran (2000 mL),
- Step 1 To a round bottle flask was added 2-amino-5-fluoronicotinaldehyde (0.97g, 6.92mmol), 1-bromo-4-chloro-2-nitrobenzene (1.80g, 7.62mmol), Pd 2 (dba) 3 (0.32g, 0.35mmol), Xantphos (0.44g, 0.76mmol), Cs 2 CO 3 (3.38g, 10.38mmol) and dioxane (20mL). The reaction mixture was bubbled with nitrogen gas for 5 min and refluxed for 3 h. The reaction was cooled to RT, followed by addition of di-tert-butyl dicarbonate (1.96g, 9.0mmol) and DMAP (0.85g,
- Step 2 Under nitrogen gas flow, 3% Pt - 0.6% V/C (280mg, 0.197mmol) was added to the solid of tert-butyl (4-chloro-2-nitrophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate (1.87g, 4.72mmol), followed by addition of MeOH (24mL) and ethyl acetate (12mL). The reaction mixture was vacuum/N 2 exchanged and then vacuum/H 2 exchanged three times each. The reaction mixture was stirred with H 2 balloon at RT for 16 h. After completion, the reaction mixture was diluted in DCM and filtered over celite, washed with DCM and EtOAc, and concentrated.
- Step 1 2-Amino-5-fluoronicotinaldehyde (4.0 g, 28mmol), 1,4-dibromo-2-nitrobenzene (8.8g, 31mmol), Xantphos (1.8g, 3.1mmol), Pd 2 (dba) 3 (1.3g, 1.4mmol) and Cs 2 CO 3 (14g, 43mmol) were combined in dioxane (80mL) and stirred at 100°C for 2 h. The reaction mixture was then cooled to RT, and stabilized with a water bath. DMAP (0.35g, 2.8mmol) was added followed carefully and portionwise by di-tert-butyl dicarbonate (8.1g, 37mmol).
- Step 2 Tert-butyl (2-amino-4-bromophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate (0.70g, 1.6mmol) and platinum and vanadium (1%:2%) on Carbon (0.52g, 0.064mmol) were added to a round bottom flask and the flask was sealed and purged with N 2 gas. The mixture was then diluted with 2:1 MeOH:EtOAc (16mL) and subjected to alternating vacuum and H 2 gas three times. The reaction mixture was then stirred at RT for 16 h under an atmosphere of H 2 . The mixture was then subjected to alternating vacuum and N 2 gas three times.
- Step 1 A mixture of 2-amino-5-fluoronicotinaldehyde (500mg, 3.57mmol), 1-bromo-4-chloro- 5-fluoro-2-nitrobenzene (999mg, 3.93mmol), Pd 2 (dba) 3 (163mg, 0.178mmol), (9,9-dimethyl-9H- xanthene-4,5-diyl)bis(diphenylphosphine) (227mg, 0.393mmol) and cesium carbonate (1.74g, 5.35mmol) in dioxane (10mL) was degassed with N 2 /vacuum exchange three times.
- Step 2 Triethylamine (0.347mL, 2.487mmol) and DMAP (234mg, 1.913mmol) were added to a stirred mixture of Boc 2 O (2.87mmol) and 2-((4-chloro-5-fluoro-2-nitrophenyl)amino)-5- fluoronicotinaldehyde (600mg, 1.913mmol) in CH 2 Cl 2 (15mL) and the mixture was stirred at RT for 1 h.
- Step 3 A mixture of tert-butyl (4-chloro-5-fluoro-2-nitrophenyl)(5-fluoro-3-formylpyridin-2- yl)carbamate (470mg, 1.136mmol) in MeOH (6mL) and EtOAc (3mL), and 3%Pt-0.6%V/C (47mg, 0.182mmol) were loaded into a flask fitted with a hydrogen gas balloon. The reaction mixture was H 2 /vacuum exchanged three times, and stirred overnight at RT. The reaction mixture was diluted in DCM and filtered through a short pad of celite. The solvent was removed under reduced pressure and the residue was purified with ISCO column (40g gold,
- Step 1 A mixture of 2-aminonicotinaldehyde (500mg, 4.09mmol), 1-bromo-4-chloro-5-fluoro- 2-nitrobenzene (1.15g, 4.50mmol), Pd 2 (dba) 3 (187mg, 0.205mmol), (9,9-dimethyl-9H-xanthene- 4,5-diyl)bis(diphenylphosphine) (261mg, 0.450mmol), and cesium carbonate (2.0g, 6.14mmol) in dioxane (10mL) was degassed with vacuum/nitrogen exchange three times. The mixture was heated to reflux for 4 h before cooled to RT.
- reaction mixture was diluted with DCM and filtred through a pad of celite, washed three times with DCM.
- the solvent was concentrated to ⁇ 20 mL and a solid was collected with filtration and washed with hexane/ethyl acetate (9/1) to afford 2-((4-chloro-5-fluoro-2-nitrophenyl)amino)nicotinaldehyde as a solid.
- Step 2 Triethylamine (0.674mL, 4.84mmol) and DMAP (455mg, 3.72mmol) were added to a stirred mixture of Boc 2 O (1.3mL, 5.58mmol) and 2-((4-chloro-5-fluoro-2- nitrophenyl)amino)nicotinaldehyde (1.10g, 3.72mmol) in CH 2 Cl 2 (35mL) and the mixture was stirred at RT for 1 h.
- Step 3 A mixture of tert-butyl (4-chloro-5-fluoro-2-nitrophenyl)(3-formylpyridin-2- yl)carbamate (1.10g, 2.78mol) in MeOH (14mL) and ethyl acetate (7mL), and 3%Pt-0.6%V/C (165mg, 0.639mmol) was loaded into a flask fitted with a hydrogen gas balloon. The reaction mixture was H 2 /vacuum exchanged three times before it was stirred for overnight at RT. The reaction mixture was diluted with CH 2 Cl 2 and filterd through a short pad of celite and washed with CH 2 Cl 2 .
- Step 4 1-(2,2,2-Trifluoroethyl)piperidine-4-carboxylic acid (266mg, 1.258mmol) was dissolved in CH 2 Cl 2 (3mL) and one drop of DMF. Oxalyl chloride (0.11mL, 1.26mmol) was added at RT. The solvent was evaporated in 1 h to give the acyl chloride intermediate.
- the aqueous phase was extracted with EtOAc, and organic phase was washed with brine and dried over Mg 2 SO 4 .
- the solvent was removed under reduced pressure and the residue was subjected to column chromatography (40g silica gel, eluting with 0-70% EtOAc/Hex) to give a mixture of products.
- the mixture of products was dissolved in DCM (3mL) and treated with Boc 2 O (0.319mL, 1.372mmol), triethylamine (0.191mL, 1.372mmol) and DMAP (140mg, 1.144mmol). The mixture was stirred at RT for 1 h.
- Step 1 To a microwave vial containing 8-bromo-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine, HCl salt (300mg, 0.960mmol) and PS-PPh 3 (2.06mmol/g loading, 1.4g, 2.9mmol) was added a mixture of trans 4-isopropoxycyclohexanecarboxylic acid (0.18g, 0.96mmol) dissolved in acetonitrile (12mL). Trichloroacetonitrile (0.48mL, 4.8mmol) was added and the vial was heated to 100°C for 15 min in a microwave reactor.
- Step 2 To a vial containing (8-bromo-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((trans)-4-isopropoxycyclohexyl)methanone (0.20g, 0.45mmol) was added 2-oxa-5- azabicyclo[2.2.2]octane hemioxalate (0.10g, 0.90mmol) and (2-dicyclohexylphosphino-2',6'- diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium methanesulfonate (RuPhos Pd G3) (38mg, 0.045mmol).
- the purified compound was then further purified by chiral SFC (IC, 2.1 X 25 cm, methanol with 0.25% DMEA and 25% modifer in CO 2 ) to afford (trans-4-isopropoxycyclohexyl) ⁇ 8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]- 5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl ⁇ methanone and (trans-4- isopropoxycyclohexyl) ⁇ 8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl ⁇ methanone.
- acyl chloride was redissolved in DCE (1mL) and added to a hot suspension of tert-butyl 8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (100mg, 0.286mmol) in DCE (1mL) at 80°C.
- DMAP 1.7mg, 0.014mmol
- DCE 0.5mL
- Trans-4-isopropoxycyclohexanecarboxylic acid (223mg, 1.196mmol) was dissolved in DCM (8mL) and one drop DMF.
- Oxalyl chloride (0.114mL, 1.305mmol) was added at RT and the reaction mixture was stirred at RT for 1.5 h. All volatiles were evaporated.
- a separate microwave vail was charged with tert-butyl 8-chloro-3,9-difluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (400mg, 1.088mmol) and DCE (15mL). The mixture was heated to 80°C.
- the vial was evacuated and filled with nitrogen and then lithium bis(trimethylsilyl)amide (1.0M in THF, 1.1mL, 1.1mmol) was added via syringe. The reaction was heated to 80°C overnight. Upon cooling to RT, the mixture was diluted with water, extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
- Examples 33 and 34 (8-((S)-1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone and (8-((R)-1,4- dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5- isopropoxytetrahydro-2H-pyran-2-yl)methanone
- Step 1 To a round bottle flask equipped with a stir bar was added 8-bromo-3-fluoro-6,11- dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine (24 g, 82 mmol), 2-(5,6-dihydro-1,4-dioxin-2- yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (26.0 g, 122 mmol), potassium phosphate, tribasic (204 ml, 408 mmol) and THF (272 ml).
- the 3rd Generation X-Phos precatalyst (3.45 g, 4.08 mmol) was added last and the flask was purged with nitrogen. The reaction mixture was refluxed for 45 min under nitrogen (70 o C internal temperature). Upon cooling, the reaction mixture was diluted with water, extracted with EtOAc (3x), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was diluited with DCM and triturated with hexanes. The solid was filtered off and washed with hexanes. The filtrate was again concentrated in vacuo, dissolved in minimal DCM and with hexanes. The solid was filtered off and washed with hexanes.
- Step 2 8-(5,6-Dihydro-1,4-dioxin-2-yl)-3-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine (1.7g, 5.68 mmol) and palladium on carbon (0.60 g, 0.568 mmol) were added to a round bottle flask purged with N 2 gas. MeOH (114 ml) was added and a three-way stop cock with a H 2 balloon was attached and the mixture was subjected to alternating vacuum and H 2 gas 3 times. The mxiture was then stirred under an atomosphere of H 2 for 20 h.
- the mixture was then subjected to alternating vacuum and N 2 gas 3 times before the balloon was removed and the reaction vessel was flushed with a stream of N 2 gas.
- the mixture was then carefuly filtered through celite and washed with DCM:MeOH.
- the filtrate was concentrated in vacuo and then dissolved in mninmal DCM and triturated with hexanes.
- the solid was filtered off, washed with hexanes and dried in vacuo to afford the product 8-(1,4-dioxan-2-yl)-3-fluoro-6,11-dihydro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine.
- the filtrate was concentrated in vacuo.
- Step 3 (2R,5S)-5-Isopropoxytetrahydro-2H-pyran-2-carboxylic acid (0.137 g, 0.730 mmol) was dissolved in DCM (6.64 ml) and one drop DMF was added. Oxalyl chloride (0.067 ml, 0.763 mmol) was added at RT. After 15 min, the reaction was evaporated and dried.
- Step 4 (2R,5S)-5-Isopropoxytetrahydro-2H-pyran-2-carboxylic acid (0.350 g, 1.862 mmol) was dissolved in DCM (17 ml) and catalytic DMF was added. Oxalyl chloride (0.170 ml, 1.95 mmol) was added at RT. After 30 min, the reaction was evaporated and dried.
- Step 1 To a microwave vial equipped with a stir bar was added tert-butyl 8-chloro-3,9-difluoro- 5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (446mg, 1.21mmol), 2-(5,6- dihydro-1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (514mg, 2.42mmol), potassium phosphate, tribasic (12.1mL, 6.06mmol) and THF (7.5mL).
- the 3rd Generation X- Phos Pd precatalyst (103mg, 0.121mmol) was added last and the vial was purged with nitrogen. The vial was sealed and heated to 100°C for 45 min in the microwave. The mixture was cooled, water (10 mL) was added and the mixture was extracted with EtOAc (2 x 10mL). The combined organic fractions were washed with brine (saturated, 1 x 10 mL), dried (Na 2 SO 4 ), filtered and the solvent evaporated under reduced pressure.
- Step 2 Under nitrogen gas flow, palladium on carbon (143mg, 0.134mmol) was added to the solid of tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (560mg, 1.342mmol), followed by addition of MeOH (15mL). The reaction mixture was N 2 /vacuum exchanged and then H 2 /vacuum exchanged for 3 times each. The reaction mixture was stirred with H 2 balloon at RT overnight.
- racemate was resolved by SFC (Chiral OD-H (2 x 25cm) OD-H (25 x 0.46cm) 20% methanol (0.1% DEA)/CO2, 100 bar 65mL/min, 220nm inj vol.: 0.5mL , 20mg/mL, (3:1) methanol:DCM) to afford two enantiomers of tert-butyl 8-(1,4- dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate.
- Step 3 (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (12.0 mg, 0.064 mmol), tert-butyl 8-(1,4-dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate (26.7mg, 0.064mmol, enantiomer 1), PS-PPh 3 (93mg, 0.191mmol),
- trichloroacetonitrile (31.9 ⁇ l, 0.318mmol) were dissolved in acetonitrile (637 ⁇ l), placed in a sealed tube and heated under microwave irridation at 100°C for 10 min. The mixture was cooled and filtered through a syringe filter disk. TFA (487 ⁇ l, 6.37mmol) was added to the filtrate and the mixture was stirred at RT overnight. The mixture was diluted with dichloromethane (20mL), washed with aqueous sodium hydrogen carbonate (saturated, 2 x 10mL), dried (Na 2 SO 4 ), filtered and the solvent evaporated under reduced pressure.
- Example 36 can be synthesized from the other enantiomer of of tert-butyl 8-(1,4-dioxan-2-yl)- 3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate using reaction conditions in step 3.
- the compounds in Table 2 were prepared using the methodology herein and the general procedure described in Example 35 and 36. Table 2.
- Example 39 (3-Fluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro- 6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone
- Step 1 A solution of tert-butyl 8-chloro-3-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine- 11(6H)-carboxylate (1.93g, 5.52mmol), TEA (6.15mL, 44.1mmol), DMAP (0.81g, 6.62mmol), di-tert-butyl dicarbonate (4.82g, 22.07mmol) in THF (79mL) was stirred at 70°C for 4 h. To the reaction mixture was added another di-tert-butyl dicarbonate (2g), DMAP (0.5g) and TEA (2mL).
- Step 2 To a microwave vial was added di-tert-butyl 8-chloro-3-fluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-6,11-dicarboxylate (150mg, 0.33mmol), (1R,3r,5S)-3-methoxy-8- azabicyclo[3.2.1]octane, HCl (89mg, 0.50mmol), Cs 2 CO 3 (652 mg, 2.00 mmol), and SPhos G2 Pd catalyst (24.0mg, 0.033mmol). The vial was sealed and vacuum/N 2 exchanged three times. DME (3.3mL) was added and the reaction was heated to 88°C overnight.
- DME 3mL
- Step 3 To a stirred solution of di-tert-butyl 3-fluoro-8-((1R,3r,5S)-3-methoxy-8- azabicyclo[3.2.1]octan-8-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-6,11-dicarboxylate (127mg, 0.23mmol) in DCM (1 mL) was added TFA (1 mL, 12.98 mmol) at RT. The reaction was stirred at RT for 1h. The solvents were removed under vacuum.
- Step 4 To a stirred solution of (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (41.8mg, 0.222mmol) in DCM (0.35mL) and one drop DMF was added oxalyl chloride (20.5 ⁇ l, 0.233mmol) at RT. The reaction was stirred at RT for 1 h and then concentrated to dryness.
- Example 45 (3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone
- Step 1 To a microwave vial was charged with a solution of tert-butyl 8-chloro-3,9-difluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (0.1g, 0.272mmol), 6-oxa-2- azaspiro[3.5]nonane (0.086g, 0.680mmol), (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'- biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (RuPhos Pd G3) (0.011g, 0.014mmol) in THF (1.36mL), and lithium bis(trimethylsilyl)amide in THF (1M, 2.72mL, 2.72mmol).
- Step 2 To a solution of tert-butyl 3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (0.04g, 0.087mmol) in CH 2 Cl 2 (0.5mL) was added TFA (0.5mL) and the reaction mixture was stirred for 1h. The mixture was concentrated and then taken up in DCM. The reaction mixture was washed with aq. sat.
- Example 50 (3,9-Difluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
- Step 1 To a mixture of methanesulfonato(2-dicyclohexylphosphino-2’,4’6’-tri-isopropyl-1,1’- biphenyl)(2’-amino-1,1’-biphenyl-2yl)palladium(II) (11.69mg, 0.014mmol), 1-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (38.3mg, 0.184mmol), and tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (50mg, 0.092mmol) in a microwave vial was added dioxane (1.5mL
- Step 2 TFA (0.5mL) was added to a stirred mixture of tert-butyl 9-fluoro-8-(1-methyl-1H- pyrazol-4-yl)-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (20mg, 0.034mmol) in DCM (1mL) and the mixture was stirred at RT for 1 h.
- Step 1 To a microwave vial equipped with a stir bar was added tert-butyl 8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (300mg, 0.858mmol), 2-(5,6-dihydro- 1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (364mg, 1.715mmol), potassium phosphate, tribasic (8.58mL, 0.5 M, 4.29mmol) and THF (7.5mL).
- the X-Phos G3 Pd precatalyst (72.6mg, 0.086mmol) was added last and the vial was sealed.
- the reaction mixture was degassed by bubbling nitrogen gas for 10 min.
- the reaction was microwave heated to 100°C for 45 min.
- the mixtuer was diluted with water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated.
- Step 2 Under nitrogen gas flow, palladium on carbon (83mg, 0.078mmol) was added to the solid of tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-3-fluoro-5,6-dihydro-11H- benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate (310 mg, 0.776 mmol), followed by addition of MeOH (15 mL). The reaction mixture was N 2 /vacuum exchanged and then
- Step 3 To a stirred solution of 1-(2,2,2-trifluoroethyl)piperidine-4-carboxylic acid (171mg, 0.808mmol) in DCM (1.5mL) and one drop DMF was added oxalyl chloride (77 ⁇ l, 0.882mmol) at RT. The reaction was stirred at RT for 1.5 h and then concentrated to dryness.
- acyl chloride was redissolved in DCE (1.5 mL) and added to a hot suspension of tert-butyl 8- (1,4-dioxan-2-yl)-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate (295mg, 0.735mmol) in DCE (3mL) at 80°C. DMAP (4.5mg) in DCE (0.5mL) was added subsequently. The mixture was heated overnight.
- Examples 56 and 57 (R)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone and (S)-(8-(1,4-dioxan-2- yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone
- Step 1 To chloro[(di-(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (70.9mg, 0.106mmol), 2-(5,6-dihydro-1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (225mg, 1.061mmol), and tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4- carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (288mg, 0.530mmol) in a microwave vial under nitrogen was added dioxane (3mL) followed by a solution of potassium phosphate tribasic (0.27mL, 1.326mmol) in water (
- Step 2 Tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine- 4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (15mg, 0.025mmol) was dissolved in MeOH (2mL). Pd-C (10wt%, 3mg, 2.82 ⁇ mol) was added and the reaction mixture was degassed and refilled with hydrogen in a balloon. The mixture was stirred at RT overnight. The mixture was filtered through a short celite pad, washed with EtOAc, and concentrated. The residue was used directly in the next step. MS: 595 (M+1).
- Step 3 TFA (0.5 mL) was added to a stirred mixture of tert-butyl 8-(1,4-dioxan-2-yl)-9-fluoro- 6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine- 11(6H)-carboxylate (15 mg, 0.025 mmol) in DCM (1 mL) and the mixture was stirred at RT for 1 h. LCMS showed clean reaction.
- Examples 62 and 63 [9-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone and [7-fluoro- 8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6- yl](trans-4-isopropoxycyclohexyl)methanone
- Example 64 (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone
- Step 1 To an oven-dried, N 2 (g) cooled 20 mL microwave vial was added di-tert-butyl 8-chloro- 9-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-6,11-dicarboxylate (237mg, 0.527mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)[2-(2- aminoethylphenyl)]palladium(II), methyl-t-butylether adduct (43.0mg, 0.053mmol), and (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane, HCl (107mg, 0.790mmol).
- Step 2 To a mixture of tert-butyl 8-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro- 5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (146mg, 0.354mmol) in DCM (1.42mL) was added hydrochloric acid (4 M in water, 1.77mL, 7.08mmol).
- Step 3 To a mixture of (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (16mg, 0.083mmol), (1S,4S)-5-(9-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-8-yl)-2- oxa-5-azabicyclo[2.2.1]heptane (26mg, 0.083mmol), PS-PPh3 (2.06mmol/g loading, 121mg, 0.250mmol), and trichloroacetonitrile (42 ⁇ l, 0.416mmol) in a microwave vial was added acetonitrile (832 ⁇ l).
- Example 65 (8-Chloro-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone
- Step 1 To a solution of 4-chloro-2-nitroaniline (474mg, 2.75mmol), 1-(2-bromopyridin-3- yl)ethanone (500mg, 2.500mmol), Pd 2 (dba) 2 (114mg, 0.125mmol), (9,9-dimethyl-9H-xanthene- 4,5-diyl)bis(diphenylphosphine) (Xantphos) (217mg, 0.375mmol), cesium carbonate (3.2g, 10.00mmol) in 1,4-dioxane (10mL) was degassed by bubbling nitrogen through the reaction mixture. The mixture was heated to reflux and left overnight and then cooled to RT.
- 4-chloro-2-nitroaniline 474mg, 2.75mmol
- 1-(2-bromopyridin-3- yl)ethanone 500mg, 2.500mmol
- Pd 2 (dba) 2 114mg, 0.125mmol
- Step 2 Under nitrogen gas flow, 3%Pt-0.6%V/C (299mg) was added to tert-butyl (3- acetylpyridin-2-yl)(4-chloro-2-nitrophenyl)carbamate (600mg, 1.531mmol), followed by addition of methanol (20mL) and ethyl acetate (10mL). The reaction mixture was degassed with nitrogen and then stirred under hydrogen at RT overnight.
- reaction mixture was diluted with dichloromethane and filtered over celite, washed with dichloromethane, concentrated and absorbed on silica gel and purified by ISCO chromatography (40g column, 0-100% Hexane- Ethylacetate) to afford tert-butyl (3-acetylpyridin-2-yl)(2-amino-4-chlorophenyl)carbamate as a solid.
- Step 3 To a solution of tert-butyl (3-acetylpyridin-2-yl)(2-amino-4-chlorophenyl)carbamate (300mg, 0.829mmol) in 1,2-dichloroethane (5mL) was added sodiumtriacetoxyborohydride (527mg, 2.487mmol) and heated at 80°C for 4 h. The reaction mixture was cooled to RT, taken into a separatory funnel, diluted with EtOAc, washed with water, brine and dried over anhydrous sodium sulfate.
- Step 4 To a solution of trans-4-isopropoxycyclohexanecarboxylic acid (118mg, 0.636mmol) in dichloromethane (3mL) was added oxalyl chloride (0.101mL, 1.157mmol), followed by a drop of DMF and stirred for 1 h at RT. The reaction mixture was concentrated to dryness and vacuum was applied for 5 min to remove any residual oxalyl chloride.
- reaction mixture was stirred for 24 h, poured into a separatory funnel, washed with water, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and the solvent removed to give crude mixture which was taken in dichloromethane (1mL) and treated with trifluoroacetic acid (1mL) and stirred at RT for 1 h.
- the vial was evacuated and refilled with N 2 gas. Lithium bis(trimethylsilyl)amide (0.19mL, 0.188mmol) in tetrahydrofuran was added via a syringe, followed by morpholine (3.3mg, 0.038mmol). The vial was sealed and the reaction mixture was heated to 80°C overnight. Another batch of all the reagents was added and heating continued for one more day. Reaction mixture was cooled to RT, diluted with ethylacetate, and solvents were removed under reduced pressure.
- Step 1 A mixture of 4-methoxybenzene-1,2-diamine (2.0g, 14.48mmol) and 1-(2-fluoropyridin- 3-yl)ethanone (2.01g, 14.48mmol) in dioxane (20mL) was heated at 100°C overnight. The reaction mixture was cooled to RT. The solvent was removed under reduced pressure, and the crude was purified by ISCO silica gel chromatography using hexane and ethyl acetate (0-100%) to afford 1-(2-((2-amino-4-methoxyphenyl)amino)pyridin-3-yl)ethan-1-one as an oil. MS: 258 (M+1).
- Step 2 To a solution of 1-(2-((2-amino-4-methoxyphenyl)amino)pyridin-3-yl)ethanone (910mg, 3.54mmol) in 1,2-dichloroethane (20mL) was added sodium triacetoxyborohydride (2.25g, 10.61mmol) and heated at 80°C for 4 h. The reaction mixture was cooled to RT and taken into a separatory funnel, diluted with ethylacetate, washed with water, sodium bicarbonate saturated solution, water and brine.
- Step 3 To a solution of1-(2,2,2-trifluoroethyl)piperidine-4-carboxylic acid (96mg, 0.456mmol) in dichloromethane (3mL) was added oxalyl chloride (0.073mL, 0.829mmol) followed by a drop of DMF and stirred for 1 h at RT. The reaction mixture was concentrated to dryness and vacuum was applied for 5 min to remove any residual oxalyl chloride.
- Example 69 (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
- potassium phosphate tribasic (74.7 ⁇ l, 0.075mmol) was added to a stirred mixture of 2 nd generation Xphos Pd precatalyst (1.96mg, 2.49 ⁇ mol), iodomethane (15.5 ⁇ l, 0.249mmol) and (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone (15mg, 0.025mmol) in THF (0.25mL).
- the vial was sealed, and the reaction mixture was stirred at 70°C overnight.
- the mixture was cooled, diluted with ethyl acetate (1mL), washed with aqueous sodium hydrogen carbonate (saturated, 3x.5mL), dried over Na 2 SO 4 , filtered and the solvent was evaporated under reduced pressure.
- Example 70 (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(methylsulfonyl)-5,11- dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
- Example 71 (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-chloro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
- the reaction mixture was heated at 80°C for 2 h.
- the reaction mixture was diluted with EtOAc and water.
- the aqueous was extracted with EtOAc, the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated.
- test compound (10mM stock in DMSO) is diluted in DMSO to make a 10- point, 3-fold dilution series. 125nL of each dilution or DMSO alone is dispensed to a 384-well Greiner Lumitrac 200 assay plate using an Echo® Liquid Handler. To each well of the plate is added 20 uL of enzyme in assay buffer or assay buffer alone. Assay buffer consists of 50 mM sodium phosphate, pH 7.0, 50mM magnesium chloride, 50mM sodium chloride, and 0.01% (w/v) bovine serum albumin. When present, the R132H mutant IDH1 enzyme is at a working concentration of 1.875nM (final concentration in assay of 1.5nM). The assay plate is allowed to incubate for 30 minutes at room temperature and 5uL of 5x substrate mixture (2.5uM
- nicotinamide adenine dinucleotide phosphate 100uM adenosine diphosphate, 7.5mM glyceraldehyde-3-phosphate, 7.5ug/mL of spinach glyceraldehyde-3-phosphate dehydrogenase, 25nM phosphoglycerate kinase, and 5mM alpha-ketoglutarate in assay buffer) is added to all wells. The reaction plate is incubated for 60 minutes followed by addition of 25uL of Promega Kinase-GLO reagent to all wells and 10-minute incubation.
- Luminescence is measured using a PerkinElmer Envision plate reader. The percent activity of each dilution is determined as the ratio of background corrected signal to the background corrected signal of wells receiving only DMSO. IC50 values are determined by fitting percent activity data to a four-parameter logistic dose response equation. The IC50 values of the exemplified compounds are included in Table 8. Table 8. IC50 values of the Exemplified Compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
Description
TITLE OF THE INVENTION
NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES BACKGROUND OF THE INVENTION
Isocitrate dehydrogenase (IDH) is a family of enzymes found in cellular metabolism. They are NADP+/NAD+ and metal dependent oxidoreductases of the enzyme class EC 1.1.1.42. The wild type proteins catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, generating carbon dioxide and NADPH/NADH in the process. They are also known to convert oxalosuccinate into alpha-ketoglutarate. Mutations in IDH1 (cytosolic) and IDH2 (mitochondrial) have been identified in multiple cancer types including, but not limited to, glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma. (See L. Dang et al., Trends Mol. Med., 2010, 16, 387; T. Shibata et al., Am. J. Pathol., 2011 , 178(3), 1395; Gaal et al., J. Clin. Endocrinol. Metab.2010, 95(3), 1274; Balss et al., Acta Neuropathol., 2008, 116, 597). The mutations have been found at or near key residues in the active site: G97D, R100Q, R132H, H133Q, and A134D for IDH1, and R140 and R172 for IDH2. (See L. Dang et al., Nature, 2009, 462, 739; L. Sellner et al., Eur. J. Haematol., 2010, 85, 457).
These mutant forms of IDH are believed to have a neomorphic activity, reducing alpha-ketoglutarate to 2-hydroxyglutarate (2-HG). (See P.S. Ward et al., Cancer Cell, 2010, 17, 225) In general, production of 2-HG is enantiospecific, resulting in generation of the D- enantiomer (also known as the R enantiomer or R-2-HG). Normal cells generally have low native levels of 2-HG, whereas cells harboring these mutations in IDH1 or IDH2 show significantly elevated levels of 2-HG. High levels of 2-HG have also been detected in tumors harboring the mutations. High levels of 2-HG have been detected in the plasma of patients with mutant IDH containing AML. (See S. Gross et al., J. Exp. Med., 2010, 207(2), 339).
Mutations in IDH1 have been associated with multiple cancers and patients having these disorders often have increased levels of 2-HG in their urine, plasma or
cerebrospinal fluid. (See M. Kranendijk et al., Science, 2010, 330, 336) There is a continuing need for small molecule inhibitors of mutant IDH enzymes, or more specifically IDH1 enzymes, for the treatment of diseases and disorders associated with these enzymes.
SUMMARY OF THE INVENTION
Disclosed herein are novel tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. Also disclosed herein are uses of these novel tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of such cancers. DETAILED DESCRIPTION OF THE INVENTION
Disclosed herein is a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein
A is–CH(R1)- or–N(R2)-; R1 is selected from the group consisting of hydrogen,–O-C1-10alkyl, and C1-10alkyl optionally substituted with one to four halogens; and R2 is selected from the group consisting of hygrogen, -S(O)2-C1-4alkyl, and C1-10alkyl optionally substituted with one to four halogens;
B is–CH2- or -O-;
R is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) -C1-10alkyl,
(4) –O-C1-10alkyl,
(5) -NRxRy, wherein each of Rx and Ry is independently selected from the group consisting of (a) hydrogen and (b) C1-6alkyl, optionally substituted with one to four substituents independently selected from halogen and heterocyclyl; wherein the heterocyclyl is optionally substituted with one to four substituents
independently selected from methyl, ethyl, propyl, butyl, -CH2-Cl, -CH2-F, - CH2CH2-Cl, -CH2CH2-F, and–CH2CF3; and
(6) heterocyclyl, optionally substituted with one to four substituents independently selected from halogen, hydroxyl, -C1-10alkyl, and–O-C1-10alkyl;
Re is selected from the group consisting of:
(1) hydrogen,
(2) halogen, and
(3) C1-6alkyl; and
g p
each of R f , R , R h , R m , R n and R is independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C1-6alkyl, and
(4) -S(O)2-C1-4alkyl;
with the proviso that when Re is hydrogen, at least one of
In one embodiment of the compounds of formula (I), each occurrence of a heterocyclyl is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 2-azaspiro[3.3]heptanyl, azaindolyl, 1,6-diazaspiro[3.3]heptanyl, 2,3-dihydro-1,4-dioxinyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, hexahydro- 1H-furo[3,4-c]pyrrolyl, imidazolyl, isoxazolyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 1- oxa-8-azaspiro[4.5]decanyl, 6-oxa-2-azaspiro[3.4]octanyl, 3-oxa-1,7-diazaspiro[4.4]nonanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl, piperazinyl, piperidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl and tetrahydro- pyranyl.
In one embodiment of the compounds of formula (I), each occurrence of a heterocyclyl is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl, pyrazolyl, and tetrahydropyranyl.
In one embodiment of the compounds of formula (I):
A is–CH(R1)- or–N(R2)-; R1 is selected from the group consisting of hydrogen, -C1-6alkyl and– O-C1-6alkyl; R2 is selected from the group consisting of hygrogen, methyl, ethyl, propyl, butyl,–CH2CF3, and -S(O)2-C1-4alkyl; and
B is–CH2- or -O-.
In an embodiment of each previous embodiment of formula (I):
A is–CH(R1)- or–N(R2)-; R1 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, -O-methyl,–O-ethyl,–O-propyl and–O-isopropyl; R2 is selected from the group consisting of hygrogen,–CH2CF3, and -S(O)2-ethyl; and
B is–CH2- or -O-.
In an embodiment of each previous embodiment of formula (I):
R is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) -C1-6alkyl,
(4) –O-C1-6alkyl,
(5) -NHRy , wherein Ry is selected from the group consisting of (a) hydrogen and (b) C1-4alkyl, optionally substituted with one to four substituents independently selected from halogen and heterocyclyl; wherein the heterocyclyl is optionally substituted with methyl, ethyl, propyl, -CH2-Cl, -CH2-F, or–CH2CF3; and (6) heterocyclyl, optionally substituted with one to four substituents independently selected from halogen, hydroxyl, -C1-6alkyl, and–O-C1-6alkyl.
In an embodiment of each previous embodiment of formula (I):
R is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) –O-C1-4alkyl,
(4) -NH-C1-2alkyl, wherein the–C1-2alkyl is substituted with a heterocyclyl; wherein the heterocyclyl is optionally substituted with methyl, ethyl, propyl, -CH2Cl or– CH2CF3; and
(5) heterocyclyl, optionally substituted with one to four substituents independently selected from halogen, C1-4alkyl, and -O-C1-4alkyl;
wherein each occurrence of the heterocyclyl of (4) and (5) is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 2- azaspiro[3.3]heptanyl, azaindolyl, 1,6-diazaspiro[3.3]heptanyl, 2,3-dihydro-1,4- dioxinyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, hexahydro-1H- furo[3,4-c]pyrrolyl, imidazolyl, isoxazolyl, morpholinyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 6-oxa-2- azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3-oxa-8- azabicyclo[3.2.1]octanyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 1-oxa-8- azaspiro[4.5]decanyl, 6-oxa-2-azaspiro[3.4]octanyl, 3-oxa-1,7- diazaspiro[4.4]nonanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl, piperazinyl, piperidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrrolyl, tetrahydro- furanyl, and tetrahydropyranyl.
In an embodiment of each previous embodiment of formula (I):
R is selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) –O-methyl,
(6) –O-ethyl,
(7) -NH-CH2-heterocyclyl, wherein the heterocyclyl is substituted with–CH2Cl, and (8) heterocyclyl, optionally substituted with one to two substituents independently selected from–F, -Cl, methyl, ethyl, propyl,–O-methyl,–O-ethyl, and–O-propyl; wherein each occurrence of the heterocyclyl of (7) and (8) is independently selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl, pyrazolyl, and tetrahydropyranyl.
In an embodiment of each previous embodiment of formula (I):
R is selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) –O-methyl,
(6) –O-ethyl,
(7) -NH-CH2-tetrahydropyranyl, wherein the tetrahydropyranyl is substituted with– CH2Cl, and
(8) heterocyclyl, optionally substituted with one to two substituents independently selected from -Cl, -F, methyl, ethyl, propyl,–O-methyl,–O-ethyl, and–O-propyl; wherein the heterocyclyl is selected from the group consisting of 2- azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro- 3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
In an embodiment of each previous embodiment of formula (I):
Re is hydrogen, -F, -Cl, methyl or ethyl; and
each of R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) methyl,
(6) ethyl,
(7) propyl, and
(8) -S(O)2-C1-2alkyl;
hydrogen.
In an embodiment of each previous embodiment of formula (I):
Re is -F, -Cl, methyl or ethyl; and
each of R f , R g , R h , R m , R n and R p is hydrogen.
In an embodiment of each previous embodiment of formula (I):
Re is hydrogen; and
each of Rf, Rg, Rh, Rm, Rn and Rp is independently selected from the group consisting of:
(1) -F,
(2) -Cl,
(3) -Br,
(4) methyl,
(5) ethyl, and
(6) -S(O)2-methyl.
In an embodiment of each previous embodiment of formula (I):
A is–CH(R1)- or–N(R2)-; R1 is selected from the group consisting of hydrogen, methyl, -O- methyl, -O-ethyl and–O-propyl and–O-isopropyl; R2 is selected from the group consisting of hygrogen,–CH2CF3, and-S(O)2-ethyl;
B is–CH2- or -O-;
R is selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) –O-methyl,
(5) –O-ethyl,
(6) -NH-CH2-tetrahydropyranyl, wherein the tetrahydropyranyl is substituted with– CH2Cl, and
(7) heterocyclyl, optionally substituted with one to two substituents independently selected from -Cl, -F, methyl, ethyl, propyl,–O-methyl,–O-ethyl,–O-propyl and –O-isopropyl;
wherein the heterocyclyl is selected from the group consisting of 2- azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro- 3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl;
Re is hydrogen, -Cl, -F, methyl or ethyl; and
each of R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) methyl,
(6) ethyl,
(7) propyl, and
(8) -S(O)2-methyl;
with the proviso that when Re is hydrogen, at least one of Rf, Rg, Rh, Rm, Rn and Rp is not hydrogen.
In one embodiment, a compound disclosed herein is of formula (Ia), or a pharmaceutically acceptable salt thereof:
wherein
A is–CH(R1)- or–N(R2)-; R1 is selected from the group consisting of hydrogen, methyl, -O- propyl and–O-isopropryl; R2 is–CH2CF3 or -S(O)2-ethyl;
Re is hydrogen, -Cl, -F, methyl or ethyl; and
each of R f , R g , R h , R m , R n and R p is independently selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) methyl,
(6) ethyl,
(7) propyl, and
(8) -S(O)2-methyl;
with the proviso that when R e is hydrogen, at least one of R f , R g , R h , R m , R n and R p is not hydrogen; and
R is as defined for formula (I).
In an embodiment of the compounds of formula (Ia), or a pharmaceutically acceptable salt thereof:
Re is–F or methyl; and
each of R f , R g , R h , R m , R n and R p is hydrogen.
In an embodiment of the compounds of formula (Ia), or a pharmaceutically acceptable salt thereof:
Re is hydrogen;
each of Rm and Rn is hydrogen; and
each of Rf, Rg, Rh, and Rp is independently selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) methyl, and
(5) -S(O)2-methyl;
with the proviso that at least one of R f , R g , R h and R p is not hydrogen.
In one embodiment, a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof:
wherein
A is–CH(R1)-; and R1 is -O-propyl or–O-isopropyl;
Re is hydrogen;
each of R f , R g , R m and R n is hydrogen;
each of Rh and Rp is independently selected from the group consisting of:
(1) hydrogen,
(2) -F, and
(3) -Cl;
with the proviso that at least one of R h and R p is not hydrogen; and
R is as defined for formula (I).
In one embodiment of formula (Ib) above, R is a heterocyclyl selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-
oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5-azabicyclo[2.2.2]octanyl, 3,9-dioxa-7- azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
In one embodiment, a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof, wherein:
A is–CH(R1)-; and R1 is -O-propyl or–O-isopropyl;
Re is hydrogen;
each of R f , R g , R m and R n is hydrogen;
each of Rh and Rp is independently selected from the group consisting of:
(1) hydrogen,
(2) -F, and
(3) -Cl;
with the proviso that at least one of R h and R p is not hydrogen; and
R is a heterocyclyl selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8- azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl.
In one embodiment, a compound disclosed herein is of formula (Ib), or a pharmaceutically acceptable salt thereof, wherein:
A is–CH(R1)-; and R1 is -O-propyl or–O-isopropyl;
Re is hydrogen;
each of R f , R g , R m , R n and R p is hydrogen;
Rh is -F or–Cl; and
R is a heterocyclyl selected from the group consisting of 1,4-dioxanyl, morpholinyl, oxazolidinyl and pyrazolyl.
In one embodiment, a compound is selected from the group consisting of:
(8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Bromo-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (3-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3-Fluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((2S,5S)-2,5-Dimethylmorpholino)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3-Fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
[3-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(8-((1R,5S)-3,9-Dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, [3-Fluoro-8-(6-oxa-2-azaspiro[3.5]non-2-yl)-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin- 6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(3-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(cis-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro- 6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((2S,5S)-2,5-Dimethylmorpholino)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
{3,9-Difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl}[trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]non-2-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3,9-Difluoro-8-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (9-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((1R,4R)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((S)-1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((R)-1,4-dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)((2R,5S)-5- isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(3-Fluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3-Fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((1R,5S)-3,9-Dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-(((3-(Chloromethyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(ethylsulfonyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3,9-Difluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-((1R,4R)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3,9-Difluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-(1H-pyrazol-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(9-Fluoro-8-(1-methyl-1H-pyrazol-4-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(9-Fluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(S)-(8-(1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(R)-(8-(1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(R)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(S)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(Trans-4-isopropoxycyclohexyl){9-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){7-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){9-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){7-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
[9-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone,
[7-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone, (8-Chloro-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(Trans-4-isopropoxycyclohexyl)(5-methyl-8-morpholino-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)methanone,
(8-Methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(Trans-4-isopropoxycyclohexyl)(8-methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(methylsulfonyl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-chloro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(3,9-Difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, and
(9-Fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
or a pharmaceutically acceptable salt thereof.
In one embodiment, a compound disclosed herein or a pharmaceutically acceptable salt thereof is used in medicine.
In one embodiment, disclosed herein is a composition which comprises an inert carrier or excipient and a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof.
In one embodiment, disclosed herein is a method for treating or preventing a disease or disorder associated with mutant IDH enzyme activity in a subject which comprises administering to the subject an effective amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof.
In one embodiment, disclosed herein is the use of a compound of formula (I), (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease or disorder associated with mutant IDH enzyme activity.
In one embodiment, a method for treating a disease or disorder associated with mutant IDH enzyme activity in a subject comprises administering to the subject an effective amount of a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, in combination with another anti-cancer agent.
In one embodiment, the disease or disorder associated with mutant IDH enzyme activity is cancer. In one embodiment, the cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), breast cancer, prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma. In one embodiment, the cancer is selected from glioma, glioblastoma multiforme, acute myeloid leukemia and breast cancer.
"Alkyl" refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups of 1 to 18 carbon atoms, or more specifically, 1 to 12 carbon atoms.
Examples of such groups include, but are not limited to, methyl (Me), ethyl (Et), n-propyl (Pr), n-butyl (Bu), n-pentyl, n-hexyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), sec-butyl (s-Bu), tert-butyl (t-Bu), isopentyl, and isohexyl. Alkyl groups may be optionally substituted with one or more substituents as defined herein.“C1-66alkyl" refers to an alkyl group as defined herein having 1 to 6 carbon atoms.
“Halo” or“halogen” refers to fluoro, chloro, bromo or iodo, unless otherwise noted.
"Heterocycle" refers to a saturated, partially unsaturated or aromatic ring moiety having at least one ring heteroatom and at least one ring carbon atom. In one embodiment, the heteroatom is oxygen, sulfur, or nitrogen. A heterocycle containing more than one heteroatom may contain different heteroatoms. Heterocyclyl moieties include both monocyclic and multicyclic (e.g., bicyclic) ring moieties. Bicyclic ring moieties include fused, spirocycle and bridged bicyclic rings and may comprise one or more heteroatoms in either of the rings. The ring attached to the remainder of the molecule may or may not contain a heteroatom. Either ring of a bicyclic heterocycle may be saturated, partially unsaturated or aromatic. The heterocycle may be attached to the rest of the molecule via a ring carbon atom, a ring oxygen atom or a ring nitrogen atom. Non-limiting examples of heterocycles are described below.
In one embodiment, partially unsaturated and aromatic 4-7 membered monocyclic heterocyclyl moieties include, but are not limited to, 2,3-dihydro-1,4-dioxinyl, dihydropyranyl, dihydropyrazinyl, dihydropyridazinyl, dihydropyridinyl, dihydropyrimidinyl, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydropyrazinyl, tetrahydropyridazinyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, thiophenyl, and triazolyl.
In one embodiment, saturated 4-7 membered monocyclic heterocyclyl moieties include, but are not limited to, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, morpholinyl, 1,4- oxazepanyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiomorpholinyl, tetrahydrothienyl, and
tetrahydrothiophenyl.
In one embodiment, a heterocyclyl is a spirocycle (“spiro”) bicyclic moiety wherein two rings are connected through one atom, and either or both of the rings comprise at least one heteroatom. In one embodiment, a spiro bicyclic heterocycle comprises a 4-7 membered heterocyclic ring comprising 1-4 heteroatoms selected from oxygen, sulfur and nitrogen connected through a single atom to either a 3-6 membered ring comprising 1-2 heteroatoms selected from oxygen, sulfur and nitrogen or a 3-6 membered carbocyclic ring. Exemplary spiro heteroc cles of this type include, but are not limited to:
(2- azaspiro[3.3]heptane),
(2-oxa-6-azaspiro[3.3]heptane),
(1,6- diazaspiro[3.3]heptane),
(2,6-diazaspiro[3.3]heptane),
(6-oxa-2- azaspiro[3.4]octane),
(7-oxa-2,5-diazaspiro[3.4]octane),
(6-oxa-2- azaspiro[3.5]nonanyl), -oxa-1,7-diazaspiro[4.4]nonane),
(4-oxa-7-
Such spiro bicyclic moieties may be attached to the rest of the molecule via a carbon atom or a nitrogen atom on either ring.
In one embodiment, a heterocycle is a bridged bicyclic moiety selected from the group consisting of:
(6-oxa-3-azabicyclo[3.1.1]heptane),
(8-oxa-3- azabicyclo[3.2.1]octane),
(2-oxa-5-azabicyclo[2.2.2]octane),
(3-oxa-8-
azabicyclo[3.2.1]octane),
(2-oxa-5-azabicyclo[2.2.1]heptane),
(3,8- diazabicyclo[3.2.1]octane),
(2,5-diazabicyclo[2.2.2]octane),
(8- azabicyclo[3.2.1]octane), and
(5-oxa-6-azabicyclo[2.1.1]hexane). Such bridged bicyclic moieties may be attached to the rest of the molecule via a carbon atom or a nitrogen atom on either ring.
Heterocyclic groups may be optionally substituted with one or more substituents as defined herein.
“Optionally substituted” refers to“unsubstituted or substituted,” and therefore, the generic structural formulas described herein encompass compounds containing the specified optional substituent(s) as well as compounds that do not contain the optional substituent(s). Each substituent is independently defined each time it occurs within the generic structural formula definitions. Polymorphism
A compound of formula (I), including a salt or solvate thereof, may exist in crystalline form, non-crystalline form, or a mixture thereof. A compound or a salt or solvate thereof may also exhibit polymorphism, i.e. the capacity of occurring in different crystalline forms. These different crystalline forms are typically known as "polymorphs". Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, all of which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing a compound of formula (I). Optical Isomers - Diastereomers - Geometric Isomers– Tautomers
Included herein are various isomers of the compounds of formula (I). The term "isomers" refers to compounds that have the same composition and molecular weight but differ
in physical and/or chemical properties. The structural difference may be in constitution
(geometric isomers) or in the ability to rotate the plane of polarized light (stereosiomers).
With regard to stereoisomers, a compound of formula (I) may have one or more asymmetric carbon atom and may occur as a racemic mixture or as individual enantiomers or diastereomers. All such isomeric forms are included herein, including mixtures thereof. If a compound of formula (I) contains a double bond, the substituent may be in the E or Z configuration. If a compound of formula (I) contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans- configuration. All tautomeric forms are also intended to be included.
Any asymmetric atom (e.g., carbon) of a compound of formula (I) can be present in racemic mixture or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
A compound of formula (I) can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
Any resulting racemates of the final compounds of the examples or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor- 10-sulfonic acid. Racemic compounds can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl– CH2C(O)- groups (keto forms) may undergo tautomerism to form hydroxyl–CH=C(OH)- groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are included within the scope of the present invention. Isotopic Variations
Compounds of formula (I) include unlabeled forms, as well as isotopically labeled forms. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, iodine and chlorine, such as 2H (i.e., Deuterium or“D”), 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 35S, 18F, 123I, 125I and 36Cl. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, may be particularly desirable for PET or SPECT studies.
Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art. Furthermore, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. Pharmaceutically Acceptable Salts
The term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid, including inorganic or organic base and inorganic or organic acid. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium,
sodium, zinc, and the like. Particular embodiments include ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene-diamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl- morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine,
isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When a compound of formula (I) is basic, a salt may be prepared from a pharmaceutically acceptable non-toxic acid, including an inorganic and organic acid. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, trifluoroacetic acid (TFA) and the like. Particular embodiments include the citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, tartaric and
trifluoroacetic acids. It will be understood that, as used herein, references to the compounds disclosed herein are meant to also include pharmaceutically acceptable salts thereof. Methods of Use
The compounds disclosed herein are inhibitors of a mutant IDH enzyme. These compounds are potentially useful in treating diseases or disorders associated with such enzymes including, but not limited to, cell proliferation disorders, such as cancer.
Examples of these mutant IDH enzymes are mutant IDH1 and mutant IDH2. A mutation in human IDH1 enzyme includes a mutation at amino acid residue 97, 100, or 132, e.g. G97D, R100Q, R132H, R132C, R132S, R132G, R132L, or R132V. A mutation in human IDH2 enzyme includes a mutation at amino acid residue 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, or R172W.
Cell-proliferation disorders that may be associated with a mutant IDH enzyme activity include, but are not limited to, cancer. Examples of such cancers include, but are not limited to, Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Adrenocortical
Carcinoma; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma; Bile Duct Cancer; Bladder Cancer; Bone Cancer, Osteosarcoma/Malignant Fibrous
Histiocytoma; Brain Stem Glioma; Brain Tumor, Cerebellar Astrocytoma; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma; Brain Tumor, Ependymoma; Brain Tumor,
Medulloblastoma; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors; Brain Tumor, Visual Pathway and Hypothalamic Glioma; Breast Cancer; Bronchial
Adenomas/Carcinoids; Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Central Nervous System Lymphoma, Primary; Cerebral Astrocytoma/Malignant Glioma; Cervical Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer; Ewing's Family of Tumors; Extracranial Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor;
Glioma, Childhood Brain Stem; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer; Hodgkin's Lymphoma; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Leukemia, Acute Lymphoblastic; Leukemia, Acute Myeloid; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia; Lymphoma, AIDS- Related; Lymphoma, Central Nervous System (Primary);
Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's; Lymphoma, Hodgkin's During
Pregnancy; Lymphoma, Non-Hodgkin's; Lymphoma, Primary Central Nervous System;
Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Hodgkin's Lymphoma;
Non-Small Cell Lung Cancer; Oral Cancer; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; steosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors; Pituitary Tumor; Plasma Cell
Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer;
Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma; Salivary Gland Cancer; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Soft Tissue; Sezary Syndrome; Skin Cancer; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Supratentorial Primitive
Neuroectodermal Tumors; T- Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Malignant; Thyroid Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter;
Trophoblastic Tumor, Gestational; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.
In one embodiment, a cancer potentially associated with mutant IDH enzyme activity is brain cancer, such as an astrocytic tumor (e.g., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma); oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma); oligoastrocytic tumor (e.g.,
oligoastrocytoma, and anaplastic oligoastrocytoma); ependymoma (e.g., myxopapillary ependymoma, and anaplastic ependymoma); medulloblastoma; primitive neuroectodermal tumor, schwannoma, meningioma, meatypical meningioma, anaplastic meningioma; and pituitary adenoma. In another embodiment, the brain cancer is glioma, glioblastoma multiforme, paraganglioma, or suprantentorial primordial neuroectodermal tumors (sPNET).
In another embodiment, a cancer potentially associated with mutant IDH enzyme activity is leukemia, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML,
post-MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma and acute lymphoblastic leukemia.
In one embodiment, a cancer potentially associated with mutant IDH enzyme activity is skin cancer, including melanoma. In another embodiment, a cancer potentially associated with mutant IDH enzyme activity is prostate cancer, breast cancer, thyroid cancer, colon cancer, or lung cancer. In another embodiment, a cancer potentially associated with mutant IDH enzyme activity is sarcoma, including central chondrosarcoma, central and periosteal chondroma, and fibrosarcoma. In another embodiment, a cancer potentially associated with mutant IDH enzyme activity is cholangiocarcinoma.
A subject administered with a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is generally a mammal, such as a human being, male or female. A subject also refers to cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, and birds. In one embodiment, the subject is a human.
As used herein, the terms "treatment" and "treating" refer to all processes wherein there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of a disease or disorder described herein that may be associated with mutant IDH enzyme activity. The terms do not necessarily indicate a total elimination of all disease or disorder symptoms. The terms also include the potential prophylactic therapy of the mentioned conditions, particularly in a subject that is predisposed to such disease or disorder.
The terms "administration of" and or "administering a" compound should be understood to include providing a compound described herein, or a pharmaceutically acceptable salt thereof, and compositions of the foregoing to a subject.
The amount of a compound administered to a subject is an amount sufficient to inhibit mutant IDH enzyme activity in the subject. In an embodiment, the amount of a compound can be an“effective amount”, wherein the subject compound is administered in an amount that will elicit a biological or medical response of a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. An effective amount does not necessarily include considerations of toxicity and safety related to the administration of a compound. It is recognized that one skilled in the art may affect physiological disorders associated with an IDH mutation by treating a subject presently afflicted with the disorders, or by prophylactically treating a subject likely to be afflicted with the disorders, with an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
An effective amount of a compound will vary with the particular compound chosen (e.g. considering the potency, efficacy, and/or half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the subject being treated; the medical history of the subject being treated; the duration of the treatment; the nature of a concurrent therapy; the desired therapeutic effect; and like factors and can be routinely determined by the skilled artisan.
The compounds disclosed herein may be administered by any suitable route including oral and parenteral administration. Parenteral administration is typically by injection or infusion and includes intravenous, intramuscular, and subcutaneous injection or infusion.
The compounds disclosed herein may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound disclosed herein depend on the pharmacokinetic properties of that compound, such as absorption, distribution and half-life which can be determined by a skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound disclosed herein depend on the disease or condition being treated, the severity of the disease or condition, the age and physical condition of the subject being treated, the medical history of the subject being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual subject's response to the dosing regimen or over time as the individual subject needs change. Typical daily dosages may vary depending upon the particular route of administration chosen. Typical daily dosages for oral administration, to a human weighing approximately 70 kg would range from about 0.1 mg to about 2 grams, or more specifically, 0.1 mg to 500 mg, or even more specifically, 0.2 mg to 100 mg, of a compound of formula (I).
One embodiment of the present invention provides for a method of treating a disease or disorder associated with mutant IDH enzyme activity comprising administration of an effective amount of a compound of formula (I) to a subject in need of treatment thereof. In one embodiment, the disease or disorder associated with a mutant IDH enzyme is a cell proliferation disorder.
In one embodiment, the cell proliferation disorder is cancer. In another embodiment, the cancer is a cancer associated with mutant IDH1 enzyme activity. In another embodiment, the cancer is associated with human mutant IDH1 enzyme activity, having a mutation at amino acid residue 97, 100, or 132, such as G97D, R100Q, R132H, R132C, R132S, R132G, R132L, or R132V.
In one embodiment, the cancer is associated with human mutant IDH2 enzyme activity having a mutation at amino acid residue 140 or 172, e.g. R140Q, R140G, R172K, R172M, R172S, R172G, or R172W.
In one embodiment, the cancer is brain cancer, leukemia, skin cancer, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma. In another embodiment the cancer is glioma, glioblastoma multiforme, paraganglioma, suprantentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, breast, prostate, thyroid, colon, lung, central chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and cholangiocarcinoma.
In one embodiment, disclosed herein is the use of a compound of formula (I) in a therapy. The compound may be useful in a method of inhibiting mutant IDH enzyme activity in a subject, such as a mammal in need of such inhibition, comprising administering an effective amount of the compound to the subject.
In one embodiment, disclosed herein is a pharmaceutical composition comprising at least one compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in potential treatment of a disorder or disease related to mutant IDH1 enzyme activity.
In one embodiment, disclosed herein is the use of a compound of formula (I) in the manufacture of a medicament for the treatment of a disease or disorder associated with mutant IDH enzyme activity. In one embodiment, the disease or disorder associated with a mutant IDH is a cell proliferation disorder. In another embodiment, the cell proliferation disorder is cancer. In another embodiment, the cancer is brain cancer, leukemia, skin cancer, breast, prostate cancer, thyroid cancer, colon cancer, lung cancer or sarcoma. In another embodiment, the cancer is glioma, glioblastoma multiforme, paraganglioma, suprantentorial primordial neuroectodermal tumors, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, melanoma, breast, prostate, thyroid, colon, lung, central
chondrosarcoma, central and periosteal chondroma tumors, fibrosarcoma, and/or
cholangiocarcinoma.
Compositions
The term "composition" as used herein is intended to encompass a dosage form comprising a specified compound in a specified amount, as well as any dosage form which results, directly or indirectly, from combination of a specified compound in a specified amount. Such term is intended to encompass a dosage form comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. Accordingly, the compositions of the present invention encompass any composition made by admixing a compound of the present invention and one or more pharmaceutically acceptable carrier or excipients. By "pharmaceutically acceptable" it is meant the carriers or excipients are compatible with the compound disclosed herein and with other ingredients of the composition.
In one embodiment, disclosed herein is a composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The composition may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to a subject, such as with powders or syrups. Alternatively, the composition may be prepared and packaged in unit dosage form wherein each physically discrete unit contains an effective amount of a compound of formula (I). When prepared in unit dosage form, the composition of the invention typically contains from about 0.1 mg to 2 grams, or more specifically, 0.1 mg to 500 mg, or even more specifically, 0.2 mg to 100 mg, of a compound of formula (I), or a
pharmaceutically acceptable salt thereof.
The compounds disclosed herein and a pharmaceutically acceptable carrier or excipient(s) will typically be formulated into a dosage form adapted for administration to a subject by a desired route of administration. For example, dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution. Suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition. For example, certain
pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain
pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the carrying or transporting of a compound disclosed herein, once administered to the subject, from one organ or portion of the body to another organ or another portion of the body. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, lubricants, binders, disintegrants, fillers, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
A skilled artisan possesses the knowledge and skill in the art to select suitable pharmaceutically acceptable carriers and excipients in appropriate amounts for the use in the invention. In addition, there are a number of resources available to the skilled artisan, which describe pharmaceutically acceptable carriers and excipients and may be useful in selecting suitable pharmaceutically acceptable carriers and excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
The compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
In one embodiment, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives, (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch) gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and
sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The composition can also be prepared to prolong or sustain the release as, for example, by coating or embedding particulate material in polymers, wax, or the like.
The compounds disclosed herein may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyrancopolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or
polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates and cross- linked or amphipathic block copolymers of hydrogels.
In one embodiment, the invention is directed to a liquid oral dosage form. Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound disclosed herein. Syrups can be prepared by dissolving the compound of the invention in a suitably flavored aqueous solution; while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing a compound disclosed herein in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or other natural sweeteners or saccharin or other artificial sweeteners and the like can also be added.
In one embodiment, the invention is directed to compositions for parenteral administration. Compositions adapted for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
Combinations
A compound disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents, that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition (e.g., cell proliferation disorders). In one embodiment, a compound disclosed herein is combined with one or more other anti-cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful. Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
When a compound disclosed herein is used contemporaneously with one or more other active agents, a composition containing such other active agents in addition to the compound disclosed herein is contemplated. Accordingly, the compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound disclosed herein. A compound disclosed herein may be administered either simultaneously with, or before or after, one or more other therapeutic agent(s). A compound disclosed herein may be administered separately, by the same or different route of
administration, or together in the same pharmaceutical composition as the other agent(s).
Products provided as a combined preparation include a composition comprising a compound of formula (I) and one or more other active agent(s) together in the same
pharmaceutical composition, or a compound of formula (I) and one or more other therapeutic agent(s) in separate form, e.g. in the form of a kit.
The weight ratio of a compound disclosed herein to a second active agent may be varied and will depend upon the effective dose of each agent. Generally, an effective dose of each will be used. Thus, for example, when a compound disclosed herein is combined with another agent, the weight ratio of the compound disclosed herein to the other agent will generally range from about 1000:1 to about 1:1000, such as about 200:1 to about 1:200. Combinations of a compound disclosed herein and other active agents will generally also be within the aforementioned range, but in each case, an effective dose of each active agent should be used. In such combinations, the compound disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
In one embodiment, the invention provides a composition comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or disorder associated with mutant IDH enzyme activity.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
A kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist with compliance, a kit of the invention typically comprises directions for administration.
Disclosed herein is a use of a compound of formula (I) for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the medicament is prepared for administration with another active agent. The invention also provides the use of another active agent for treating a disease or disorder associated with a mutant IDH enzyme, wherein the medicament is administered with a compound of formula (I).
The invention also provides the use of a compound of formula (I) for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the patient has previously (e.g. within 24 hours) been treated with another active agent. The invention also provides the use of another therapeutic agent for treating a disease or disorder associated with mutant IDH enzyme activity, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I). The second agent may be applied a week, several weeks, a month, or several months after the administration of a compound disclosed herein.
In one embodiment, the other active agent is selected from the group consisting of vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, immunomodulatory agents including but not limited to anti-cancer vaccines, CTLA-4, LAG-3 and PD-1 antagonists.
Examples of vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark AVASTIN by
Genentech/Roche), axitinib, (N-methyl-2-[[3-[([pound])-2-pyridin-2-ylethenyl]-1 H-indazol-6-
yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No. WO 01 /002369), Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1 H-indoi-6-y!)-2-[(4- pyridinyimethyj)amino]-3-pyfidinecarboxamide. and described in PCT Publication No. WO 02/068470), pasireotide (also known as SO 230, and described in PCT Publication No. WO 02/010192), and sorafenib (sold under the tradename NEXAVAR).
Examples of topoisomerase II inhibitors, include but are not limited to, etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames TOPOSAR, VEPESID and ETOPOPHOS), and teniposide (also known as VM-26, sold under the tradename VUMON).
Examples of alkylating agents, include but are not limited to, 5-azacytidine (sold under the trade name VIDAZA), decitabine (sold under the trade name of DECOGEN), temozolomide (sold under the trade names TEMODAR and TEMODAL by Schering- Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename COSMEGEN), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename ALKERAN), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename HEXALEN), carmustine (sold under the tradename BCNU), bendamustine (sold under the tradename TREANDA), busulfan (sold under the tradenames Busulfex(R) and Myleran(R)), carboplatin (sold under the tradename Paraplatin(R)), lomustine (also known as CCNU, sold under the tradename CeeNU(R)), cisplatin (also known as CDDP, sold under the tradenames Platinol(R) and Platinol(R)-AQ), chlorambucil (sold under the tradename Leukeran(R)), cyclophosphamide (sold under the tradenames Cytoxan(R) and Neosar(R)), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-Dome(R)), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename Hexalen(R)), ifosfamide (sold under the tradename Ifex(R)), procarbazine (sold under the tradename Matulane(R)), mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, sold under the tradename Mustargen(R)), streptozocin (sold under the tradename Zanosar(R)), thiotepa (also known as thiophosphoamide, TESPA and TSPA, and sold under the tradename Thioplex(R).
Examples of anti-tumor antibiotics include, but are not limited to, doxorubicin (sold under the tradenames Adriamycin(R) and Rubex(R)), bleomycin (sold under the tradename lenoxane(R)), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and
rubidomycin hydrochloride, sold under the tradename Cerubidine(R)), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome(R)), mitoxantrone (also known as DHAD, sold under the tradename Novantrone(R)), epirubicin (sold under the tradename Ellence(TM)), idarubicin (sold under the tradenames Idamycin(R), Idamycin
PFS(R)), and mitomycin C (sold under the tradename Mutamycin(R)).
Examples of anti-metabolites include, but are not limited to, claribine (2- chlorodeoxyadenosine, sold under the tradename leustatin(R)), 5-fluorouracil (sold under the tradename Adrucil(R)), 6-thioguanine (sold under the tradename Purinethol(R)), pemetrexed (sold under the tradename Alimta(R)), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U(R)), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt(TM)), decitabine (sold under the tradename Dacogen(R)), hydroxyurea (sold under the tradenames Hydrea(R), Droxia(TM) and Mylocel(TM)), fludarabine (sold under the tradename Fludara(R)), floxuridine (sold under the tradename FUDR(R)), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename
Leustatin(TM)), methotrexate (also known as amethopterin, methotrexate sodium (MTX), sold under the tradenames Rheumatrex(R) and Trexall(TM)), and pentostatin (sold under the tradename Nipent(R)).
Examples of retinoids include, but are not limited to, alitretinoin (sold under the tradename Panretin(R)), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid(R)), Isotretinoin (13-c/s-retinoic acid, sold under the tradenames
Accutane(R), Amnesteem(R), Claravis(R), Clarus(R), Decutan(R), Isotane(R), Izotech(R), Oratane(R), Isotret(R), and Sotret(R)), and bexarotene (sold under the tradename Targretin(R)).
"PD-1 antagonist" means any chemical compound or biological molecule that blocks binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T cell, B cell or NKT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279 and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274 and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc and CD273 for PD-L2. In any of the treatment method, medicaments and uses of the present invention in which a human individual is being treated, the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1. Human PD-1 amino acid sequences can be found in NCBI Locus No.: NP_005009. Human PD-L1 and PD-L2
amino acid sequences can be found in NCBI Locus No.: NP_054862 and NP_079515, respectively.
PD-1 antagonists useful in any of the treatment method, medicaments and uses of the present invention include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1. The mAb may be a human antibody, a humanized antibody or a chimeric antibody, and may include a human constant region. In some embodiments the human constant region is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv and Fv fragments.
Examples of mAbs that bind to human PD-1, and useful in the treatment method, medicaments and uses of the present invention, are described in US7488802, US7521051, US8008449, US8354509, US8168757, WO2004/004771, WO2004/072286, WO2004/056875, and US2011/0271358.
Examples of mAbs that bind to human PD-L1, and useful in the treatment method, medicaments and uses of the present invention, are described in WO2013/019906, W02010/077634 A1 and US8383796. Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, MSB0010718C and an antibody which comprises the heavy chain and light chain variable regions of SEQ ID NO:24 and SEQ ID NO:21, respectively, of WO2013/019906.
Other PD-1 antagonists useful in any of the treatment method, medicaments and uses of the present invention include an immunoadhesin that specifically binds to PD-1 or PD- L1, and preferably specifically binds to human PD-1 or human PD-L1, e.g., a fusion protein containing the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region such as an Fc region of an immunoglobulin molecule. Examples of immunoadhesion molecules that specifically bind to PD-1 are described in WO2010/027827 and
WO2011/066342. Specific fusion proteins useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present invention include AMP-224 (also known as B7- DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
Examples of other cytotoxic agents include, but are not limited to, arsenic trioxide (sold under the tradename Trisenox(R)), asparaginase (also known as L-asparaginase, and Erwinia L-asparaginase, sold under the tradenames Elspar(R) and Kidrolase(R)). EXPERIMENTAL
The following examples are intended to be illustrative only and not limiting in any way. Abbreviations used are those conventional in the art or the following.
ACN acetonitrile
BSA bovine serum albumin
°C degree Celsius
DCE 1,2-dichloroethene
DCM dichloromethane
DMF N,N-dimethylformamide
DMAP 4-dimethylaminopyridine
DMSO dimethylsulfoxide
DTT dithiothreitol
EtOAc ethyl acetate
EtOH ethanol
g gram
h hour(s)
HMDS hexamethyldisilazane
HPLC high pressure liquid chromatography
kg kilogram
L liter
LC liquid chromatography
LCMS liquid chromatography and mass spectrometry
MeOH methanol
MS mass spectrometry
MTBE methyl tert-butyl ether
min minutes
mL milliliter(s)
m/z mass to charge ratio
nm nanometer
nM nanomolar
N normal
NMR nuclear magnetic resonance
PS-PPh3 polymer supported-triphenylphosphine
RT room temperature
sat. saturated
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran GENERAL SYNTHETIC SCHEMES
The compounds of formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and synthetic procedures and conditions for the illustrative intermediates and examples.
In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
In general scheme 1, compounds of formula (8) can be formed in multiple ways. Substituted aminopyridine (1) and a nitro bromobenzene (2) can be combined in a palladium- mediated C-N coupling reaction to afford (3). Formation of a carbamate followed by reduction of the nitro group with palladium on carbon affords the substituted tricyclic compound (5). Deprotection followed by amide coupling affords the desired tricycle (8). Alternatively, a direct amide coupling can lead to the bis-Boc-protected tricyclic compound (7). Deprotection of the Boc groups affords the tricyclic compound (8).
In general scheme 2, compound (9) can be used in a multitude of reactions. TFA deprotection followed by amide coupling affords tricycle (11), which can be further derivatized either through C-N coupling reaction with appropriate amines affording product (12) or via Suzuki reaction affording product (13). Alternatively, compound (9) can be protected to afford the bis-Boc protected tricycle (14). C-N coupling reaction between (14) and appropriate amines affords (15). TFA deprotection of (15) affords de-Boc tricycle (16). Alternatively, (16) can be obtained from (9) via a C-N coupling/TFA reaction sequence. Amide coupling of (16) affords compounds of formula (12). Alternatively, amide coupling of compound (9) affords compound (18). Suzuki cross-coupling between (18) and boronate ester affords (19), which undergoes Pd- catalyzed hydrogenation and TFA deprotection to afford compounds of formula (20).
In general scheme 3, compound (21) can be used in a multitude of reactions. Boc-protection affords (22). A three-step reaction sequence involving C-N
coupling/deprotection/amide coupling affords the final product (23). Alternatively, amide coupling of (21) with appropriate amines affords (24). Compound (24) can be used in a multitude of reactions. Compounds of formula (26) can be prepared from (24) through Suzuki coupling reaction with appropriate boronate ester followed by Boc-deprotection with TFA. Alternatively, Suzuki coupling between (24) and boronate ester affords C-C coupling product (27) and de-halogenated product (28). Pd-catalyzed hydrogenation of (27) affords compound (29). Boc-deprotection of (29) affords the final product (30). Likewise, Boc-deprotection of (28) affords the product (31).
In general scheme 4, compounds of formula (35) can be prepared via a three-step sequence starting with aryl chloride (32). Suzuki coupling between (32) and boronate ester affords (33). Pd-catalyzed hydrogenation of alkene (33) affords (34). Amide coupling between (34) with an appropriate amine affords compounds of formula (35).
In general scheme 5, compounds of formula (38) can be prepared in two steps from (36) through an amide coupling and C-N coupling. Compound (38) can be used in a
multitude of reactions. Radical reaction of (38) with t-butyl peroxyacetate under LED light affords (39) and (40). Electrophilic fluorination of (38) with selectfluor affords (41) and (42). Iridium-catalyzed regioselective C-H borylation of (38) affords boronate ester (43). Pd- catalyzed alkylation of (43) with iodomethane affords the product (44). Copper-mediated sulfonylation of (43) affords compounds of formula (45). Copper(II) chloride reacts with boronate ester (43) affording compounds of formula (46).
In general scheme 6, substituted nitroaniline (47) and a formyl bromopyridine (48) can be combined in a palladium-mediated C-N coupling reaction to afford (49). Formation of a carbamate followed by reduction of the nitro group with platinum on carbon affords aniline (50). Reductive amination of (50) affords the substituted tricyclic compound (51). Amide coupling followed by deprotection affords the desired tricycle (52). Further Pd-catalyzed C-N coupling of (52) with morpholine affords compound of formula (53).
In general scheme 7, SNAr reaction between dianiline (54) and formyl fluoropyridine (55) affords (56). Reductive amination of (56) affords the substituted tricyclic compound (57). Amide coupling affords the desired tricycle (58).
In general scheme 8, ketone (59) reacts with TMS-protected isopropanol to give (60). Saponification of ester (60) with lithium hydroxide affords compound of formula (61). Protection with benzylbromide followed by chiral separation affords (62). Hydrogenation of (62) affords compound of formula (63).
In general scheme 9, Iridium-catalyzed conversion of 1,4-dioxene (64) with bis(pinacolato)diboron affords the vinyl boronate ester (65). INTERMEDIATES
Step 1: A flask containing ethyl 5-oxotetrahydro-2H-pyran-2-carboxylate (2.0g, 12mmol) and dichloromethane (100mL) was cooled to -78°C. Isopropoxytrimethylsilane (2.5mL, 14mmol), followed by trimethylsilyl trifluoromethanesulfonate (0.53 mL, 2.9 mmol) were added and the mixture was stirred for 1 h at -78°C. Triethylsilane (2.0mL, 13mmol) was added, the dry ice bath was removed and the reaction was allowed to warm to RT for 18 h. The mixture was
quenched with methanol (5mL), concentrated under reduced pressure and purified by column chromatography on silica gel to afford trans ethyl 5-isopropoxytetrahydro-2H-pyran-2- carboxylate as a mixture of isomers that was taken on to the next step.
Step 2: To a mixture of trans ethyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (8.4g, 39mmol) in THF (100mL), water (32mL) and ethanol (32mL) was added lithium hydroxide (3.5g, 0.15mol) and the mixture was stirred at RT for 18 h. HCl (2.0 M in water, 78mL, 0.16mmol) was added and then the mixture was extracted with ethyl acetate (2X 150mL). The organic extracts were combined, dried over sodium sulfate, filtered and concentrated to afford trans 5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid that was taken on to the next step without further purification.
Step 3: To a mixture of trans 5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (10.3g, 54.5mmol), potassium carbonate (15.1g, 109mmol) and sodium iodide (1.6g, 11mmol) in DMF (160mL) was added benzyl bromide (7.1mL, 60mmol). The mixture was stirred for 16 h. The reaction mixture was diluted with ethyl acetate (500mL) and washed with water (6 x 100mL) and brine (1 x 50mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product. The residue was purified by column chromatography on silica gel to afford trans benzyl 5-isopropoxytetrahydro-2H-pyran-2- carboxylate. The purified product was then further purified by chiral SFC (IC, 2.1 X 25 cm, methanol with 0.25% DMEA and 10% modifer in CO2) to separate the enantiomers.
Characterization data for the first peak isolated from SFC: MS: 279 (M + 1).
Characterization data for the second peak isolated from SFC: MS: 279 (M + 1).
Step 4: To a mixture of trans benzyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (peak 2 from SFC, 3.4g, 12mmol) in ethyl acetate (120 mL) was added palladium on carbon (10% by weight, 2.60g, 2.4mmol) under an atmosphere of argon. The flask was fitted with a hydrogen balloon and the mixture was evacuated and purged 5 times with hydrogen. The mixture was stirred overnight at RT, then filtered through celite and the celite was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to afford trans 5-isopropoxytetrahydro-2H- pyran-2-carboxylic acid as a single enantiomer (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ 12.61 (s, 1H), 3.89 (ddd, 1H), 3.82 (dd, 1H), 3.68 (hept, 1H), 3.39– 3.31 (m, 1H), 3.05 (dd, 1H), 2.02– 1.95 (m, 1H), 1.95– 1.88 (m, 1H), 1.55– 1.45 (m, 1H), 1.41– 1.31 (m, 1H), 1.06 (d, 3H), 1.04 (d, 3H).
Trans benzyl 5-isopropoxytetrahydro-2H-pyran-2-carboxylate (peak 1 from SFC) can be hydrogenated as described in Step 4 to afford trans 5-isopropoxytetrahydro-2H-pyran-2- carboxylic acid as a single enantiomer. Intermediate 2: 2-(5,6-Dihydro-1,4-dio -tetramethyl-1,3,2-dioxaborolane
To a 40mL vial was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.47g, 5.81mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (47mg, 0.174mmol) and (1,5- cyclooctadiene)(methoxy)iridium(I) dimer (98mg, 0.148mmol) in a glovebox. The vial was sealed and degassed hexane (2.5mL) and 2,3-dihydro-1,4-dioxine (926 µl, 11.62mmol) were added subsequently. The reaction was stirred at RT overnight, filtered over celite and concentrated. The residue was purified by column chromatography (40g silica, 0-60% EtOAc in hexane) to give 2-(5,6-dihydro-1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as an oil. MS: 213 (M + 1). Intermediate 3: 8-Bromo-3-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine
Step 1: Into a 20-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed 2-chloro-5-fluoro-pyridine (750 g, 5.70 mol), xantphos (165 g, 285.16 mmol), Cs2CO3 (5600 g), Pd(OAc)2 (120 g) and dioxane (8000 mL). This was followed by the addition of benzophenone imine (1139 g) dropwise with stirring. The resulting solution was stirred overnight at 50 oC. The reaction was then quenched by the addition of water/ice. The resulting solution was extracted with 3x1000 mL of ethyl acetate and the organic layers were combined. The resulting mixture was washed with x1000 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford N-(diphenylmethylidene)-5- fluoropyridin-2-amine as a solid.
Step 2: Into a 20-L 4-necked round-bottom flask was placed a solution of N- (diphenylmethylidene)-5-fluoropyridin-2-amine (1100 g, 3.98 mol) in dichloromethane (8000
mL). This was followed by the addition of trifluoroacetic acid (4500 g, 39.81 mol) dropwise with stirring. The resulting solution was stirred overnight at RT. The reaction was then quenched by the addition of water/ice. The resulting solution was extracted with 2x2000 mL of ethyl acetate and the aqueous layers combined and the organic layers combined. The pH value of the solution was adjusted to 9-10 with sodium carbonate. The resulting solution was extracted with 3x2000 mL of ethyl acetate and the organic layers were combined. The resulting mixture was washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford 5-fluoropyridin-2-amine as a solid.
Step 3: Into a 5-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 5-fluoropyridin-2-amine (230 g, 2.05 mol), TEA (415 g, 4.10 mol), and dichloromethane (3000 mL). This was followed by the addition of 2,2-dimethylpropanoyl chloride (271 g, 2.25 mol, 1.10 equiv) dropwise with stirring. The resulting solution was stirred for 5 h at RT. The resulting mixture was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford N-(5-fluoropyridin-2-yl)-2,2- dimethylpropanamide as a solid.
Step 4: Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed N-(5-fluoropyridin-2-yl)-2,2-dimethylpropanamide (332 g, 1.69 mol) and ether (6000 mL). This was followed by the addition of t-BuLi (3257 mL, 2.50 equiv) dropwise with stirring at -78oC. The mixture was stirred for 1h at -78 oC. To this was added N,N-dimethylformamide (1236 g, 16.91 mol) dropwise with stirring. The resulting solution was stirred for 2 h at -60 oC. The reaction was then quenched by the addition of water. The resulting solution was extracted with 3x2000 mL of ethyl acetate and the organic layers were combined. The resulting mixture was washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting mixture was washed with petrolium ether to afford N-(5-fluoro-3-formylpyridin-2-yl)-2,2-dimethylpropanamide as a solid.
Step 5: Into a 5-L 4-necked round-bottom flask, was placed N-(5-fluoro-3-formylpyridin-2-yl)- 2,2-dimethylpropanamide (300 g, 1.34 mol) and hydrogen chloride(2N) (3500 mL). The resulting solution was stirred for 2 h at 100 oC and then cooled to RT. The pH value of the solution was adjusted to 8-9 with sodium bicarbonate. The solids were collected by filtration to afford 2-amino-5-fluoropyridine-3-carbaldehyde as a solid.
Step 6: Into a 3-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-amino-5-fluoropyridine-3-carbaldehyde (130 g, 927.81 mmol), xantphos (53.7 g, 92.81 mmol), Pd2(dba)3/CHCl3 (28.8 g) and 1,4-dibromo-2-nitrobenzene (285
g, 1.01 mol). This was followed by the addition of dioxane (1500 mL). The mixture was degassed by N2. To this was added Cs2CO3 (455 g). The resulting solution was stirred for 3 h at 100oC. The reaction mixture was cooled and then quenched by the addition of water/ice. The solids were collected by filtration, washed with EtOH and DCM:petrolium ether (1:3) to afford 2-[(4-bromo-2-nitrophenyl)amino]-5-fluoropyridine-3-carbaldehyde as a solid.
Step 7: Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-[(4-bromo-2-nitrophenyl)amino]-5-fluoropyridine-3- carbaldehyde (280 g, 823.28 mmol), tetrahydrofuran (3000 mL), water (3000 mL), sodium carbonate (219 g, 2.07 mol) and Na2S2O4 (326 g). The resulting solution was stirred for 5 h at RT and the reaction mixture was cooled. The organic was collected and diluted with brine. The solids were collected by filtration to afford 2-[(2-amino-4-bromophenyl)amino]-5- fluoropyridine-3-carbaldehyde as a solid.
Step 8: Into a 2000-mL 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-[(2-amino-4-bromophenyl)amino]-5- fluoropyridine-3-carbaldehyde (150 g, 483.68 mmol) in tetrahydrofuran (2000 mL),
trifluoroacetic acid (337 g, 2.98 mol) and TES (338 g). The resulting solution was stirred overnight at 80oC. The reaction mixture was cooled to RT and then concentrated under vacuum. The resulting mixture was washed with DCM and the resulting solution was diluted with DCM and H2O. The pH value of the solution was adjusted to 8-9 with sodium bicarbonate. The organic layer was collected and washed with brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was washed with ether to afford 8- bromo-3-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine as a solid. MS: 294 (M+1).1H NMR: (300MHZ, DMSO-d6): δ 9.03 (1H, s), 7.98 (1H, d), 7.45 (1H, dd), 6.98 (1H, d), 6.91 (1H, d), 6.79 (1H, dd), 4.02 (2H, d) Intermediate 4: Tert-butyl 8-chloro-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3- e][1,4]diazepine-11-carboxylate
Step 1: To a round bottle flask was added 2-amino-5-fluoronicotinaldehyde (0.97g, 6.92mmol), 1-bromo-4-chloro-2-nitrobenzene (1.80g, 7.62mmol), Pd2(dba)3 (0.32g, 0.35mmol), Xantphos
(0.44g, 0.76mmol), Cs2CO3 (3.38g, 10.38mmol) and dioxane (20mL). The reaction mixture was bubbled with nitrogen gas for 5 min and refluxed for 3 h. The reaction was cooled to RT, followed by addition of di-tert-butyl dicarbonate (1.96g, 9.0mmol) and DMAP (0.85g,
6.92mmol). The resulting mixture was stirred at RT for 1 h, diluted with DCM and filtred through a pad of celite, and washed with DCM. The filtrate was aborsorbed on silica gel and purified by column chromatography (120g silica, 0-10% EtOAc in hexane) to afford tert-butyl (4-chloro-2-nitrophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate.
Step 2: Under nitrogen gas flow, 3% Pt - 0.6% V/C (280mg, 0.197mmol) was added to the solid of tert-butyl (4-chloro-2-nitrophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate (1.87g, 4.72mmol), followed by addition of MeOH (24mL) and ethyl acetate (12mL). The reaction mixture was vacuum/N2 exchanged and then vacuum/H2 exchanged three times each. The reaction mixture was stirred with H2 balloon at RT for 16 h. After completion, the reaction mixture was diluted in DCM and filtered over celite, washed with DCM and EtOAc, and concentrated. The residue was purified by column chromatography (120g, 0-30% EtOAc in hexane) to afford tert-butyl 8-chloro-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3- e][1,4]diazepine-11-carboxylate. MS: 350 (M + 1). Intermediate 5: Tert-butyl-8-bromo-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3- e][1,4]diazepine-11-carboxylate
Step 1: 2-Amino-5-fluoronicotinaldehyde (4.0 g, 28mmol), 1,4-dibromo-2-nitrobenzene (8.8g, 31mmol), Xantphos (1.8g, 3.1mmol), Pd2(dba)3 (1.3g, 1.4mmol) and Cs2CO3 (14g, 43mmol) were combined in dioxane (80mL) and stirred at 100°C for 2 h. The reaction mixture was then cooled to RT, and stabilized with a water bath. DMAP (0.35g, 2.8mmol) was added followed carefully and portionwise by di-tert-butyl dicarbonate (8.1g, 37mmol). The resulting mixture was stirred at RT for 2 h, then diluted with DCM, filtrered through celite, then concentrated onto silica gel and purified by flash chromatography (0-80% EtOAc:hexane) to afford tert-butyl (2- amino-4-bromophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate. MS: 384 (M - tBu).
Step 2: Tert-butyl (2-amino-4-bromophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate (0.70g, 1.6mmol) and platinum and vanadium (1%:2%) on Carbon (0.52g, 0.064mmol) were added to a
round bottom flask and the flask was sealed and purged with N2 gas. The mixture was then diluted with 2:1 MeOH:EtOAc (16mL) and subjected to alternating vacuum and H2 gas three times. The reaction mixture was then stirred at RT for 16 h under an atmosphere of H2. The mixture was then subjected to alternating vacuum and N2 gas three times. The reaction flask was purged with N2, and the mixture was diluted with DCM. The mixture was carefully filtered through celite under a stream of argon, and the celite was flushed with DCM:MeOH. The filtrate was concentrated in vacuo and then purified by flash chromatography (0-80% EtOAc:Hexane) to afford tert-butyl 8-bromo-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11- carboxylate. MS: 338 (M - tBu). Intermediate 6: Tert-butyl 8-chloro-3,9-difluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3- e][1,4]diazepine-11-carboxylate
Step 1: A mixture of 2-amino-5-fluoronicotinaldehyde (500mg, 3.57mmol), 1-bromo-4-chloro- 5-fluoro-2-nitrobenzene (999mg, 3.93mmol), Pd2(dba)3 (163mg, 0.178mmol), (9,9-dimethyl-9H- xanthene-4,5-diyl)bis(diphenylphosphine) (227mg, 0.393mmol) and cesium carbonate (1.74g, 5.35mmol) in dioxane (10mL) was degassed with N2/vacuum exchange three times. The mixture was refluxed for 4 h, cooled and diluted with DCM and filtred through a pad of celite, and washed with DCM three times. The solvent was concentrated to ~20mL and a solid was collected with filtration and washed with hexane/ethyl acetate (9/1) to afford 2-((4-chloro-5- fluoro-2-nitrophenyl)amino)-5-fluoronicotinaldehyde as a solid. MS: 314.2 (M+1).
Step 2: Triethylamine (0.347mL, 2.487mmol) and DMAP (234mg, 1.913mmol) were added to a stirred mixture of Boc2O (2.87mmol) and 2-((4-chloro-5-fluoro-2-nitrophenyl)amino)-5- fluoronicotinaldehyde (600mg, 1.913mmol) in CH2Cl2 (15mL) and the mixture was stirred at RT for 1 h. The solvent was removed and the residue was purified with ISCO column (80g silica gel eluting with 0-50% EtOAc/hxeane gradient) to afford tert-butyl (4-chloro-5-fluoro-2- nitrophenyl)(5-fluoro-3-formylpyridin-2-yl)carbamate as a syrup. MS: 414 (M+1).
Step 3: A mixture of tert-butyl (4-chloro-5-fluoro-2-nitrophenyl)(5-fluoro-3-formylpyridin-2- yl)carbamate (470mg, 1.136mmol) in MeOH (6mL) and EtOAc (3mL), and 3%Pt-0.6%V/C (47mg, 0.182mmol) were loaded into a flask fitted with a hydrogen gas balloon. The reaction
mixture was H2/vacuum exchanged three times, and stirred overnight at RT. The reaction mixture was diluted in DCM and filtered through a short pad of celite. The solvent was removed under reduced pressure and the residue was purified with ISCO column (40g gold,
EtOAc/hexane 0-100% then MeOH/DCM 0-10%) to afford tert-butyl 8-chloro-3,9-difluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate as a solid. MS: 368 (M+1). Intermediate 7: Tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)- 5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate
Step 1: A mixture of 2-aminonicotinaldehyde (500mg, 4.09mmol), 1-bromo-4-chloro-5-fluoro- 2-nitrobenzene (1.15g, 4.50mmol), Pd2(dba)3 (187mg, 0.205mmol), (9,9-dimethyl-9H-xanthene- 4,5-diyl)bis(diphenylphosphine) (261mg, 0.450mmol), and cesium carbonate (2.0g, 6.14mmol) in dioxane (10mL) was degassed with vacuum/nitrogen exchange three times. The mixture was heated to reflux for 4 h before cooled to RT. The reaction mixture was diluted with DCM and filtred through a pad of celite, washed three times with DCM. The solvent was concentrated to ~20 mL and a solid was collected with filtration and washed with hexane/ethyl acetate (9/1) to afford 2-((4-chloro-5-fluoro-2-nitrophenyl)amino)nicotinaldehyde as a solid. MS: 296 (M+1) Step 2: Triethylamine (0.674mL, 4.84mmol) and DMAP (455mg, 3.72mmol) were added to a stirred mixture of Boc2O (1.3mL, 5.58mmol) and 2-((4-chloro-5-fluoro-2- nitrophenyl)amino)nicotinaldehyde (1.10g, 3.72mmol) in CH2Cl2 (35mL) and the mixture was stirred at RT for 1 h. The solvent was removed under reduced pressure and the residue was purified with ISCO column (80 g silica gel eluting with 0-50% EtOAc/hexane gradient) to afford tert-butyl (4-chloro-5-fluoro-2-nitrophenyl)(3-formylpyridin-2-yl)carbamate as a syrup.
Step 3: A mixture of tert-butyl (4-chloro-5-fluoro-2-nitrophenyl)(3-formylpyridin-2- yl)carbamate (1.10g, 2.78mol) in MeOH (14mL) and ethyl acetate (7mL), and 3%Pt-0.6%V/C (165mg, 0.639mmol) was loaded into a flask fitted with a hydrogen gas balloon. The reaction mixture was H2/vacuum exchanged three times before it was stirred for overnight at RT. The reaction mixture was diluted with CH2Cl2 and filterd through a short pad of celite and washed
with CH2Cl2. The solvent was removed under reduced pressure to afford tert-butyl 8-chloro-9- fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate. MS: 350 (M+1)
Step 4: 1-(2,2,2-Trifluoroethyl)piperidine-4-carboxylic acid (266mg, 1.258mmol) was dissolved in CH2Cl2 (3mL) and one drop of DMF. Oxalyl chloride (0.11mL, 1.26mmol) was added at RT. The solvent was evaporated in 1 h to give the acyl chloride intermediate. To another 2 drum vial with a vent cap was charged with tert-butyl 8-chloro-9-fluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (400mg, 1.144mmol), DMAP (140mg, 1.144mmol) and DCE (3mL). The mixture was heated to 80°C. The previously made acyl chloride was suspended in DCE (1mL) and added to the hot mixture. The reaction vial was sealed and heated for 1 hour. The reaction was quenched with saturated aqueous sodium bicarbonate solution. The aqueous phase was extracted with EtOAc, and organic phase was washed with brine and dried over Mg2SO4. The solvent was removed under reduced pressure and the residue was subjected to column chromatography (40g silica gel, eluting with 0-70% EtOAc/Hex) to give a mixture of products. The mixture of products was dissolved in DCM (3mL) and treated with Boc2O (0.319mL, 1.372mmol), triethylamine (0.191mL, 1.372mmol) and DMAP (140mg, 1.144mmol). The mixture was stirred at RT for 1 h. The solvent was removed and the residue was subjected to column chromatography (40g silica gel, eluting with 0-70% EtOAc/hexane gradient) to afford tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate as a foam. MS: 543 (M+1). Intermediate 8: (Trans-4-isopropoxycyclohexyl){8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5- yl]-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone
Step 1: To a microwave vial containing 8-bromo-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine, HCl salt (300mg, 0.960mmol) and PS-PPh3 (2.06mmol/g loading, 1.4g, 2.9mmol) was added a mixture of trans 4-isopropoxycyclohexanecarboxylic acid (0.18g, 0.96mmol) dissolved in acetonitrile (12mL). Trichloroacetonitrile (0.48mL, 4.8mmol) was added and the vial was heated to 100°C for 15 min in a microwave reactor. Upon cooling, the mixture was diluted with methanol, filtered, and concenterated. The residue was diluted with
EtOAc and washed with sat. aq. sodium bicarbonate. The organic layer was then washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel (5-50% ethyl acetate gradient in hexanes to afford (8- bromo-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((trans)-4- isopropoxycyclohexyl)methanone.
Step 2: To a vial containing (8-bromo-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((trans)-4-isopropoxycyclohexyl)methanone (0.20g, 0.45mmol) was added 2-oxa-5- azabicyclo[2.2.2]octane hemioxalate (0.10g, 0.90mmol) and (2-dicyclohexylphosphino-2',6'- diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium methanesulfonate (RuPhos Pd G3) (38mg, 0.045mmol). To the mixture was added lithium bis(trimethylsilyl)amide (1M in THF, 4.5mL, 4.5mmol). The vial was capped and heated to 80°C for 4 h. Upon cooling to RT, the mixture was filtered and concentrated. The residue was purified by column chromatography on silica gel to afford the title compound as the racemate. The purified compound was then further purified by chiral SFC (IC, 2.1 X 25 cm, methanol with 0.25% DMEA and 25% modifer in CO2) to afford (trans-4-isopropoxycyclohexyl){8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]- 5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone and (trans-4- isopropoxycyclohexyl){8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone.
Characterization data for the first peak isolated from SFC: MS: 477 (M + 1). 1H NMR (500 MHz, DMSO-d6) δ 8.96 (s, 1H), 7.96 (d, 1H), 7.38 (d, 1H), 7.18 (d, 1H), 6.68– 6.58 (m, 2H), 6.55 (s, 1H), 5.18 (d, 1H), 4.02– 3.84 (m, 5H), 3.68– 3.54 (m, 2H), 3.20– 3.08 (m, 1H), 2.46– 2.40 (m, 1H), 2.06– 1.80 (m, 5H), 1.75– 1.62 (m, 2H), 1.54– 1.38 (m, 1H), 1.27– 1.18 (m, 2H), 1.15– 1.01 (m, 1H), 1.01– 0.94 (m, 6H), 0.93– 0.81 (m, 1H), 0.76– 0.61 (m, 1H).
Characterization data for the second peak isolated from SFC: MS: 477 (M + 1). 1H NMR (500 MHz, DMSO-d6) δ 8.96 (s, 1H), 7.96 (d, 1H), 7.38 (d, 1H), 7.18 (d, 1H), 6.68– 6.58 (m, 2H), 6.55 (s, 1H), 5.18 (d, 1H), 4.01– 3.85 (m, 5H), 3.67– 3.54 (m, 2H), 3.20– 3.08 (m, 1H), 2.46– 2.39 (m, 1H), 2.06– 1.83 (m, 5H), 1.75– 1.62 (m, 2H), 1.53– 1.40 (m, 1H), 1.26– 1.19 (m, 2H), 1.13– 1.02 (m, 1H), 1.01– 0.94 (m, 6H), 0.94– 0.82 (m, 1H), 0.74– 0.62 (m, 1H). Intermediate 9: (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone
To a solution of (1,5-cyclooctadiene)(methoxy)iridium(I)dimer (69.5mg, 0.105mmol) in 2- methyl-THF (10.5mL) in a glove box was added bis(pinacolato)diboron (293mg, 1.15mmol), 3,4,7,8-tetramethyl-1,10-phenanthroline (44.6mg, 0.189mmol) and stirred for 2 min, then added (trans-4-isopropoxycyclohexyl){8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone (500mg, 1.05mmol) and the vial was sealed. The reaction mixture was microwaved at 100°C for 60 min, cooled down, diluted with DCM, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica (0-100% EtOAc in hexane) to afford (8-((1S,4S)-2-oxa-5- azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone as a solid. MS: 521 (M+1). EXAMPLES
Example 1: (8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone
To a stirred solution of 1-(2,2,2-trifluoroethyl)piperidine-4-carboxylic acid (63.4mg, 0.30mmol) in DCM (500µl) and one drop DMF was added oxalyl chloride (27.5µl, 0.31mmol) at RT. The reaction was stirred at RT for 1.5 h and then concentrated to dryness. The resulting acyl chloride was redissolved in DCE (1mL) and added to a hot suspension of tert-butyl 8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (100mg, 0.286mmol) in DCE (1mL) at 80°C. DMAP (1.7mg, 0.014mmol) in DCE (0.5mL) was added subsequently. The mixture was heated overnight. Upon cooling to RT, the mixture was diluted with water, extracted with ethyl acetate (3x) and the combined organic layers were washed with brine, dried over sodium sulfate,
filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (24g silica gel, EtOAc:EtOH (3:1) in hexanes, 0-70%) to afford (8-chloro-3- fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 443 (M + 1). Example 2: (8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone
To a stirred solution of trans-4-isopropoxycyclohexanecarboxylic acid (56mg, 0.30mmol) in DCM (500µl) and one drop DMF was added oxalyl chloride (28µl, 0.31mmol) at RT. The reaction was stirred at RT for 1.5 h and then concentrated to dryness. The resulting (1r,4r)-4- isopropoxycyclohexane-1-carbonyl chloride was redissolved in DCE (1mL) and added to a hot suspension of tert-butyl 8-chloro-3-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate (100mg, 0.286mmol) in DCE (1mL) at 80°C. DMAP (1.7mg, 0.014mmol) in DCE (0.5mL) was added subsequently. The mixture was heated overnight. Another 1 equiv of trans- 4-isopropoxycyclohexane-1-carbonyl chloride and 0.05 equivalent of DMAP were added to the reaction mixture. The reaction was heated for another 16 h before quenching with water and aq. sodium bicarbonate solution. The mixture was extracted with EtOAc, washed with brine, dried over sodium sulfate and concentrated. The residue was further treated with TFA/DCM (1mL, 1:1) at RT for 1 h. The volatiles were removed under reduced pressure. The residue was purified by column chromatography (24 g silica gel, 0-60% EtOAc in hexane) to afford (8- chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone as a solid. MS: 418 (M + 1). Example 3: (8-Bromo-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone
To a stirred solution of trans-4-isopropoxycyclohexanecarboxylic acid (275mg, 1.48mmol) in DCM (2.2mL) and one drop DMF was added oxalyl chloride (0.144mL, 1.65mmol) at RT. The reaction was stirred at RT for 1.5 h and then concentrated to dryness. The resulting (1r,4r)-4- isopropoxycyclohexane-1-carbonyl chloride was redissolved in DCE (1.5 mL) and added to a hot suspension of tert-butyl 8-bromo-3-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate (500mg, 1.27mmol) in DCE (4.5mL) at 80°C. DMAP (7.7mg, 0.063mmol) in DCE (0.5mL) was added subsequently. The mixture was heated overnight before quenching with water and aq. sodium bicarbonate solution. The mixture was extracted with EtOAc, washed with brine, dried over sodium sulfate and concentrated. The residue was further treated with
TFA/DCM (3mL, 1:1) at RT for 1 h. The volatiles were removed under reduced pressure. The residue was diluted with EtOAc, quenched with aq. NaHCO3 solution (0.5mL) for 5 min, dried over sodium sulfate, filtered, and concentrated. The residue was purified by column
chromatography (80 g silica gel, 0-30% EtOAc in hexane) to afford (8-bromo-3-fluoro-5,11- dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone as a yellow solid. MS: 464 (M + 1). Example 4: (8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone
Trans-4-isopropoxycyclohexanecarboxylic acid (223mg, 1.196mmol) was dissolved in DCM (8mL) and one drop DMF. Oxalyl chloride (0.114mL, 1.305mmol) was added at RT and the reaction mixture was stirred at RT for 1.5 h. All volatiles were evaporated. A separate microwave vail was charged with tert-butyl 8-chloro-3,9-difluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (400mg, 1.088mmol) and DCE (15mL). The mixture was
heated to 80°C. The previously made acyl chloride was suspended in DCE and added to the hot mixture. DMAP (133mg, 1.088mmol) was added afterwards. The reaction vial was sealed and heated for overnight. TFA (1.666mL, 21.75mmol) was added and the mixture was stirred at RT for 1 h. The mixture was cooled, diluted with DCM (50mL), washed with sat. aqueous sodium bicarbonate (40mL), dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel ISCO 40g, eluting with EtOAc/hexane to afford (8-chloro-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(trans-4-isopropoxycyclohexyl)methanone as a solid. MS: 436 (M + 1). Example 5: (8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
1-(2,2,2-Trifluoroethyl)piperidine-4-carboxylic acid (189mg, 0.897mmol) was dissolved in DCM (2mL) and one drop DMF. Oxalyl dichloride (0.079mL, 0.897mmol) was added at RT for 1 h before solvent was evaporated under reduced pressure to give the acyl chloride intermediate. To another 2 drum vial with vent cap was charged with tert-butyl 8-chloro-3,9-difluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (300mg, 0.816mmol), DMAP (100mg, 0.816mmol), and DCE (3.5mL). The mixture was heated to 80°C. The previously made acyl chloride was suspended in DCE (0.5mL) and added to the hot mixture. The reaction vial was sealed and heated for 1 h. The reaction was quenched with sodium bicarbonate solution and extracted with EtOAc. The organic phase was washed with brine, dried over Mg2SO4, and filtered. Solvent was removed under reduced pressure and the residue was subjected to column chromatography eluting with 0-70% EtOAc/Hex on ISCO silica gel column (24 g) to afford (8- chloro-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 461 (M+1). Example 6: (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
To an oven-dried, nitrogen cooled microwave vial was added (8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone (80mg, 0.18mmol), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane (36mg, 0.36mmol), RuPhos-G3- palladacycle (7.4mg, 9.03µmol) and Ruphos (4.2mg, 9.03µmol). The vial was evacuated and filled with nitrogen and then lithium bis(trimethylsilyl)amide (1.0M in THF, 1.1mL, 1.1mmol) was added via syringe. The reaction was heated to 80°C overnight. Upon cooling to RT, the mixture was diluted with water, extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by mass triggered reverse phase HPLC (ACN/water) to afford (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 506 (M + 1).
1H NMR (500 MHz, Methanol-d4) δ 7.88 (d, J = 2.8 Hz, 1H), 7.36– 7.29 (m, 1H), 7.09 (dd, J = 8.8, 2.1 Hz, 1H), 6.67 (dd, J = 8.8, 2.7 Hz, 1H), 6.55 (dd, J = 5.4, 2.7 Hz, 1H), 5.30 (dd, J = 15.2, 3.5 Hz, 1H), 4.65 (t, J = 1.9 Hz, 1H), 4.48 (dt, J = 15.7, 1.5 Hz, 1H), 4.03 (dd, J = 15.1, 1.8 Hz, 1H), 3.90– 3.82 (m, 2H), 3.58 (td, J = 9.2, 1.6 Hz, 1H), 3.11– 2.89 (m, 4H), 2.82– 2.75 (m, 1H), 2.63 (dtt, J = 15.3, 11.6, 3.7 Hz, 1H), 2.23 (dtd, J = 19.2, 11.7, 3.0 Hz, 1H), 2.09– 1.74 (m, 5H), 1.52– 1.40 (m, 1H), 1.36– 1.27 (m, 1H). The compounds in Table 1 were prepared using the methodology herein and the general procedure described in Example 6.
Table 1.
Examples 33 and 34: (8-((S)-1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone and (8-((R)-1,4- dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5- isopropoxytetrahydro-2H-pyran-2-yl)methanone
Step 1: To a round bottle flask equipped with a stir bar was added 8-bromo-3-fluoro-6,11- dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine (24 g, 82 mmol), 2-(5,6-dihydro-1,4-dioxin-2- yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (26.0 g, 122 mmol), potassium phosphate, tribasic (204 ml, 408 mmol) and THF (272 ml). The 3rd Generation X-Phos precatalyst (3.45 g, 4.08 mmol) was added last and the flask was purged with nitrogen. The reaction mixture was refluxed for 45 min under nitrogen (70 oC internal temperature). Upon cooling, the reaction mixture was diluted with water, extracted with EtOAc (3x), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was diluited with DCM and triturated with hexanes. The solid was filtered off and washed with hexanes. The filtrate was again concentrated in
vacuo, dissolved in minimal DCM and with hexanes. The solid was filtered off and washed with hexanes. The combined solids was dried in vacuo to afford (8-(5,6-dihydro-1,4-dioxin-2-yl)-3- fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine).
Step 2: 8-(5,6-Dihydro-1,4-dioxin-2-yl)-3-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine (1.7g, 5.68 mmol) and palladium on carbon (0.60 g, 0.568 mmol) were added to a round bottle flask purged with N2 gas. MeOH (114 ml) was added and a three-way stop cock with a H2 balloon was attached and the mixture was subjected to alternating vacuum and H2 gas 3 times. The mxiture was then stirred under an atomosphere of H2 for 20 h. The mixture was then subjected to alternating vacuum and N2 gas 3 times before the balloon was removed and the reaction vessel was flushed with a stream of N2 gas. The mixture was then carefuly filtered through celite and washed with DCM:MeOH. The filtrate was concentrated in vacuo and then dissolved in mninmal DCM and triturated with hexanes. The solid was filtered off, washed with hexanes and dried in vacuo to afford the product 8-(1,4-dioxan-2-yl)-3-fluoro-6,11-dihydro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine. The filtrate was concentrated in vacuo. The residue was purifed by MPLC (30-100% EtOAc:Hex) to afford more deisred product. The precipitate was combined with the product isoalted by MPLC and the combined batch was further purified by chiral SFC (Chiralcel OD-H, 21 X 250 mm, isopropanol +0.25% dimethyl ethyl amine modifier in CO2) to separate the enanantiomers (peak 1 and peak 2).
Step 3: (2R,5S)-5-Isopropoxytetrahydro-2H-pyran-2-carboxylic acid (0.137 g, 0.730 mmol) was dissolved in DCM (6.64 ml) and one drop DMF was added. Oxalyl chloride (0.067 ml, 0.763 mmol) was added at RT. After 15 min, the reaction was evaporated and dried. To a different flask was added with 8-(1,4-dioxan-2-yl)-3-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine (peak 1 from SFC, 0.2g, 0.664 mmol) and DCE. The mixture was heated at 80 °C, followed by the addition of a solution of the freshly made acyl chloride suspension in DCE and DMAP (4 mg, 0.033 mmol). The mixture was heated for 3h. Once completed, the reaction was extracted 3times with saturated NaHCO3 and EtOAc. The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purifed by MPLC (0- 75% EtOAc:Hex) to afford (8-((S)-1,4-dioxan-2-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone. MS: 472 (M+1).1H NMR (600 MHz, d6-DMSO): δ 9.45- 9.49 (m, 1 H); 8.02 (d, J = 2.8 Hz, 1 H); 7.52 (t, J = 10.7 Hz, 1 H); 7.16-7.29 (m, 3 H); 5.17 (t, J = 14.6 Hz, 1 H); 4.48 (t, J = 9.2 Hz, 1 H); 3.45-3.92 (m, 8 H); 2.77 (t, J = 10.3 Hz, 1 H); 2.34-2.39 (m, 1 H); 1.83-1.94 (m, 2 H); 1.43- 1.55 (m, 2 H); 1.02-1.19 (m, 2 H); 0.90-0.98 (m, 6 H).
Step 4: (2R,5S)-5-Isopropoxytetrahydro-2H-pyran-2-carboxylic acid (0.350 g, 1.862 mmol) was dissolved in DCM (17 ml) and catalytic DMF was added. Oxalyl chloride (0.170 ml, 1.95 mmol) was added at RT. After 30 min, the reaction was evaporated and dried. To a different round bottle flask was added 8-(1,4-dioxan-2-yl)-3-fluoro-6,11-dihydro-5Hbenzo[b]pyrido[2,3- e][1,4]diazepine (peak 2 from SFC, 0.51g, 1.693 mmol) and N,N-dimethylpyridin-4-amine (10.3 mg, 0.085 mmol). The mixture was stirred in DCE and the freshly made acyl chloride in DCE was added. The mixture was heated at 80 °C for 3h. The reaction mixture was cooled to RT, diluted with sat. aq. sodium bicarbonate and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue was purifed by MPLC (30-100% EtOAc:Hex) to afford (8- ((R)-1,4-dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone. MS: 472 (M+1).1H NMR (600 MHz, d6-DMSO): δ 9.45- 9.49 (m, 1 H); 8.02 (d, J = 2.8 Hz, 1 H); 7.49-7.53 (m, 1 H); 7.14- 7.31 (m, 3 H); 5.16 (dd, J = 15.0, 11.9 Hz, 1 H); 4.48 (d, J = 10.1 Hz, 1 H); 3.45-3.99 (m, 8 H); 2.75 (t, J = 10.5 Hz, 1H); 2.40 (t, J = 10.3 Hz, 1 H); 1.82-2.02 (m, 2 H); 1.40-1.66 (m, 2 H); 1.12-1.24 (m, 2 H); 0.91-0.97 (m, 6 H). Examples 35 and 36: (8-(1,4-Dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone, both enantiomers
Step 1: To a microwave vial equipped with a stir bar was added tert-butyl 8-chloro-3,9-difluoro- 5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (446mg, 1.21mmol), 2-(5,6- dihydro-1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (514mg, 2.42mmol), potassium phosphate, tribasic (12.1mL, 6.06mmol) and THF (7.5mL). The 3rd Generation X- Phos Pd precatalyst (103mg, 0.121mmol) was added last and the vial was purged with nitrogen. The vial was sealed and heated to 100°C for 45 min in the microwave. The mixture was cooled, water (10 mL) was added and the mixture was extracted with EtOAc (2 x 10mL). The combined organic fractions were washed with brine (saturated, 1 x 10 mL), dried (Na2SO4), filtered and the solvent evaporated under reduced pressure. The residue was purified by column
chromatography on silica gel (ISCO 40g, eluted with EtOAc/isohexane), and the fraction was collected to afford tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-3,9-difluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate as a gum.
Step 2: Under nitrogen gas flow, palladium on carbon (143mg, 0.134mmol) was added to the solid of tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (560mg, 1.342mmol), followed by addition of MeOH (15mL). The reaction mixture was N 2 /vacuum exchanged and then H 2 /vacuum exchanged for 3 times each. The reaction mixture was stirred with H2 balloon at RT overnight. The reaction mixture was filtered over celite, washed with MeOH, concentrated to afford tert-butyl 8-(1,4- dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (490mg, 1.168 mmol, 87 % yield) as a foam. The racemate was resolved by SFC (Chiral OD-H (2 x 25cm) OD-H (25 x 0.46cm) 20% methanol (0.1% DEA)/CO2, 100 bar 65mL/min, 220nm inj vol.: 0.5mL , 20mg/mL, (3:1) methanol:DCM) to afford two enantiomers of tert-butyl 8-(1,4- dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate.
Step 3: (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (12.0 mg, 0.064 mmol), tert-butyl 8-(1,4-dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate (26.7mg, 0.064mmol, enantiomer 1), PS-PPh3 (93mg, 0.191mmol),
trichloroacetonitrile (31.9µl, 0.318mmol) were dissolved in acetonitrile (637µl), placed in a sealed tube and heated under microwave irridation at 100°C for 10 min. The mixture was cooled and filtered through a syringe filter disk. TFA (487µl, 6.37mmol) was added to the filtrate and the mixture was stirred at RT overnight. The mixture was diluted with dichloromethane (20mL), washed with aqueous sodium hydrogen carbonate (saturated, 2 x 10mL), dried (Na2SO4), filtered and the solvent evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (ISCO 12g, eluting with EtOAc/isohexane/EtOH (76:18:6)) to afford (8-(1,4-dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone as a gum. MS: 490 (M+1) 1H NMR (500 MHz, Methanol-d4) δ 7.96 (dd, J = 8.3, 2.8 Hz, 1H), 7.52 (d, J = 7.1 Hz, 1H), 7.41 (dd, J = 8.2, 3.3 Hz, 1H), 6.99– 6.91 (m, 1H), 5.29 (dd, J = 19.0, 14.9 Hz, 1H), 4.85 (d, J = 18.1 Hz, 2H), 4.05– 3.59 (m, 11H), 3.47– 3.37 (m, 2H), 2.99 (t, J = 10.4 Hz, 1H), 2.06– 1.90 (m, 1H), 1.58– 1.40 (m, 1H), 1.18– 0.99 (m, 6H).
Example 36 can be synthesized from the other enantiomer of of tert-butyl 8-(1,4-dioxan-2-yl)- 3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate using reaction conditions in step 3.
The compounds in Table 2 were prepared using the methodology herein and the general procedure described in Example 35 and 36. Table 2.
Example 39: (3-Fluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro- 6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone
Step 1: A solution of tert-butyl 8-chloro-3-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine- 11(6H)-carboxylate (1.93g, 5.52mmol), TEA (6.15mL, 44.1mmol), DMAP (0.81g, 6.62mmol), di-tert-butyl dicarbonate (4.82g, 22.07mmol) in THF (79mL) was stirred at 70°C for 4 h. To the reaction mixture was added another di-tert-butyl dicarbonate (2g), DMAP (0.5g) and TEA (2mL). The reaction was heated for another 6 h, and then was cooled to RT and concentrated.
The reaction mixture was diluted with water and extracted with EtOAc, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (80 g silica gel, 0-30% EtOAc in hexane) to afford di-tert-butyl 8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-6,11-dicarboxylate as a foam.
Step 2: To a microwave vial was added di-tert-butyl 8-chloro-3-fluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-6,11-dicarboxylate (150mg, 0.33mmol), (1R,3r,5S)-3-methoxy-8- azabicyclo[3.2.1]octane, HCl (89mg, 0.50mmol), Cs2CO3 (652 mg, 2.00 mmol), and SPhos G2 Pd catalyst (24.0mg, 0.033mmol). The vial was sealed and vacuum/N2 exchanged three times. DME (3.3mL) was added and the reaction was heated to 88°C overnight. The reaction was cooled down to RT, filtered over celite, and concentrated. The residue was purified by column chromatography (24g silica gel, 0-70% EtOAc in hexane) to afford di-tert-butyl 3-fluoro-8- ((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine- 6,11-dicarboxylate.
Step 3: To a stirred solution of di-tert-butyl 3-fluoro-8-((1R,3r,5S)-3-methoxy-8- azabicyclo[3.2.1]octan-8-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-6,11-dicarboxylate (127mg, 0.23mmol) in DCM (1 mL) was added TFA (1 mL, 12.98 mmol) at RT. The reaction was stirred at RT for 1h. The solvents were removed under vacuum. The residue was quenched with saturated NaHCO3, extracted with EtOAc, washed with brine, dried over sodium sulfate and concentrated to afford 3-fluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-6,11- dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine.
Step 4: To a stirred solution of (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (41.8mg, 0.222mmol) in DCM (0.35mL) and one drop DMF was added oxalyl chloride (20.5 µl, 0.233mmol) at RT. The reaction was stirred at RT for 1 h and then concentrated to dryness. The resulting acyl chloride was redissolved in DCE (1.5mL) and added to a hot suspension of 3- fluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-6,11-dihydro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine (75mg, 0.212mmol) in DCE (0.7mL) at 80°C. DMAP (1.3mg) in DCE (0.5mL) was added subsequently. The mixture was heated overnight. Upon cooling to RT, the mixture was diluted with water, extracted with ethyl acetate (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by mass triggered reverse phase HPLC (ACN/water) to afford (3-fluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8- yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro- 2H-pyran-2-yl)methanone. MS: 525 (M + 1). Rotamers were observed in proton NMR. The
major peaks shown are as following: 1H NMR (500 MHz, Methanol-d4) δ 7.89 (d, J = 3.0 Hz, 1H), 7.34 (dd, J = 8.3, 2.8 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.91– 6.73 (m, 2H), 5.34 (d, J = 15.1 Hz, 1H), 4.21– 4.15 (m, 1H), 4.12 (d, J = 3.9 Hz, 2H), 4.06– 3.97 (m, 2H), 3.72– 3.64 (m, 1H), 3.38 (dq, J = 10.3, 5.9, 5.1 Hz, 2H), 2.95 (t, J = 10.4 Hz, 1H), 2.20 (d, J = 7.0 Hz, 2H), 2.08 (dt, J = 14.9, 4.7 Hz, 2H), 2.00– 1.96 (m, 4H), 1.80 (t, J = 12.1 Hz, 3H), 1.44– 1.39 (m, 1H), 1.29 (d, J = 5.2 Hz, 1H), 1.07 (d, J = 5.9 Hz, 6H), 0.92– 0.88 (m, 2H). The compounds in Table 3 were prepared using the methodology herein and the general procedure described in Example 39. Table 3.
Example 45: (3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone
Step 1: To a microwave vial was charged with a solution of tert-butyl 8-chloro-3,9-difluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (0.1g, 0.272mmol), 6-oxa-2- azaspiro[3.5]nonane (0.086g, 0.680mmol), (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'- biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (RuPhos Pd G3) (0.011g, 0.014mmol) in THF (1.36mL), and lithium bis(trimethylsilyl)amide in THF (1M, 2.72mL, 2.72mmol). The vial was sealed and heated at 80°C overnight. This mixture was cooled to RT and diluted with CH2Cl2, washed wth brine, dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (12g, eluting with 0-50%
EtOAc/hexane) to afford tert-butyl 3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate as a solid.
Step 2: To a solution of tert-butyl 3,9-difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (0.04g, 0.087mmol) in CH2Cl2 (0.5mL) was added TFA (0.5mL) and the reaction mixture was stirred for 1h. The mixture was concentrated and then taken up in DCM. The reaction mixture was washed with aq. sat.
NaHCO3, dried over MgSO4, filtered and concentrated to give a foamy-solid. This de-Boc compound, (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (0.016g, 0.087mmol), 2,2,2-trichloroacetonitrile (0.044mL, 0.436mmol), polymer bound triphenyl phosphone (0.068g, 0.262mmol) was dissolved in acetonitrile (0.872mL), placed in a sealed tube and heated under microwave irridation at 100°C for 10 min. The mixture was cooled and filtered, washed with
CH2Cl2 and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (4g, eluting with 0-50% EtOAc/hexane) to afford (3,9- difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone as a solid. MS: 529 (M+1), 1H NMR (500 MHz, Chloroform-d) δ 12.05 (s, 1H), 7.76 -7.64 (m, 2H), 7.12 (m, 1H), 6.58– 6.46 (m, 1H), 5.53– 5.20 (m, 1H), 4.03 (dd, J = 26.5, 10.2 Hz, 1H), 3.97– 3.82 (m, 1H), 3.77 (s, 4H), 3.62 (d, J = 33.9 Hz, 4H), 3.46 (s, 1H), 3.02 (t, J = 10.4 Hz, 1H), 2.79 (m, 1H), 2.07 (d, J = 12.6 Hz, 1H), 1.86 (s, 2H), 1.75 (m, 1H), 1.62 (s, 2H), 1.47 (d, J = 13.9 Hz, 1H), 1.40– 1.18 (m, 2H), 1.11 (td, J = 6.4, 3.1 Hz, 6H). The compounds in Table 4 were prepared using the methodology herein and the general procedure described in Example 45. Table 4.
Example 50: (3,9-Difluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
In a glovebox, 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (16.9mg, 0.081mmol), 2nd generation Xphos Pd precatalyst (42.7mg, 0.054mmol), THF (1.0mL) and potassium phosphate tribasic (0.5M, 0.340mL) were added to the reaction vessel with (8-chloro- 3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin- 4-yl)methanone (25 mg, 0.054 mmol). After heating at 40°C for 16h, the reaction mixture was cooled to ambient temperature and filtered. The solution was partionated between EtOAc and water, and the organic phase was separated, dried over Na2SO4, and solvent was removed under reduced pressure. The residue was purified by reverse phase HPLC (ACN/water with 0.05% TFA, gradient 10-45% in acetonitrile over 12 min.) to afford (3,9-difluoro-8-(1-methyl-1H- pyrazol-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 507 (M+H). The compound in Table 5 was prepared using the methodology herein and the general procedure described in Example 50.
Table 5.
y me anone Example 52: (9-Fluoro-8-(1-methyl-1H-pyrazol-4-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
Step 1: To a mixture of methanesulfonato(2-dicyclohexylphosphino-2’,4’6’-tri-isopropyl-1,1’- biphenyl)(2’-amino-1,1’-biphenyl-2yl)palladium(II) (11.69mg, 0.014mmol), 1-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (38.3mg, 0.184mmol), and tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (50mg, 0.092mmol) in a microwave vial was added dioxane (1.5mL) followed by a solution of potassium phosphate tribasic (0.056mL, 0.276mmol) in water (0.5mL). The reaction mixture was nitrogen/vacuum exchanged three times and it was allowed to stir at 100°C for 1 h under microwave condition. LCMS showed clean reaction. The mixture was cooled and directly loaded on to ISCO column (40 g) eluting with EtOAc/hexane gradient (0-100%) to afford tert-butyl 9-fluoro-8-(1-methyl-1H-pyrazol-4-yl)-6-(1-(2,2,2- trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate as a syrup.
Step 2: TFA (0.5mL) was added to a stirred mixture of tert-butyl 9-fluoro-8-(1-methyl-1H- pyrazol-4-yl)-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (20mg, 0.034mmol) in DCM (1mL) and the mixture was stirred at RT for 1 h. The solvent was removed and the residue was taken up in DMSO (0.5mL) and purifed with reverse phase HPLC eluting with MeCN/0.1%TFA and water gradient (10-
90%) to afford (9-fluoro-8-(1-methyl-1H-pyrazol-4-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 489 (M+1). The compound in Table 6 was prepared using the methodology herein and the general procedure described in Example 52. Table 6.
Examples 54 and 55: (S)-(8-(1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone and (R)-(8-(1,4-dioxan-2- yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroeth l i eridin-4- l methanone
Step 1: To a microwave vial equipped with a stir bar was added tert-butyl 8-chloro-3-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (300mg, 0.858mmol), 2-(5,6-dihydro- 1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (364mg, 1.715mmol), potassium phosphate, tribasic (8.58mL, 0.5 M, 4.29mmol) and THF (7.5mL). The X-Phos G3 Pd precatalyst (72.6mg, 0.086mmol) was added last and the vial was sealed. The reaction mixture was degassed by bubbling nitrogen gas for 10 min. The reaction was microwave heated to 100°C for 45 min. Upon cooling, the mixtuer was diluted with water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (eluent 0-60% EtOAc in hexane) to afford tert-butyl 8-(5,6- dihydro-1,4-dioxin-2-yl)-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11- carboxylate as a solid.
Step 2: Under nitrogen gas flow, palladium on carbon (83mg, 0.078mmol) was added to the solid of tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-3-fluoro-5,6-dihydro-11H- benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate (310 mg, 0.776 mmol), followed by addition of MeOH (15 mL). The reaction mixture was N2/vacuum exchanged and then
H2/vacuum exchanged three times each. The reaction mixture was stirred with hydrogen balloon at RT for 16 h. The reaction was filtered over celite, washed with MeOH and concentrated to afford tert-butyl 8-(1,4-dioxan-2-yl)-3-fluoro-5,6-dihydro-11H- benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate.
Step 3: To a stirred solution of 1-(2,2,2-trifluoroethyl)piperidine-4-carboxylic acid (171mg, 0.808mmol) in DCM (1.5mL) and one drop DMF was added oxalyl chloride (77µl, 0.882mmol) at RT. The reaction was stirred at RT for 1.5 h and then concentrated to dryness. The resulting acyl chloride was redissolved in DCE (1.5 mL) and added to a hot suspension of tert-butyl 8- (1,4-dioxan-2-yl)-3-fluoro-5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate (295mg, 0.735mmol) in DCE (3mL) at 80°C. DMAP (4.5mg) in DCE (0.5mL) was added subsequently. The mixture was heated overnight. Upon cooling to RT, the mixture was diluted with water, extracted with EtOAc (2x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (40g silica gel, EtOAc:EtOH (3:1) in hexanes 0-40%) to give roughly pure product, which was further purified by Gilson reverse phase HPLC (10-60% ACN/H2O with TFA modifier). The desired fractions were combined, concentrated to remove organic solvent, and the aqueous leftover was quenched with saturated NaHCO3 solution, extracted with EtOAc (3X). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, concentrated and dried to afford (8-(1,4-dioxan-2-yl)-3-fluoro-5,11- dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4- yl)methanone as a racemic mixture. Chiral resolution with Chiralcel OZ-H column and 1:1 MeOH/acetonitrile co-solvent afforded both enantiomers as follows:
Peak 1: MS: 495 (M+1). 1H NMR (500 MHz, Methanol-d4) δ 7.95 (d, J = 2.8 Hz, 1H), 7.39 (dd, J = 8.2, 2.9 Hz, 1H), 7.31– 7.24 (m, 2H), 7.19 (dd, J = 8.3, 4.5 Hz, 1H), 5.30 (dd, J = 15.1, 2.4 Hz, 1H), 4.60 (ddd, J = 9.7, 6.3, 2.7 Hz, 1H), 3.99 (dd, J = 15.0, 5.9 Hz, 1H), 3.95– 3.75 (m, 4H), 3.70 (td, J = 11.2, 3.4 Hz, 1H), 3.42 (ddd, J = 12.9, 11.6, 10.1 Hz, 1H), 3.03– 2.87 (m, 3H), 2.79– 2.69 (m, 1H), 2.51 (dtd, J = 11.3, 7.2, 3.5 Hz, 1H), 2.28– 2.17 (m, 1H), 1.97 (tt, J = 11.9, 3.2 Hz, 1H), 1.91– 1.76 (m, 2H), 1.39 (qt, J = 12.2, 3.8 Hz, 1H), 1.20 (ddd, J = 13.3, 6.2, 2.9 Hz, 1H).
Peak 2: MS: 495 (M+1). 1H NMR (500 MHz, Methanol-d4) δ 7.94 (d, J = 2.8 Hz, 1H), 7.38 (dd, J = 8.2, 2.8 Hz, 1H), 7.32– 7.23 (m, 2H), 7.18 (dd, J = 8.3, 4.3 Hz, 1H), 5.30 (dd, J = 15.1, 2.9 Hz, 1H), 4.60 (ddd, J = 9.7, 6.3, 2.7 Hz, 1H), 3.98 (dd, J = 15.0, 6.8 Hz, 1H), 3.94– 3.74 (m, 4H), 3.74– 3.65 (m, 1H), 3.42 (ddd, J = 13.2, 11.6, 10.0 Hz, 1H), 3.03– 2.87 (m, 3H), 2.75 (dt, J = 11.8, 4.0 Hz, 1H), 2.50 (dtt, J = 11.1, 7.3, 3.6 Hz, 1H), 2.22 (qd, J = 11.8, 3.0 Hz, 1H), 1.97 (tt, J = 11.9, 3.2 Hz, 1H), 1.90– 1.77 (m, 2H), 1.39 (qt, J = 12.2, 3.8 Hz, 1H), 1.20 (dd, J = 9.8, 6.0 Hz, 1H).
Examples 56 and 57: (R)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone and (S)-(8-(1,4-dioxan-2- yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone
Step 1: To chloro[(di-(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (70.9mg, 0.106mmol), 2-(5,6-dihydro-1,4-dioxin-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (225mg, 1.061mmol), and tert-butyl 8-chloro-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4- carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (288mg, 0.530mmol) in a microwave vial under nitrogen was added dioxane (3mL) followed by a solution of potassium phosphate tribasic (0.27mL, 1.326mmol) in water (1.0mL). The reaction mixture was
N2/vacuum exchanged for 3 times before it was allowed to stir at 100°C for 1 h under microwave condition. LCMS showed the formation of the desired product. The mixture was directly loaded on ISCO column (40g silica gel, eluting with EtOAc/hexane gradient (0-100%)) to afford a mixture of products. This mixture was purifed with reverse phase HPLC eluting with
MeCN/0.1%TFA and water gradient (10-90%) to afford tert-butyl 8-(5,6-dihydro-1,4-dioxin-2- yl)-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate as a foam. MS: 593 (M+1).
Step 2: Tert-butyl 8-(5,6-dihydro-1,4-dioxin-2-yl)-9-fluoro-6-(1-(2,2,2-trifluoroethyl)piperidine- 4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (15mg, 0.025mmol)
was dissolved in MeOH (2mL). Pd-C (10wt%, 3mg, 2.82µmol) was added and the reaction mixture was degassed and refilled with hydrogen in a balloon. The mixture was stirred at RT overnight. The mixture was filtered through a short celite pad, washed with EtOAc, and concentrated. The residue was used directly in the next step. MS: 595 (M+1).
Step 3: TFA (0.5 mL) was added to a stirred mixture of tert-butyl 8-(1,4-dioxan-2-yl)-9-fluoro- 6-(1-(2,2,2-trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine- 11(6H)-carboxylate (15 mg, 0.025 mmol) in DCM (1 mL) and the mixture was stirred at RT for 1 h. LCMS showed clean reaction. The solvent was removed and the residue was purifed with chiral SFC to afford (R)-(8-(1,4-dioxan-2-yl)-9-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone (MS: 495 (M+1)) and (S)-(8-(1,4- dioxan-2-yl)-9-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 495 (M+1). Examples 58 and 59: (Trans-4-isopropoxycyclohexyl){9-methyl-8-[(1S,4S)-2-oxa-5- azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone and (trans-4-isopropoxycyclohexyl){7-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]- 5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone
Inside a glovebox at 25°C, a mixture of tert-butyl peroxyacetate (27.7mg, 0.210mmol) in acetonitrile (0.42mL) was added to an oven-dried vial containing a mixture of (trans-4- isopropoxycyclohexyl){8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone (40mg, 0.084mmol) in acetonitrile (0.42mL). TFA (64.7µl, 0.839mmol) was added. The reaction was transferred out of the glovebox and stirred under an LED light for 4 h. Upon cooling, the mixture was diluted with 10mL of EtOAc, washed with sat. aqueous sodium hydrogen carbonate (3X 5mL), brine (5mL), dried over Na2SO4, filtered and the mixture was evaporated under reduced pressure. The residue was purified by mass triggered reverse phase HPLC (ACN/water) to afford (trans-4- isopropoxycyclohexyl){9-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro- 6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone and (trans-4-isopropoxycyclohexyl){7-
methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl}methanone. MS: 491 (M + 1). The compounds in Table 7 were prepared using the methodology herein and the general procedure described in Examples 58 and 59. Table 7.
Examples 62 and 63: [9-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H- pyrido[2,3-b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone and [7-fluoro- 8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6- yl](trans-4-isopropoxycyclohexyl)methanone
To a mixture of (trans-4-isopropoxycyclohexyl)[8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl]methanone (200mg, 0.420mmol) in DMA (1mL)/MeOH (1.0mL) was added selectfluor (171mg, 0.483mmol) and the mixture was allowed to stir at RT for 1 h. The mixture was purified via reverse-phase chromatography to provide a
single peak as a mixture of products. The mixture was purified via achiral SFC (ES, Ethyl Pyridine II, 21 x 250 (mm)) to afford [9-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone (Peak 1 SFC), MS 495 (M+H), and [7-fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone (Peak 2 SFC), MS 495 (M+H).
Example 64: (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone
Step 1: To an oven-dried, N2(g) cooled 20 mL microwave vial was added di-tert-butyl 8-chloro- 9-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-6,11-dicarboxylate (237mg, 0.527mmol), chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)[2-(2- aminoethylphenyl)]palladium(II), methyl-t-butylether adduct (43.0mg, 0.053mmol), and (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane, HCl (107mg, 0.790mmol). Sodium tert-butoxide (506mg, 5.27mmol) was added and the vial was evacuated and filled with N2(g). THF (10mL) was added, the vial was sealed and the reaction mixture was heated to 80°C overnight. Upon cooling to room temperature, trifluoroacetic acid (0.807mL, 10.5mmol) was added. After 1 hour, saturated aqueous sodium hydrogen carbonate (50mL) was added and the mixture was extracted with EtOAc (3 x 30mL). The combined organic fractions were washed with brine (30mL), dried over Na2SO4, filtered and the mixture was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (ISCO 24g, eluting with 0-30% ethyl acetate gradient in isohexane) to afford tert-butyl 8-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9- fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate as a foam.
Step 2: To a mixture of tert-butyl 8-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro- 5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)-carboxylate (146mg, 0.354mmol) in DCM (1.42mL) was added hydrochloric acid (4 M in water, 1.77mL, 7.08mmol). After 2 hours, the
volatiles were evaporated under reduced pressure to afford (1S,4S)-5-(9-fluoro-6,11-dihydro-5H- benzo[b]pyrido[2,3-e][1,4]diazepin-8-yl)-2-oxa-5-azabicyclo[2.2.1]heptane as the HCl salt. Step 3: To a mixture of (2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-carboxylic acid (16mg, 0.083mmol), (1S,4S)-5-(9-fluoro-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-8-yl)-2- oxa-5-azabicyclo[2.2.1]heptane (26mg, 0.083mmol), PS-PPh3 (2.06mmol/g loading, 121mg, 0.250mmol), and trichloroacetonitrile (42µl, 0.416mmol) in a microwave vial was added acetonitrile (832µl). The mixture was heated under microwave irridation to 100°C for 10 min. Upon cooling to room temperature, the mixture was filtered through a syringe filter disk and the filtrate was purified by preparative HPLC to afford (8-((1S,4S)-2-Oxa-5- azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone as a gum. MS: 483 (M+1). 1H NMR (500 MHz, Methanol-d4) δ 8.07– 7.94 (m, 2H), 7.13 (td, J = 11.9, 10.7, 2.0 Hz, 1H), 7.04 (ddd, J = 7.0, 5.9, 4.2 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 5.41 (dd, J = 21.7, 15.1 Hz, 1H), 4.72– 4.48 (m, 2H), 4.21– 4.04 (m, 2H), 4.04– 3.82 (m, 3H), 3.78– 3.60 (m, 3H), 3.41 (td, J = 10.5, 10.0, 4.9 Hz, 1H), 3.22 (ddd, J = 35.1, 10.1, 3.1 Hz, 1H), 3.03– 2.93 (m, 1H), 2.74– 2.62 (m, 1H), 2.17– 1.92 (m, 3H), 1.54 (tdd, J = 13.2, 11.1, 3.8 Hz, 1H), 1.46– 1.34 (m, 1H), 1.21– 0.98 (m, 6H).
Example 65: (8-Chloro-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone
Step 1: To a solution of 4-chloro-2-nitroaniline (474mg, 2.75mmol), 1-(2-bromopyridin-3- yl)ethanone (500mg, 2.500mmol), Pd2(dba)2 (114mg, 0.125mmol), (9,9-dimethyl-9H-xanthene- 4,5-diyl)bis(diphenylphosphine) (Xantphos) (217mg, 0.375mmol), cesium carbonate (3.2g, 10.00mmol) in 1,4-dioxane (10mL) was degassed by bubbling nitrogen through the reaction mixture. The mixture was heated to reflux and left overnight and then cooled to RT. Boc2O (818mg, 3.75mmol) and DMAP (458mg, 3.75mmol) were added and stirred for 3-4 h. When the reaction was complete it was diluted with dichloromethane and filtered through a pad of celite
washed three times with dichloromethane, and the solvent removed to afford crude tert-butyl (3- acetylpyridin-2-yl)(4-chloro-2-nitrophenyl)carbamate as a solid which was used in the next step without further purification. MS: 392 (M+1).
Step 2: Under nitrogen gas flow, 3%Pt-0.6%V/C (299mg) was added to tert-butyl (3- acetylpyridin-2-yl)(4-chloro-2-nitrophenyl)carbamate (600mg, 1.531mmol), followed by addition of methanol (20mL) and ethyl acetate (10mL). The reaction mixture was degassed with nitrogen and then stirred under hydrogen at RT overnight. The reaction mixture was diluted with dichloromethane and filtered over celite, washed with dichloromethane, concentrated and absorbed on silica gel and purified by ISCO chromatography (40g column, 0-100% Hexane- Ethylacetate) to afford tert-butyl (3-acetylpyridin-2-yl)(2-amino-4-chlorophenyl)carbamate as a solid. MS: 362 (M+1).
Step 3: To a solution of tert-butyl (3-acetylpyridin-2-yl)(2-amino-4-chlorophenyl)carbamate (300mg, 0.829mmol) in 1,2-dichloroethane (5mL) was added sodiumtriacetoxyborohydride (527mg, 2.487mmol) and heated at 80°C for 4 h. The reaction mixture was cooled to RT, taken into a separatory funnel, diluted with EtOAc, washed with water, brine and dried over anhydrous sodium sulfate. Filtration and removal of the solvent afforded the crude, which was purified by ISCO silica gel chromatography using hexane and EtOAc (0-100%) to afford tert-butyl 8-chloro- 5-methyl-5,6-dihydro-11H-benzo[b]pyrido[2,3-e][1,4]diazepine-11-carboxylate as an oil. MS: 246 (M-tBu).
Step 4: To a solution of trans-4-isopropoxycyclohexanecarboxylic acid (118mg, 0.636mmol) in dichloromethane (3mL) was added oxalyl chloride (0.101mL, 1.157mmol), followed by a drop of DMF and stirred for 1 h at RT. The reaction mixture was concentrated to dryness and vacuum was applied for 5 min to remove any residual oxalyl chloride. The residue was dissolved in 1,2- dichloroethane (3.0mL) and tert-butyl 8-chloro-5-methyl-5H-benzo[b]pyrido[2,3- e][1,4]diazepine-11(6H)-carboxylate (200mg, 0.578mmol) was added followed by N,N- dimethylpyridin-4-amine (3.53mg, 0.029mmol) and stirred at 80°C overnight. The reaction mixture was stirred for 24 h, poured into a separatory funnel, washed with water, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and the solvent removed to give crude mixture which was taken in dichloromethane (1mL) and treated with trifluoroacetic acid (1mL) and stirred at RT for 1 h. Removal of the solvent afforded the crude product, which was purified by Gilson reverse phase HPLC using acetonitrile and water both containing 0.05% TFA to afford (8-chloro-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone as a solid. MS: 414 (M+1).
Example 66: (Trans-4-isopropoxycyclohexyl)(5-methyl-8-morpholino-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)methanone
To a microwave vial was added (8-chloro-5-methyl-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(trans-4-isopropoxycyclohexyl)methanone (13mg, 0.031mmol), chloro(2- dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(II), methyl-t-butylether adduct (1.3mg, 1.570µmol) and 2-di-cyclohexylphosphino-2',6'-di-i- propoxy-1,1'-biphenyl (0.7mg, 1.570µmol). The vial was evacuated and refilled with N2 gas. Lithium bis(trimethylsilyl)amide (0.19mL, 0.188mmol) in tetrahydrofuran was added via a syringe, followed by morpholine (3.3mg, 0.038mmol). The vial was sealed and the reaction mixture was heated to 80°C overnight. Another batch of all the reagents was added and heating continued for one more day. Reaction mixture was cooled to RT, diluted with ethylacetate, and solvents were removed under reduced pressure. The residue was redissolved in DMF (2mL) and purified by Gilson reverse phase HPLC using acetonitrile and water (both containing 0.05% TFA) to afford (trans-4-isopropoxycyclohexyl)(5-methyl-8-morpholino-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)methanone as a solid. MS: 465 (M+1). Example 67: (8-Methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone
Step 1: A mixture of 4-methoxybenzene-1,2-diamine (2.0g, 14.48mmol) and 1-(2-fluoropyridin- 3-yl)ethanone (2.01g, 14.48mmol) in dioxane (20mL) was heated at 100°C overnight. The reaction mixture was cooled to RT. The solvent was removed under reduced pressure, and the
crude was purified by ISCO silica gel chromatography using hexane and ethyl acetate (0-100%) to afford 1-(2-((2-amino-4-methoxyphenyl)amino)pyridin-3-yl)ethan-1-one as an oil. MS: 258 (M+1).
Step 2: To a solution of 1-(2-((2-amino-4-methoxyphenyl)amino)pyridin-3-yl)ethanone (910mg, 3.54mmol) in 1,2-dichloroethane (20mL) was added sodium triacetoxyborohydride (2.25g, 10.61mmol) and heated at 80°C for 4 h. The reaction mixture was cooled to RT and taken into a separatory funnel, diluted with ethylacetate, washed with water, sodium bicarbonate saturated solution, water and brine. Removal of the solvent afforded the crude, which was purified by ISCO silica gel chromatography using hexane/ethyl acetate (0-100%) to afford 8-methoxy-5- methyl-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepine as a solid. MS: 242 (M+1).
Step 3: To a solution of1-(2,2,2-trifluoroethyl)piperidine-4-carboxylic acid (96mg, 0.456mmol) in dichloromethane (3mL) was added oxalyl chloride (0.073mL, 0.829mmol) followed by a drop of DMF and stirred for 1 h at RT. The reaction mixture was concentrated to dryness and vacuum was applied for 5 min to remove any residual oxalyl chloride. The residue was redissolved in 1,2-dichloroethane (3.00mL) and 8-methoxy-5-methyl-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine (100mg, 0.414mmol) was added followed by N,N-dimethylpyridin-4-amine (2.5mg, 0.021mmol) and stirred at 80°C overnight. The reaction mixture was poured into a separatory funnel, washed with water, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and the solvent removed to afford the crude which was purified by Gilson reverse phase HPLC using acetonitrile and water both containing 0.05% TFA to afford (8-methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone. MS: 568 (M+1). Example 68: (Trans-4-isopropoxycyclohexyl)(8-methoxy-5-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)methanone
To a solution of trans-4-isopropoxycyclohexanecarboxylic acid (331mg, 1.778mmol) in DCM (5mL) was added oxalyl dichloride (0.283mL, 3.23mmol) followed by a drop of DMF and
stirred for 1 h at RT. The reaction mixture was concentrated to dryness and vacuum was applied for 5 min to remove any residual oxalyl chloride. The residue was redissolved in 1,2- dichloroethane (10mL) and 8-methoxy-5-methyl-6,11-dihydro-5H-benzo[b]pyrido[2,3- e][1,4]diazepine (390mg, 1.616mmol) was added followed by N,N-dimethylpyridin-4-amine (9.87mg, 0.081mmol) and stirred at 80°C for overnight. The reaction mixture was poured into a separatory funnel, washed with saturated sodium bicarbonate solution, water, brine, dried over anhydrous sodium sulfate, filtered and the solvent was removed to afford crude product which was purified by ISCO silica gel chromatography using hexane and ethyl acetate (40g column, 0- 100%) to afford (trans-4-isopropoxycyclohexyl)(8-methoxy-5-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)methanone as a solid. MS: 410 (M+1).
Example 69: (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
In glove box, potassium phosphate tribasic (74.7 µl, 0.075mmol) was added to a stirred mixture of 2nd generation Xphos Pd precatalyst (1.96mg, 2.49µmol), iodomethane (15.5µl, 0.249mmol) and (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone (15mg, 0.025mmol) in THF (0.25mL). The vial was sealed, and the reaction mixture was stirred at 70°C overnight. The mixture was cooled, diluted with ethyl acetate (1mL), washed with aqueous sodium hydrogen carbonate (saturated, 3x.5mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by reverse phase HPLC (ACN/water with 0.05% TFA , gradient 10-70% in acetonitrile over 15 min.) to afford (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-methyl-5,11-dihydro- 6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone as a solid. MS: 491 (M+H).
Example 70: (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(methylsulfonyl)-5,11- dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
To a solution of (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone (15mg, 0.025mmol) in DMF (0.25mL) was added molecular sieves (30mg), copper(II) acetate (5.0mg, 0.027mmol), potassium carbonate (7.0mg, 0.050mmol) and sodium methanesulfinate (3.8mg, 0.037mmol). The mixture was stirred at 70°C for 2 h, cooled, diluted with ethyl acetate (2mL), washed with water (1 x 1mL), and the solvent was evaporated under reduced pressure. The residue was purified by reverse phase HPLC
(ACN/water with 0.05% TFA, gradient 15-60% in acetonitrile over 15 min) to afford (8- ((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(methylsulfonyl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone. MS: 555 (M+H).
Example 71: (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-chloro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone
To the solution of (8-((1S,4S)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone (25mg, 0.041mmol) in MeOH (0.415mL) was added a solution of copper (II) chloride (19.5mg, 0.145mmol) in water (0.415mL), then the reaction mixture was stirred at RT overnight. The mixture was diluted with ethyl acetate (2mL), washed with water (1 x 1mL), dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by reverse phase HPLC (ACN/water with 0.05% TFA, gradient 35-65% in acetonitrile over 12 min) to afford (8-((1S,4S)-2-oxa-5-
azabicyclo[2.2.2]octan-5-yl)-3-chloro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(trans-4-isopropoxycyclohexyl)methanone as a solid. MS: 511 (M+H). Examples 72 and 73: (3,9-Difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone and (8-(2-oxa-5-azabicyclo[2.2.2]octan-5- yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone
A mixture of (8-chloro-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone (80 mg, 0.174 mmol), 2-oxa-5-azabicyclo[2.2.2]octane (67.6mg, 0.347mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'- biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos Palladacycle Gen.3) (14.52mg, 0.017mmol) was vaccumed/N2 exchanged three times, and lithium bis(trimethylsilyl)amide (1.0M in THF, 1.389mL, 1.389mmol) was added to the mixture. The reaction mixture was heated at 80°C for 2 h. The reaction mixture was diluted with EtOAc and water. The aqueous was extracted with EtOAc, the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was separated by ISCO column (40g gold, 0- 80% EtOAc in hexane gradient) to afford (3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone (MS: 427 (M+1)) and (8-(2-oxa-5- azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone (MS: 538 (M+1)) as a foam (racemate). Example 74: (9-Fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone
TFA (1mL) was added to a stirred mixture of tert-butyl 9-fluoro-6-(1-(2,2,2- trifluoroethyl)piperidine-4-carbonyl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepine-11(6H)- carboxylate (70mg, 0.138mmol) in DCM (2mL) and the mixture was stirred at RT for 1 h. The solvent was removed, the residue was taken up in 0.5 mL DMSO and was purifed by reverse phase HPLC eluting with MeCN/0.1%TFA and water gradient (10-90%) to afford (9-fluoro-5H- benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone as a solid. MS: 409 (M+1). R132H IDH1 Enzymatic Assay
Each test compound (10mM stock in DMSO) is diluted in DMSO to make a 10- point, 3-fold dilution series. 125nL of each dilution or DMSO alone is dispensed to a 384-well Greiner Lumitrac 200 assay plate using an Echo® Liquid Handler. To each well of the plate is added 20 uL of enzyme in assay buffer or assay buffer alone. Assay buffer consists of 50 mM sodium phosphate, pH 7.0, 50mM magnesium chloride, 50mM sodium chloride, and 0.01% (w/v) bovine serum albumin. When present, the R132H mutant IDH1 enzyme is at a working concentration of 1.875nM (final concentration in assay of 1.5nM). The assay plate is allowed to incubate for 30 minutes at room temperature and 5uL of 5x substrate mixture (2.5uM
nicotinamide adenine dinucleotide phosphate , 100uM adenosine diphosphate, 7.5mM glyceraldehyde-3-phosphate, 7.5ug/mL of spinach glyceraldehyde-3-phosphate dehydrogenase, 25nM phosphoglycerate kinase, and 5mM alpha-ketoglutarate in assay buffer) is added to all wells. The reaction plate is incubated for 60 minutes followed by addition of 25uL of Promega Kinase-GLO reagent to all wells and 10-minute incubation.
Luminescence is measured using a PerkinElmer Envision plate reader. The percent activity of each dilution is determined as the ratio of background corrected signal to the background corrected signal of wells receiving only DMSO. IC50 values are determined by fitting percent activity data to a four-parameter logistic dose response equation. The IC50 values of the exemplified compounds are included in Table 8.
Table 8. IC50 values of the Exemplified Compounds
While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention.
Claims
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) -Br,
(5) methyl,
(6) ethyl,
(7) propyl, and
(8) -S(O)2-methyl;
with the proviso that when R e is hydrogen, at least one of R f , R g , R h , R m , R n and R p is not hydrogen. 11. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein:
Re is–F or methyl; and
each of R f , R g , R h , R m , R n and R p is hydrogen. 12. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein:
Re is hydrogen;
each of R m and R n is hydrogen; and
each of Rf, Rg, Rh, and Rp is independently selected from the group consisting of:
(1) hydrogen,
(2) -F,
(3) -Cl,
(4) methyl, and
(5) -S(O)2-methyl;
with the proviso that at least one of R f , R g , R h and R p is not hydrogen. 13. The compound of Claim 1 of formula (Ib), or a pharmaceutically acceptable salt thereof:
wherein
A is–CH(R1)-; and R1 is -O-propyl or–O-isopropyl;
Re is hydrogen;
each of R f , R g , R m and R n is hydrogen;
each of Rh and Rp is independently selected from the group consisting of:
(1) hydrogen,
(2) -F, and
(3) -Cl;
with the proviso that at least one of R h and R p is not hydrogen; and
R is a heterocyclyl selected from the group consisting of 2-azabicyclo[2.2.2]octanyl, 8- azabicyclo[3.2.1]octanyl, 1,4-dioxanyl, hexahydro-3,6-epiminofuro[3,2-b]furanyl, morpholinyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-5- azabicyclo[2.2.2]octanyl, 3,9-dioxa-7-azabicyclo[3.3.1]nonanyl, oxazolidinyl and pyrazolyl. 14. The compound of Claim 1 selected from the group consisting of:
(8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-Chloro-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Bromo-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(8-Chloro-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (3-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3-Fluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(8-((2S,5S)-2,5-Dimethylmorpholino)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3-Fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
[3-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(8-((1R,5S)-3,9-Dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, [3-Fluoro-8-(6-oxa-2-azaspiro[3.5]non-2-yl)-5,11-dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin- 6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(3-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(cis-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro- 6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((2S,5S)-2,5-Dimethylmorpholino)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
{3,9-Difluoro-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl}[trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]non-2-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
[3,9-Difluoro-8-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl][trans-4-(propan-2-yloxy)cyclohexyl]methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (9-Fluoro-8-((3R,3aR,6R,6aR)-hexahydro-3,6-epiminofuro[3,2-b]furan-7-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(3,9-Difluoro-8-((1R,3r,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((1R,4R)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (8-((S)-1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((R)-1,4-dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-6(11H)-yl)((2R,5S)-5- isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(3-Fluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3-Fluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((1R,5S)-3,9-Dioxa-7-azabicyclo[3.3.1]nonan-7-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-(((3-(Chloromethyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)(1-(ethylsulfonyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(3,9-Difluoro-8-(6-oxa-2-azaspiro[3.5]nonan-2-yl)-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-3,9-difluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3,9-Difluoro-8-((1R,3S,5S)-3-methoxy-8-azabicyclo[3.2.1]octan-8-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-((1R,4R)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-fluoro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2- yl)methanone,
(3,9-Difluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H- benzo[b]pyrido[2,3e][1,4]diazepin-6-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, (3,9-Difluoro-8-(1H-pyrazol-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(9-Fluoro-8-(1-methyl-1H-pyrazol-4-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(9-Fluoro-8-(1-methyl-1H-pyrazol-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6- yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(S)-(8-(1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(R)-(8-(1,4-Dioxan-2-yl)-3-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(R)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(S)-(8-(1,4-Dioxan-2-yl)-9-fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1- (2,2,2-trifluoroethyl)piperidin-4-yl)methanone,
(Trans-4-isopropoxycyclohexyl){9-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){7-methyl-8-[(1S,4S)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){9-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
(Trans-4-isopropoxycyclohexyl){7-methyl-8-[(1R,4R)-2-oxa-5-azabicyclo[2.2.2]oct-5-yl]-5,11- dihydro-6H-pyrido[2,3-b][1,5]benzodiazepin-6-yl}methanone,
[9-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone,
[7-Fluoro-8-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6-yl](trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-9-fluoro-5H-benzo[b]pyrido[2,3- e][1,4]diazepin-6(11H)-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone, (8-Chloro-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4- isopropoxycyclohexyl)methanone,
(Trans-4-isopropoxycyclohexyl)(5-methyl-8-morpholino-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)methanone,
(8-Methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(Trans-4-isopropoxycyclohexyl)(8-methoxy-5-methyl-5,11-dihydro-6H-benzo[b]pyrido[2,3- e][1,4]diazepin-6-yl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-methyl-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-(methylsulfonyl)-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(8-((1S,4S)-2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3-chloro-5,11-dihydro-6H- benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(trans-4-isopropoxycyclohexyl)methanone,
(3,9-Difluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
(8-(2-Oxa-5-azabicyclo[2.2.2]octan-5-yl)-3,9-difluoro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin- 6(11H)-yl)(1-(2,2,2-trifluoroethyl)piperidin-4-yl)methanone, and
(9-Fluoro-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)(1-(2,2,2- trifluoroethyl)piperidin-4-yl)methanone,
or a pharmaceutically acceptable salt thereof. 15. A composition which comprises an inert carrier and a compound of any of Claims 1-14, or a pharmaceutically acceptable salt thereof. 16. Use of a compound of any of Claims 1-14 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of a disease or disorder associated with mutant IDH enzyme activity. 17. A method for treating or preventing a disease or disorder associated with mutant IDH enzyme activity in a mammalian subject which comprises administering to the subject an effective amount of a compound of any of Claims 1-14 or a pharmaceutically acceptable salt thereof. 18. A method for treating a disease or disorder associated with mutant IDH enzyme activity in a mammalian subject which comprises administering to the subject an effective amount of a compound of any of Claims 1-14 or a pharmaceutically acceptable salt thereof in combination with another anti-cancer agent. 19. The method of any of Claims 17 and 18, wherein the disease or disorder associated with mutant IDH enzyme activity is a cancer selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, supratentorial primordial neuroectodermal tumors, acute myeloid leukemia (AML), breast cancer, prostate cancer, thyroid cancer, colon cancer, chondrosarcoma, cholangiocarcinoma, peripheral T-cell lymphoma, and melanoma. 20. The method of Claims 19, wherein the cancer is selected from glioma, glioblastoma multiforme, acute myeloid leukemia and breast cancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16860602.8A EP3371191B1 (en) | 2015-10-29 | 2016-10-25 | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
US15/769,414 US10399972B2 (en) | 2015-10-29 | 2016-10-25 | Tricyclic compounds as inhibitors of mutant IDH enzymes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562247930P | 2015-10-29 | 2015-10-29 | |
US62/247,930 | 2015-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017074914A1 true WO2017074914A1 (en) | 2017-05-04 |
Family
ID=58630683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/058614 WO2017074914A1 (en) | 2015-10-29 | 2016-10-25 | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
Country Status (3)
Country | Link |
---|---|
US (1) | US10399972B2 (en) |
EP (1) | EP3371191B1 (en) |
WO (1) | WO2017074914A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10399970B2 (en) | 2015-06-09 | 2019-09-03 | Femtogenix Limited | Pyrridinobenzodiazepine and benzopyrridodiazecine compounds |
CN112543750A (en) * | 2018-08-03 | 2021-03-23 | 日产化学株式会社 | Process for producing fluorinated secondary aromatic amine compound |
US10975072B2 (en) | 2015-08-21 | 2021-04-13 | Femtogenix Limited | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents |
US10975074B2 (en) | 2015-08-21 | 2021-04-13 | Femtogenix Limited | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines |
WO2023143389A1 (en) * | 2022-01-29 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | Fused heterocyclic compound, preparation method therefor, and medical application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903134A (en) * | 1971-07-21 | 1975-09-02 | Rorer Inc William H | Phenyl propionic acids and derivatives thereof |
US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
US6194407B1 (en) * | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
US20020198191A1 (en) * | 2001-04-12 | 2002-12-26 | Wyeth | Cyclohexylphenyl vasopressin agonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891872A (en) * | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
KR20150127197A (en) | 2013-03-14 | 2015-11-16 | 노파르티스 아게 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
EP3226688B1 (en) * | 2014-12-05 | 2020-07-01 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant idh enzymes |
-
2016
- 2016-10-25 US US15/769,414 patent/US10399972B2/en active Active
- 2016-10-25 EP EP16860602.8A patent/EP3371191B1/en active Active
- 2016-10-25 WO PCT/US2016/058614 patent/WO2017074914A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903134A (en) * | 1971-07-21 | 1975-09-02 | Rorer Inc William H | Phenyl propionic acids and derivatives thereof |
US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
US6194407B1 (en) * | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
US20020198191A1 (en) * | 2001-04-12 | 2002-12-26 | Wyeth | Cyclohexylphenyl vasopressin agonists |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10399970B2 (en) | 2015-06-09 | 2019-09-03 | Femtogenix Limited | Pyrridinobenzodiazepine and benzopyrridodiazecine compounds |
US10975072B2 (en) | 2015-08-21 | 2021-04-13 | Femtogenix Limited | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents |
US10975074B2 (en) | 2015-08-21 | 2021-04-13 | Femtogenix Limited | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines |
US11912700B2 (en) | 2015-08-21 | 2024-02-27 | Pheon Therapeutics Ltd | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines |
CN112543750A (en) * | 2018-08-03 | 2021-03-23 | 日产化学株式会社 | Process for producing fluorinated secondary aromatic amine compound |
CN112543750B (en) * | 2018-08-03 | 2023-11-03 | 日产化学株式会社 | Process for producing fluorinated aromatic secondary amine compound |
WO2023143389A1 (en) * | 2022-01-29 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | Fused heterocyclic compound, preparation method therefor, and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3371191B1 (en) | 2020-08-26 |
US10399972B2 (en) | 2019-09-03 |
EP3371191A1 (en) | 2018-09-12 |
EP3371191A4 (en) | 2019-04-17 |
US20180305352A1 (en) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3371191B1 (en) | Novel tricyclic compounds as inhibitors of mutant idh enzymes | |
TWI547493B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
AU2018368332B2 (en) | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | |
US10442819B2 (en) | Tricyclic compounds as inhibitors of mutant IDH enzymes | |
EP4240363A1 (en) | 7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1 | |
US20230416225A1 (en) | Diaminopyrimidine carboxamide inhibitors of hpk1 | |
US20230406864A1 (en) | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 | |
US10508108B2 (en) | Tricyclic compounds as inhibitors of mutant IDH enzymes | |
EP3840747B1 (en) | Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | |
EP3982959A2 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
US11103493B2 (en) | Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | |
EP3226690B1 (en) | Novel tricyclic compounds as inhibitors of mutant idh enzymes | |
WO2020081381A1 (en) | Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | |
WO2019231870A1 (en) | Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16860602 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15769414 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016860602 Country of ref document: EP |